Antibody_ID,HC_germline,CDR_H3,LC_germline,CDR_L3,Antigen_target,Neutralization,Source,Reference
CR3022,IGHV5-51,AGGSGISTPMDV,IGKV4-1,QQYYSTPYT,RBD,No,SARS_infection,Yuan et al. A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV. Science. 368:630-633.
S110,IGHV3-30,AKDRFQFARSWYGDYFDY,IGKV2-30,-,S_protein,-,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
S124,IGHV2-26,ARINTAAYDYDSTTFDI,IGKV1-39,-,RBD,-,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
S309,IGHV1-18,ARDYTRGAWFGESLIGGFDN,IGKV3-20,-,RBD,Yes,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
S315,IGHV3-7,ARDLWWNDQAHYYGMDV,IGLV3-25,-,RBD,Yes,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
S303,IGHV3-23,ARERDDIFPMGLNAFDI,IGKV1-5,-,RBD,No,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
S304,IGHV3-13,ARGDSSGYYYYFDY,IGKV1-39,-,non-RBD,Yes,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
S305,IGHV1-18,ASDYFDSSGYYHSFDY,IGKV3-11,-,non-RBD,-,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
S310,IGHV1-69,ATRTYDSSGYRPYYYGLDV,IGLV2-23,-,non-RBD,No,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
P1A-1C7,IGHV1-46,length=15,IGKV1-39,length=10,RBD,No,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P1A-1C10,IGHV1-69,length=16,IGKV1-5,length=9,RBD,No,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P1A-1C11,IGHV1-69,length=16,IGKV1-5,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P1A-1C6,IGHV3-13,length=19,IGKV1-39,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P1A-1D3,IGHV3-13,length=18,IGKV1-39,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P1A-1C2,IGHV3-23,length=10,IGKV1-36,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P1A-1B2,IGHV3-30,length=12,IGLV2-14,length=10,RBD,No,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P1A-1C1,IGHV3-33,length=17,IGKV1D-13,length=9,RBD,No,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P1A-1D1,IGHV3-53,length=12,IGLV2-8,length=10,RBD,No,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P1A-1D5,IGHV3-53,length=15,IGKV1-33,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P1A-1D6,IGHV3-53,length=15,IGKV1-33,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2A-1A10,IGHV1-2,length=19,IGKV2-40,length=9,RBD,Yes,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1A4,IGHV1-2,length=19,IGKV2-40,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1B2,IGHV1-2,length=19,IGKV2-40,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-2G1,IGHV1-2,length=19,IGKV2-40,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-2G12,IGHV1-2,length=19,IGKV2-40,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1A10,IGHV1-2,length=19,IGKV2-40,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1B10,IGHV1-2,length=19,IGKV2-40,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1D6,IGHV1-2,length=19,IGKV2-40,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1D12,IGHV1-2,length=19,IGKV2-40,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1F10,IGHV1-2,length=19,IGKV2-40,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1F8,IGHV1-2,length=14,IGKV3-20,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-2G9,IGHV1-2,length=14,IGKV3-20,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1C3,IGHV1-46,length=15,IGKV1-5,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1C10,IGHV1-69,length=11,IGKV3-11,length=8,RBD,Yes,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-2G10,IGHV1-69,length=11,IGKV1-39,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1F11,IGHV1-69,length=17,IGLV1-40,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1D9,IGHV2-5,length=16,IGLV1-47,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1E2,IGHV2-5,length=12,IGKV1-5,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1E4,IGHV2-5,length=11,IGLV2-14,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1F4,IGHV2-70,length=14,IGLV1-44,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1A3,IGHV3-11,length=12,IGKV1-9,length=9,RBD,Yes,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1D6,IGHV3-15,length=24,IGLV1-44,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1B12,IGHV3-15,length=13,IGLV6-57,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1F9,IGHV3-15,length=16,IGKV1-NL1,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1D5,IGHV3-23,length=14,IGLV3-21,length=11,RBD,Yes,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1B4,IGHV3-30,length=22,IGKV1-39,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1F2,IGHV3-33,length=11,IGLV2-11,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-2G4,IGHV3-33,length=11,IGLV2-11,length=11,RBD,Yes,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1C8,IGHV3-33,length=13,IGKV2D-30,length=9,RBD,Yes,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2A-1B3,IGHV3-48,length=16,IGKV3-20,length=10,RBD,Yes,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1B11,IGHV3-48,length=16,IGKV3-20,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1B12,IGHV3-48,length=16,IGKV3-20,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1C4,IGHV3-48,length=16,IGKV3-20,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1E11,IGHV3-48,length=16,IGKV3-20,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-2H7,IGHV3-48,length=16,IGKV3-20,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1G12,IGHV3-48,length=16,IGKV3-20,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1E5,IGHV3-48,length=16,IGKV3-20,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1A10,IGHV3-53,length=15,IGKV1-33,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1F5,IGHV3-53,length=14,IGKV1-NL1,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1D7,IGHV3-53,length=12,IGKV2D-30,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1G1,IGHV3-66,length=11,IGKV3-20,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1E1,IGHV3-66,length=9,IGKV3-11,length=10,RBD,No,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1F11,IGHV3-66,length=11,IGKV3-20,length=8,RBD,Yes,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2A-1A8,IGHV3-9,length=23,IGLV2-14,length=10,RBD,Yes,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1B10,IGHV3-9,length=23,IGLV2-14,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1C10,IGHV3-9,length=23,IGLV2-14,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1D3,IGHV3-9,length=23,IGLV2-14,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-2H4,IGHV3-9,length=23,IGLV2-14,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1A5,IGHV3-9,length=23,IGLV2-14,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1A8,IGHV3-9,length=23,IGLV2-14,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1B1,IGHV3-9,length=23,IGLV2-14,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1C12,IGHV3-9,length=23,IGLV2-14,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1A6,IGHV3-9,length=23,IGLV2-14,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2A-1A9,IGHV3-9,length=17,IGLV1-40,length=11,RBD,Yes,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1A1,IGHV3-9,length=17,IGLV1-40,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-2G11,IGHV3-9,length=17,IGLV1-40,length=11,RBD,Yes,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1E12,IGHV3-9,length=17,IGLV3-20,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-2F6,IGHV4-38,length=20,IGLV2-8,length=10,RBD,Yes,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2A-1B10,IGHV4-39,length=20,IGLV1-47,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1B9,IGHV4-39,length=9,IGKV1-NL1,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-2F11,IGHV4-39,length=9,IGKV1-NL1,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1G8,IGHV4-39,length=11,IGKV1-5,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1A1,IGHV4-59,length=14,IGLV2-14,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1D11,IGHV4-59,length=22,IGLV3-25,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1F11,IGHV4-59,length=15,IGKV1-39,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1A7,IGHV5-51,length=17,IGLV3-1,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1A12,IGHV7-4-1,length=16,IGKV1-39,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1G5,IGHV7-4-1,length=12,IGLV3-21,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P3A-1F1,IGHV3-13,length=17,IGKV1-39,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P3A-1G8,IGHV3-64,length=19,IGLV1-44,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-2A10,IGHV1-46,length=26,IGLV1-40,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4B-1F6,IGHV1-69,length=15,IGLV2-23,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4B-1E11,IGHV2-5,length=18,IGLV1-36,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-2A2,IGHV3-23,length=14,IGLV1-51,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-2A8,IGHV3-23,length=11,IGLV3-21,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-2C1,IGHV3-23,length=16,IGKV2-28,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-1H5,IGHV3-30,length=21,IGKV1-39,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4B-1G2,IGHV3-30,length=21,IGKV1-39,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-2B3,IGHV3-30,length=21,IGKV1-39,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-1H6,IGHV3-30,length=21,IGKV1-39,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4B-1G5,IGHV3-30,length=22,IGLV3-21,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-2E10,IGHV3-30,length=21,IGKV1-39,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4B-1E3,IGHV3-30,length=21,IGKV1-39,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-2D9,IGHV3-30,length=21,IGKV1-39,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4B-1F4,IGHV3-30,length=22,IGKV2-30,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4B-1E7,IGHV3-43D,length=20,IGKV3-1,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4B-1F10,IGHV3-7,length=13,IGKV3-21,length=12,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-2D1,IGHV3-9,length=13,IGKV1-12,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-2D2,IGHV4-39,length=16,IGKV3-20,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4B-1E12,IGHV4-59,length=11,IGLV1-44,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-2C12,IGHV5-51,length=15,IGLV1-44,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P8A-1A8,IGHV3-23,length=11,IGLV3-21,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P8A-1C6,IGHV3-30,length=20,IGKV1-33,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P8A-1A5,IGHV5-51,length=18,IGLV1-47,length=12,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P8A-1D5,IGHV6-1,length=16,IGKV3-20,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1A1,IGHV1-24,length=15,IGKV2-28,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1C8,IGHV1-46,length=22,IGKV1-33,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2D5,IGHV1-46,length=24,IGLV1-40,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2C8,IGHV1-46,length=15,IGLV2-23,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2E9,IGHV1-46,length=22,IGLV2-14,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3B8,IGHV1-46,length=16,IGLV2-23,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3A11,IGHV1-69,length=14,IGKV1-39,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3C10,IGHV1-69,length=22,IGLV6-57,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1A2,IGHV1-8,length=21,IGLV1-40,length=12,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1C11,IGHV1-8,length=17,IGLV3-21,length=13,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2F11,IGHV1-8,length=15,IGKV4-1,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3B9,IGHV1-8,length=15,IGKV1-36,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2C12,IGHV2-5,length=16,IGKV3-11,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3C12,IGHV2-5,length=19,IGKV4-1,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3C3,IGHV2-5,length=12,IGLV6-57,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3C1,IGHV3-11,length=13,IGLV3-21,length=13,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1C4,IGHV3-13,length=20,IGKV1-39,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2G8,IGHV3-13,length=13,IGKV1-39,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2D3,IGHV3-13,length=16,IGKV1-39,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3B10,IGHV3-13,length=16,IGKV1-39,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1D8,IGHV3-13,length=18,IGLV3-19,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2G10,IGHV3-13,length=18,IGLV3-19,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2H6,IGHV3-15,length=18,IGLV3-19,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1D6,IGHV3-23,length=13,IGLV3-21,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2E12,IGHV3-23,length=14,IGLV3-21,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3D12,IGHV3-23,length=24,IGLV1-47,length=12,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1B6,IGHV3-30,length=20,IGKV1-33,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2E6,IGHV3-30,length=20,IGKV1-33,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1B1,IGHV3-33,length=14,IGKV3-15,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1C5,IGHV3-33,length=14,IGKV3-15,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2H7,IGHV3-33,length=14,IGKV3-15,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2G9,IGHV3-33,length=12,IGLV5-37,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2G11,IGHV3-33,length=17,IGLV2-14,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1B8,IGHV3-53,length=9,IGKV1-9,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1D2,IGHV3-53,length=15,IGLV1-40,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1D1,IGHV3-53,length=11,IGKV1-9,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2C9,IGHV3-7,length=14,IGKV3-20,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2E4,IGHV3-7,length=14,IGKV3-20,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2G12,IGHV3-7,length=12,IGLV6-57,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2D12,IGHV3-7,length=18,IGKV2-28,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2F1,IGHV3-74,length=12,IGLV6-57,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1C10,IGHV3-9,length=14,IGLV3-21,length=12,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2E8,IGHV3-9,length=13,IGLV3-21,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3A2,IGHV3-9,length=14,IGLV3-21,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2D6,IGHV3-9,length=14,IGLV1-40,length=12,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1B12,IGHV3-9,length=17,IGLV1-51,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3A6,IGHV3-9,length=27,IGLV2-14,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3D9,IGHV3-9,length=16,IGKV3-15,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1D10,IGHV3-11,length=21,IGLV2-14,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3A1,IGHV3-53,length=11,IGKV3-20,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3C8,IGHV3-53,length=11,IGKV1-9,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2D10,IGHV4-31,length=12,IGLV6-57,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2G5,IGHV4-31,length=14,IGLV3-21,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1A12,IGHV4-39,length=17,IGKV4-1,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2C7,IGHV4-39,length=16,IGLV2-23,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2F7,IGHV4-39,length=18,IGLV2-23,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2F9,IGHV4-39,length=14,IGLV2-23,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1A5,IGHV4-4,length=14,IGLV2-14,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1C6,IGHV4-4,length=22,IGLV1-40,length=12,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3A10,IGHV4-4,length=21,IGKV1-39,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1B9,IGHV4-59,length=22,IGKV4-1,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3A7,IGHV4-59,length=22,IGKV4-1,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3B1,IGHV4-59,length=22,IGKV4-1,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3B6,IGHV4-59,length=22,IGKV4-1,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2C10,IGHV4-59,length=17,IGLV3-21,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2E5,IGHV4-59,length=12,IGLV6-57,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2G4,IGHV4-59,length=12,IGKV1D-16,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2G7,IGHV4-61,length=20,IGLV2-14,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1B10,IGHV5-51,length=12,IGKV2-28,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1C9,IGHV5-51,length=11,IGLV3-19,length=12,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2D11,IGHV5-51,length=13,IGLV1-44,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3B4,IGHV5-51,length=13,IGLV1-44,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2H3,IGHV5-51,length=13,IGLV1-44,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2E1,IGHV5-51,length=12,IGLV3-21,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1B11,IGHV7-4-1,length=20,IGKV1-39,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2D7,IGHV7-4-1,length=10,IGKV6-21,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3C9,IGHV7-4-1,length=10,IGKV6-21,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3D11,IGHV7-4-1,length=10,IGKV6-21,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1A3,IGHV1-3,length=11,IGLV6-57,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1A8,IGHV1-46,length=20,IGLV3-21,length=13,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1B5,IGHV1-46,length=13,IGLV3-21,length=12,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1C6,IGHV1-46,length=16,IGLV3-21,length=12,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1C1,IGHV3-13,length=21,IGKV1-39,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1A5,IGHV3-33,length=15,IGKV1-33,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1A12,IGHV3-33,length=19,IGLV1-51,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1B1,IGHV3-74,length=15,IGLV1-36,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1B3,IGHV3-9,length=24,IGLV3-1,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1B12,IGHV4-34,length=16,IGLV1-51,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1B8,IGHV5-51,length=19,IGLV3-1,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1A7,IGHV7-4-1,length=14,IGLV3-21,length=12,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1A10,IGHV7-4-1,length=15,IGLV3-21,length=12,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P22A-1E10,IGHV1-46,length=15,IGKV3-11,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P22A-1D2,IGHV1-8,length=21,IGLV1-40,length=12,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P22A-1D8,IGHV3-23,length=20,IGKV3-15,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P22A-1D7,IGHV3-33,length=13,IGKV1-39,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P22A-1D1,IGHV3-53,length=11,IGKV1-9,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P22A-1E8,IGHV3-9,length=16,IGKV3-15,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P22A-1D5,IGHV4-39,length=14,IGLV2-23,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P22A-1E6,IGHV4-59,length=16,IGKV3-20,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
BD-494,IGHV3-53,ARDLVVYGMDV,IGKV1-9,QQLNSYPFT,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
BD-498,IGHV3-66,ARDLVVYGMDV,IGKV1-9,QQLNSYPLT,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
BD-500,IGHV3-53,ARDAMSYGMDV,IGKV1D-39,QQSYSTPPDT,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
BD-503,IGHV3-53,ARDAAVYGIDV,IGKV1D-39,QQSYTTPLFT,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
BD-504,IGHV3-66,ARDLISRGMDV,IGKV1-9,QQSYTTPLFT,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
BD-505,IGHV3-53,ARDRVVYGMDV,IGKV1D-33,HQYDNLPPT,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
BD-506,IGHV3-53,ARDLVSYGMDV,IGKV1-9,QQLNSYPLT,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
BD-507,IGHV3-53,ARDLVVYGMDV,IGKV1-9,QQLNSNPPIT,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
BD-508,IGHV3-53,ARDAQNYGMDV,IGKV1D-39,QQSYSTPPYT,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CC12.1,IGHV3-53,ARDLDVYGLDV,IGKV1-9,QQLNSYPPKFT,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.2,IGHV3-53,ARDYGDLYFDY,IGKV3-20,QQYGSSPRT,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.3,IGHV3-53,ARDFGDFYFDY,IGKV3-20,QQYGSSPRT,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.4,IGHV1-2,ATESWVYGSGSYSSGAFDI,IGLV2-8,TSYAGSNNFV,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.5,IGHV1-2,ARGPRYSGTYFDY,IGLV2-14,SSYTSSSTQV,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.6,IGHV1-2,ARGPRYSGTYFDY,IGLV2-14,SSYTVSSTQV,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.7,IGHV1-2,ARGPRYSGTYFDF,IGLV2-14,SSYTISSAQV,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.8,IGHV1-2,ARGPRYSGTYFDY,IGLV2-14,SSYTSSSAQL,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.9,IGHV1-2,ARGPRYSGTYFDY,IGLV2-14,SSYTSSSAQV,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.10,IGHV1-2,ARGPRYSGTHFDY,IGLV2-14,SSYAGSSTQV,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.11,IGHV1-2,ARGPRYSGTYFDY,IGLV2-14,SSYTSSSAQL,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.12,IGHV1-2,ARGPRYSGTYFDY,IGLV2-14,SSYTSGSTQV,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.13,IGHV3-53,ARDPYGYSSIWDGQGGH,IGKV1-33,QQYDNLPIT,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.14,IGHV3-21,ARGGYCSDGSCYVQDRLIYYYSGLDV,IGKV2-30,MQGTHWPPT,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.15,IGHV3-48,ARDRRRRYCTNGVCYRPEEIDY,IGLV1-40,QSYDSSLSGVV,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.16,IGHV3-33,ARDPFPGAVAGTGYLQY,IGLV3-21,QVWDSSSDPWV,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.17,IGHV3-30,AKSSGSYYYYYYGMDV,IGLV3-21,QVWDSSSDHPVV,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.18,IGHV1-46,ARLHCGGDCYLDY,IGLV6-57,QSYDSSNHEEIWV,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.19,IGHV3-23,AKGSGSGSYPNYYYYYGMDV,IGLV3-21,QVWDNNSDHLV,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.20,IGHV3-30,AKDQAYYDILTGYLNPPKNYYYYGMDV,IGLV1-47,AAWDDSLSGRVV,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.21,IGHV1-24,ATAFSIFGVVPPDY,IGLV1-44,AAWDDSLNGPV,RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.22,IGHV1-24,ATGFAQNMVLLTPY,IGKV3-15,QQYNNWPPIT,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.23,IGHV4-39,ARQGDCSTTSCAYDY,IGLV3-25,QSADSSGTYLVV,non-RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.24,IGHV3-30,AKDRTGNYYYGMDV,IGKV1-39,QQSYSTPWT,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.25,IGHV3-23,AKDRYYEFWSGYSNWFDP,IGLV1-44,AAWDDSLNGPV,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.26,IGHV5-51,ARVNYYDSSGYPSFHFDY,IGLV7-43,LLYYGGAQRWV,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.27,IGHV1-2,AREMPAAMGYYYYGMDV,IGLV2-23,YSYAGSSTFVFV,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.28,IGHV3-23,AKANKYSSSEFDF,IGLV1-47,AAWDDSLSGWV,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC6.29,IGHV7-4-1,AVYYYDSGSPGWFDP,IGKV1-39,QQSYSTPPT,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC6.30,IGHV1-69,ARDFRYCSSTRCYFWFDP,IGKV1-39,QQSYSTPRT,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC6.31,IGHV1-46,ARWYDSTGSIDY,IGKV1-17,LQHNSYPILT,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC6.32,IGHV3-9,AKDQGYSYGNYFDY,IGLV3-21,QVWDSSSDHPYV,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC6.33,IGHV1-69,ALRNQWDLLVY,IGKV3-20,QHYGSSLWT,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
COVA1-01,IGHV4-39,ARVSSGYYFTPFDY,IGKV3-20,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-02,IGHV3-30,ARARGGSYNDAFDI,IGLV2-14,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-03,IGHV3-30,AKDGQYYDFWSGYLGARTNPHYYYYMDV,IGKV1-27,-,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-04,IGHV1-69,ARIPGYDSSGYYRGDY,IGKV3-11,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-05,IGHV1-24,ATSRVRGVSNWFDP,IGLV2-23,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-06,IGHV3-9,AKDMGEAVAGTHYGMDV,IGLV3-1,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-07,IGHV1-69,ARVGAYDSSGYSNDY,IGKV3-11,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-08,IGHV3-30,AREDYYDSSGSFDY,IGLV2-14,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-09,IGHV4-59,ARHSQGWLQQAVAFDI,IGKV1-39,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-10,IGHV3-66,ARGGYYYDPSGYYSRSFSFDY,IGLV2-14,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-11,IGHV3-30,ARSASGSYYGAFGY,IGLV3-1,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-12,IGHV1-2,ARDLVWATVSGTMDV,IGLV2-8,-,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-13,IGHV3-7,ARETPTSTYSSGWYNYYYYMDV,IGKV1-5,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-14,IGHV4-59,ARRGEVNGYRGAFDI,IGKV3-20,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-15,IGHV3-30,ARPRGGNYLAGFDP,IGLV2-14,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-16,IGHV1-46,ARPPRNYYDRSGYYQRAEYFQH,IGKV1-33,-,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-17,IGHV1-2,AREAVAARPGNFDY,IGLV1-51,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-18,IGHV3-66,ARVEWAAAGTFY,IGLV7-46,-,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-19,IGHV3-21,ARWKSDYYDSSGYYPAAFDI,IGKV3-15,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-20,IGHV3-21,AGDQNLYCSGDSCYYHYYGMDV,IGLV3-21,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-21,IGHV3-30,ARDSEYYDILTGYLAPTHYYYYYMDV,IGKV3-15,-,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-22,IGHV1-18,ARDLVDTAMVQTLDDYGMDV,IGLV3-1,-,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-23,IGHV5-51,ARYYYDSRGYTSIDF,IGLV3-25,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-24,IGHV3-33,ARGPPPDDSSGWTMGYFDY,IGLV1-51,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-25,IGHV4-39,ARLNYDFWSGYYSYALYYMDV,IGKV1-5,-,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-26,IGHV4-31,ARQQLDYYDSSGCFDY,IGKV1-9,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-27,IGHV3-30,ARAMGSYRSPFDY,IGKV3-20,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-01,IGHV3-13,ARGGDRYPVGYFDL,IGKV1-39,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-02,IGHV4-39,ARRSTSRWGYYYMDV,IGKV1-39,-,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-03,IGHV3-48,AREANSDFWSGYLGYFDY,IGKV3-11,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-04,IGHV3-53,ARDLERAGGMDV,IGKV3-20,-,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-05,IGHV5-51,ARHMRPSIAARPGYQYYMDV,IGKV1-33,-,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-06,IGHV4-59,ARGGWSLDS,IGKV3-20,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-07,IGHV3-53,AREAYGMDV,IGKV3-20,-,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-08,IGHV3-30,ARVIGGNYFGAFDI,IGKV3-15,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-09,IGHV4-34,ARGRNYVLQFSEWPHPRAHFDN,IGKV4-1,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-10,IGHV3-23,AKGLRGQQLVIPTEYFQH,IGKV3-20,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-11,IGHV3-21,ARGPRGCSSTSCYGSYFDY,IGKV3-20,-,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-12,IGHV3-53,ARDQPLPDILTGYYTGPLDY,IGKV3-15,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-13,IGHV1-69,ARDLDTMGGMDV,IGKV3-20,-,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-14,IGHV1-69,ARVRYYDSSGYYEDY,IGKV3-11,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-15,IGHV3-23,AKDTGYCGDDCYIKLIRGGPDY,IGKV2-30,-,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-16,IGHV1-69,ASSDSSGFVGSRGFDY,IGKV1-17,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-17,IGHV1-69,ASFGDDSGDEGVR,IGKV3-11,-,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-18,IGHV1-69,ARVYSYDSSGYYLEY,IGKV3-11,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-19,IGHV1-18,ASVVGGRIAAAGCLGY,IGKV3-20,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-20,IGHV3-53,ASPLLLTPPDYYYYMDV,IGKV1-17,-,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-21,IGHV4-4,ARWKYNDRFDY,IGKV1-5,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-22,IGHV1-69,ARGPRYCSSTSCYAGVYFDY,IGKV1-33,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-23,IGHV1-2,ARDGFGDVEEMATIKDAFDI,IGKV3-20,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-24,IGHV5-10,ARPNPAGGYDSSGWVDAFDI,IGKV1-39,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-25,IGHV1-24,ATGPTIAAAATNWFDPG,IGLV2-14,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-26,IGHV3-15,TTDRGDSYGYYYCMDV,IGLV3-1,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-27,IGHV1-8,ARVVGSSWYPVDAFDI,IGLV2-14,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-28,IGHV3-30,AKDKAPPCSSGWYYFDY,IGKV3-15,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-29,IGHV4-30,ARGVEDPVVPAAIPWCWFDP,IGKV1-39,-,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-30,IGHV3-30,ASLPVVPAAIGPLPAFDI,IGLV3-21,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-31,IGHV1-2,RKMLTIFGKVNQTMLLISGAKGQ,IGKV2D-29,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-32,IGHV1-69,ARTHSYDNSGQYFDY,IGKV3-11,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-33,IGHV5-10,ARLKVITIFGVVRDDYGMDV,IGLV2-23,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-34,IGHV3-30,ARSASGSYYGAFDY,IGLV2-14,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-35,IGHV3-33,ARDGSNESCSGGFCSDS,IGLV3-21,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-36,IGHV5-51,ARHNPDYYDSSGPLDY,IGKV1-5,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-37,IGHV1-24,ATSPAVMSVGWVDP,IGLV1-40,-,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-38,IGHV4-39,ARQVRQWLEDDAFDI,IGKV1-17,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-39,IGHV3-53,ARAHVDTAMVESGAFDI,IGLV2-23,-,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-40,IGHV4-4,AGRYCSGGRCGWFDP,IGLV2-23,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-41,IGHV3-21,ARVQKDIVVVPVALADYYYYGMDV,IGKV3-15,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-42,IGHV4-31,AKEGSGGGSQNWFDL,IGKV3-11,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-43,IGHV1-18,ARFDYGYPYSSWSVLSIDY,IGKV1-17,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-44,IGHV3-30,AREGSRQWLVIYFDY,IGKV1-39,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-45,IGHV1-2,ARGDGDYYDSSGYYRPTLYNWLDP,IGKV3-20,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-46,IGHV4-39,ARHPSGLYQLLN,IGKV1-33,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-47,IGHV3-9,AKVATYYYDRSGYYYGGALDY,IGKV4-1,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA3-01,IGHV4-59,ARGPAATYYYYMDV,IGKV1-39,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA3-02,IGHV3-7,ARDWEEQWLVAFDY,IGLV3-1,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA3-03,IGHV3-23,AKEIAVAGCFDY,IGLV3-25,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA3-04,IGHV3-33,ARVGSVKSTAGYDFWSGDPFDY,IGLV3-21,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA3-05,IGHV1-24,ATAYSVDTAMVRGVGY,IGLV1-44,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA3-06,IGHV1-69,ARDAPDYYDSSGPTYFDY,IGKV4-1,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA3-07,IGHV3-9,AKMGPDPAHDYGRKNDAFDI,IGKV3-20,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA3-08,IGHV3-9,AKAEPEVGGYDYYMDV,IGKV1-39,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA3-09,IGHV4-59,ARGPAATYYYYMDV,IGKV1-39,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA3-10,IGHV5-51,ARRGYTYGADFYGLDV,IGKV4-1,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
B5,IGHV1-2,-,IGKV3-20,-,RBD,Yes,SARS-2_infection,Wu et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. DOI: 10.1126/science.abc2241
B38,IGHV3-53,AREAYGMDV,IGKV1-9,QQLNSYPPYT,RBD,Yes,SARS-2_infection,Wu et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. DOI: 10.1126/science.abc2241
H2,IGHV3-9,-,IGKV1-39,-,RBD,Yes,SARS-2_infection,Wu et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. DOI: 10.1126/science.abc2241
H4,IGHV1-2,ARVPYCSSTSCHRDWYFDL,IGKV2-40,MQRIEFPLT,RBD,Yes,SARS-2_infection,Wu et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. DOI: 10.1126/science.abc2241
1M-1D2,IGHV3-64,ARGAEYYDFWSGYYSAYFDY,IGLV1-47,SMGAQPDLCA,RBD,Yes,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-13A3,IGHV3-30,ARGGGSYYYWFDP,IGKV4-1,QQYYST,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-13D11,IGHV4-34,ARAGYSSSWYGVRGVDP,IGKV3-20,QQYGSSRSWT,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-14B2,IGHV3-30,AKGSDIVVVPVGNWFDP,IGKV1-39,QQSYSTFTLYT,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-10B11,IGHV3-66,ARATWLRGVMDV,IGLV6-57,QSYDSSNHWV,RBD,No,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-14E4,IGHV4-61,ARVQRYYPDSSGFYGRRFDI,IGKV1-39,QQSHSFPFT,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-14E5,IGHV3-30,ARSGGGSYRGPFDY,IGKV1-9,QQLNSYVT,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-2D4,IGHV3-23,AKIGLGLGGLLRRYFDY,IGKV3-11,QQRTNWPL,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-2G12,IGHV3-11,DANYDYVVAQTGYGR,IGKV1-39,QQNYSTWT,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-4G4,IGHV1-46,ARERGDSSGYYEIITTANRRFGMDV,IGLV2-23,CSYAVSSTWV,RBD,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-2D1,IGHV4-39,ARGDRIQLWLLDAFDI,IGLV1-47,CSTGAQPEWLG,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-7E9,IGHV1-69,ARIPGWDRGTDRNWNDD,IGKV3-11,QQRSNWPPAFT,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-8E7,IGHV1-69,ARTYSFDSSGYYYDY,IGKV3-11,QQHSNWPPKIT,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-8H10,IGHV3-30,ARAFYDSNWSVGSYFDS,IGKV4-1,QQYYNNQWT,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-9F10,IGHV3-9,AKDSVRREYTHARVPFDN,IGKV1-39,QQSFVSPRT,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-9H1,IGHV3-30,AKSSKIFYLGESREVDY,IGKV1-17,LQHKSYPLT,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-12D7,IGHV3-9,AKDVRYCSSTSCYFSAFDI,IGKV1-39,QQSYSTPRT,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0304-2F8,IGHV5-51,ARRGDGLYYYGMDV,IGKV2-28,MQALQTPQT,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0304-3H3,IGHV4-59,ARDRIAPVGKFFGWYFDL,IGKV3-15,QQYNKWPPWT,S2,Yes,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0304-4A2,IGHV4-39,ARELFTAVAGKGGIDY,IGKV4-1,HQYYNTPRT,S1,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0304-4A10,IGHV3-64,ARSSSRGFDY,IGKV4-1,QQYYSSPYA,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0317-A1,IGHV3-30,AKDFKGGSSSWYTPEIEYGMDV,IGKV3-11,QQRSNWPPT,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0317-A2,IGHV7-4-1,ARLIRHEAHTYCSGGSCYSPDYYYGMDV,IGKV1-39,QQSYSTPPT,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0317-A3,IGHV3-48,ASNPPLGEPYFDI,IGKV1-39,QQTYRPPWT,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0317-A7,IGHV3-30-3,ARWGGGMQYLDV,IGKV2-28,MQTLQTPYT,S1,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0317-A8,IGHV7-4-1,ARAGPNYDFWSGYYQTFDY,IGKV1-33,QQYDNLPLT,S1,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0317-A9,IGHV1-24,ATATAMDGYYYYYGMDV,IGKV2-24,MQATQFPYT,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0317-B1,IGHV5-51,ASAGSSWYGDAFDI,IGKV4-1,QQYYSTYGS,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0317-C4,IGHV1-24,ATATIFGVANNWFDP,IGLV1-51,GTWDSSLSVVV,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0317-C9,IGHV3-30,AKDLGYYDILTGQLGGYYYYYGMDV,IGLV1-44,AAWDDSLNGVV,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
4A8,IGHV1-24,ATSTAVAGTPDLFDYYYGMDV,IGKV2-24,TQATQFPYT,NTD,Yes,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
9A1,IGHV3-30,AKVSAIFWLGQGLSPIDV,IGKV3-15,HQYSKWPVT,S2,No,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
8D2,IGHV3-7,ARDWDYDILTGSWFGAFDI,IGKV1-17,LQHNSYPLT,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
8D9,IGHV3-7,ARPTIGYSYGSDY,IGLV3-1,QAWDSSTGV,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
10C10,IGHV3-7,ARDWDYDILTGSWFGAFDI,IGKV1-17,LQHNNYPLT,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CV1,IGHV4-38-2,-,IGLV1-44,-,non-RBD,Yes,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV2,IGHV3-30,-,IGKV3-15,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV3,IGHV7-4-1,-,IGKV1-39,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV4,IGHV3-30,-,IGKV1-5,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV5,IGHV1-46,-,IGKV4-1,-,RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV7,IGHV3-30,-,IGKV1-5,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV8,IGHV1-18,-,IGKV3-20,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV9,IGHV4-39,-,IGLV2-14,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV10,IGHV4-59,-,IGKV3-20,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV11,IGHV4-31,-,IGKV3-11,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV12,IGHV3-30,-,IGKV2-30,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV13,IGHV7-4-1,-,IGKV1-39,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV15,IGHV3-7,-,IGLV2-11,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV16,IGHV5-51,-,IGKV3-20,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV17,IGHV1-2,-,IGLV2-23,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV18,IGHV1-24,-,IGLV1-51,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV19,IGHV1-2,-,IGKV3-20,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV21,IGHV3-15,-,IGKV3-11,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV22,IGHV3-21,-,IGLV4-69,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV23,IGHV1-3,-,IGLV3-25,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV24,IGHV1-24,-,IGLV1-51,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV25,IGHV4-30-4,-,IGKV3-15,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV26,IGHV3-30-3,-,IGKV1-17,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV27,IGHV3-30,-,IGLV2-14,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV30,IGHV3-53,-,IGKV3-20,-,RBD,Yes,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV31,IGHV1-24,-,IGLV1-51,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV32,IGHV1-2,-,IGLV1-51,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV33,IGHV1-18,-,IGLV1-40,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV34,IGHV3-30-3,-,IGLV3-12,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV35,IGHV4-38,-,IGLV1-44,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV36,IGHV1-2,-,IGLV3-25,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV37,IGHV1-18,-,IGKV1-33,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV38,IGHV3-30,-,IGKV3-11,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV39,IGHV3-30,-,IGKV2-30,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV40,IGHV1-18,-,IGKV1-17,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV41,IGHV3-30,-,IGKV3-15,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV42,IGHV1-18,-,IGKV1-39,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV43,IGHV3-30,-,IGLV6-57,-,RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV44,IGHV1-46,-,IGLV3-25,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV45,IGHV1-18,-,IGLV1-40,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV46,IGHV3-30,-,IGKV2-30,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV47,IGHV1-18,-,IGKV1-17,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV48,IGHV1-69,-,IGKV2-30,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV50,IGHV3-33,-,IGLV3-10,-,non-RBD,-,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CA1,IGHV1-18,AREGYCSGGSCYSGYYYYYGMDV,IGKV3-11,QQRRNWGT,RBD,Yes,SARS-2_infection,Shi et al. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2. Nature. DOI: https://doi.org/10.1038/s41586-020-2381-y
CB6,IGHV3-66,ARVLPMYGDYLDY,IGKV1-39,QQSYSTPPEYT,RBD,Yes,SARS-2_infection,Shi et al. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2. Nature. DOI: https://doi.org/10.1038/s41586-020-2381-y
515-1,-,ARDFISRPRGYR,-,-,RBD,Yes,SARS-2_infection,Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
505-5,-,ARDFISRPRGYR,-,-,RBD,Yes,SARS-2_infection,Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
413-2,-,ARDNNYRNYYYYMDV,-,-,non-RBD,Yes,SARS-2_infection,Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
414-2,-,ARESRDYYDSSGLASRYFDL,-,-,RBD,No,SARS-2_infection,Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
553-49,-,AKDSSSWYNYYGMDV,-,-,RBD,Yes,SARS-2_infection,Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
505-3,-,ARDFISRPRGYR,-,-,RBD,Yes,SARS-2_infection,Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
553-15,-,ARVWYYYGPRDY,-,-,RBD,Yes,SARS-2_infection,Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
105-38,-,ARVQWLRGEFDY,-,-,RBD,No,SARS-2_infection,Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
415-5,-,ARAVYYYDSSGYPYAEDYFDY,-,-,RBD,No,SARS-2_infection,Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
553-20,-,ATAPVRRLGWFDP,-,-,RBD,No,SARS-2_infection,Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
105-9,-,TRDPWGTTYFDY,-,-,RBD,No,SARS-2_infection,Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
553-63,-,ARMEAPKLTLDP,-,-,RBD,Yes,SARS-2_infection,Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
414-1,-,ARGALGCSSTSCYPNNFDY,-,-,RBD,Yes,SARS-2_infection,Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
C105,IGHV3-53,ARGEGWELPYDY,IGLV2-8,SSYEGSNNFVV,RBD,Yes,SARS-2_infection,Barnes et al. Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies. doi: https://doi.org/10.1101/2020.05.28.121533
COV072_P3_HC_50-P1369,IGHV3-23,ANHPLASGDEYYYYYMDV,IGKV3-20,QQYGSSRALT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_24-P1369,IGHV3-23,ANHPLASGDDYYHYYMDV,IGKV3-20,QQYGSSRALT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_66-P1369,IGHV3-23,ANSPCSSASCKSGYYYYYMDV,IGKV3-20,QQYGSSRSLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_49-P1369,IGHV1-46,ARSRPTPDWYFDL,IGLV3-21,QVWDSSSDHPGVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_81-P1369,IGHV1-46,AKSRPTPDWYFDL,IGLV3-21,QVWDGGSDHPGVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_17-P1369,IGHV1-69,ARVNQAVTTPFSMDV,IGKV3-15,QQYNNWPIT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_21-P1369,IGHV1-69,ARANQPVTTPFSMDV,IGKV3-15,QQYNNWPIT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_51-P1369,IGHV3-23,AKDPLITGPTYQYFHY,IGLV3-21,QVWDSSSDRPGVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_93-P1369,IGHV3-23,AKDPLITGPTYQYFHY,IGLV3-21,QVWDSSSDRPGVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_53-P1369,IGHV3-30-3,ARDSDVDTSMVTWFDY,IGKV1-39,QQSYSTPPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_83-P1369,IGHV3-30-3,ARDSDVDTAMVTWFDY,IGKV1-39,QQSYSTPPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_80-P1369,IGHV3-66,ARDLGDYGMDV,IGKV1-9,QQLNSYPPYT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_36-P1369,IGHV3-66,ARDLYYYGMDV,IGKV1-9,QQLNSYSYT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_12-P1369,IGHV3-7,ARALQGPWLGADY,IGLV6-57,QSYDSSKGV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_33-P1369,IGHV3-7,AGGTWLRSSFDY,IGLV6-57,QSYDSSNWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_25-P1369,IGHV4-4,ARGGDTAMGPEYFDY,IGLV2-14,SSYTSSSTLL,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_53-P1369,IGHV4-4,AKGGDRAMGPEYFDY,IGLV2-14,SSFTSSSTLL,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_9-P1369,IGHV1-18,ARDGITGTIEYYFDY,IGKV3-11,QQRSNWPPGVT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_44-P1369,IGHV1-18,ARVLGIIVAGSLN,IGLV6-57,QSYDSSTWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_34-P1369,IGHV1-24,ATNAEIAARKGGMDV,IGKV2-28,MQALQTPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_40-P1369,IGHV1-46,ARDLGYIPASDAFDI,IGLV2-11,CSYAGSYTRYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_10-P1369,IGHV1-46,ARDIALVPAAMGLDY,IGKV1-39,QQSYRTRLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_42-P1369,IGHV1-58,AAVDCNSTSCYDAFDI,IGKV3-20,QQYDISPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_31-P1369,IGHV1-69,AKVSLTLPIAAAPRFWFDS,IGKV3-15,QQYHNWPPALT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_30-P1369,IGHV1-69,ARGVVAATPGNFDI,IGKV3-15,QQYNNGLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_48-P1369,IGHV1-69,ARDLLDPQLDDAFDI,IGKV3-20,QQYGSSPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_40-P1369,IGHV1-69,ARGGYSYGQLYYFDY,IGKV3-20,QQYANSRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_77-P1369,IGHV1-69,ARFSNYCTSTSCYDY,IGLV1-40,QSYDSSLSGSV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_58-P1369,IGHV3-11,ARDRGYSGYGLDRFDY,IGKV1-33,QQYDNLPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_64-P1369,IGHV3-11,ARDNITMVRGVIVRPNDGGYYYALDV,IGKV1-39,QQSYSTRALT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_55-P1369,IGHV3-15,TTDYSIRYYYGMDV,IGLV3-25,QSADSSGTYEV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_38-P1369,IGHV3-21,ARAKLEIAHYGGSPGFDY,IGLV3-1,QAWDSSTGVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_36-P1369,IGHV3-21,ARMGLELPGLDYGMDV,IGLV1-36,AAWDDSFNGPV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_94-P1369,IGHV3-23,AKVDYGEYVFSNAFDI,IGLV2-23,CSYAGTSTYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_5-P1369,IGHV3-23,AKSKTVERLPYCGGDCFSAIDY,IGKV1-33,QQYDNLPPFT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_92-P1369,IGHV3-23,AKAGPAAAYGWYYYYMDV,IGKV1-27,QKYNSALGFT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_15-P1369,IGHV3-30,AKGPRFGWSYRGGPGFDI,IGKV1-33,QQYDNLPIT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_45-P1369,IGHV3-30,ASSSGYLFHSDY,IGKV1-5,QQYNSYPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_31-P1369,IGHV3-30,AKGPRFGWSYRGGSGFDI,IGKV1-33,QQYDNLPIT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_3-P1369,IGHV3-30,AKQLGLYCSGGNCYSGALDY,IGKV1-33,QQYDNLPFT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_37-P1369,IGHV3-30,AKQNGLYCSGGSCYLGYFDY,IGKV1-33,LQYDNLPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_56-P1369,IGHV3-30,AKAGGRDYYDSSGYYLLDHYYGMDV,IGLV1-40,QSYDSSLSGFYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_63-P1369,IGHV3-30,AKGGAYSYYYYMDV,IGKV1-33,QQYDNLPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_69-P1369,IGHV3-30-3,ARDSDTAMVDYFDY,IGKV1-39,QQSYSTFMYT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_74-P1369,IGHV3-30-3,AKVDLKYSYGLYYFDY,IGKV1-39,QQTYITPPS,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_12-P1369,IGHV3-30-3,ASSSGYLFHFDY,IGKV1-5,QQYNSYPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_54-P1369,IGHV3-30-3,ARNDGSSGWYPERGGGFDY,IGLV1-40,QSYDSSLSGLWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_94-P1369,IGHV3-30-3,ARALSFIAVAGIDY,IGLV6-57,QSYDSTTHVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_91-P1369,IGHV3-30-3,ARADLGYCTNGVCYVDY,IGLV6-57,QSYDSSNWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_23-P1369,IGHV3-30-3,ARVRLGAYYNYFGMDV,IGKV2-28,MQALQTFT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_68-P1369,IGHV3-30-3,AKKGQPYCGGDCYFYYFDY,IGKV1-33,QQYDNLPPIT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_72-P1369,IGHV3-33,ARDGTGIAAAGTANPPFDY,IGKV1-33,QQYDNLPYT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_25-P1369,IGHV3-33,ATSLFGIISLDY,IGKV1-6,LQDYNYPYT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_54-P1369,IGHV3-33,ARDWEIVVAGMDV,IGKV2-30,MQGTHCPFT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_71-P1369,IGHV3-33,ARGEWDSGSYQYYDYYMDV,IGLV8-61,VLYMGSSNWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_78-P1369,IGHV3-43,AKGLNYRPQYYYYYGMDV,IGKV2-28,MQALQTPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_26-P1369,IGHV3-53,ARSFYFDAFDI,IGKV1-9,QQLNSYPLLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_67-P1369,IGHV3-53,TRDPVPGRGDAY,IGKV1-33,QQYDNLPIT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_1-P1369,IGHV3-53,ARVVGYDFWSGYDGGYFDY,IGLV2-23,CSYAGSSTWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_89-P1369,IGHV3-53,ARDLYYYGMDV,IGKV1-9,QQLNSYPT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_22-P1369,IGHV3-64D,VKDITMIVDVFEY,IGKV1-39,QQSYTTPYT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_47-P1369,IGHV3-66,ARDIAGRLDY,IGKV1-33,QHYDSLSRLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_59-P1369,IGHV3-66,ARDLVVYGADY,IGKV1-9,QQLNSYPPP,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_16-P1369,IGHV3-66,ARDLQYYGMDV,IGKV1-9,QQPDSFT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_14-P1369,IGHV3-66,ASHLMPDAFDI,IGLV2-23,CSYGGSSTSFYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_37-P1369,IGHV3-7,ARDQVSWYNLDAFDI,IGKV2-30,MQGTHWPKT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_5-P1369,IGHV3-7,ARDTGRITFGGGDDAFDI,IGLV3-21,QVWDSSSDHRV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_86-P1369,IGHV4-30-4,VRVVMSGIAAAGQNDY,IGKV1-33,QQYDILPPMYT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_32-P1369,IGHV4-30-4,ARTYYYDSSGYYFQYYFDC,IGKV3-20,QQYGSSPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_67-P1369,IGHV4-31,ATNYDDYVPAEYFQD,IGKV3-11,QQRSNWPPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_88-P1369,IGHV4-31,ARSCSSTSCPFDY,IGKV1-33,QQYDNLPFT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_71-P1369,IGHV4-31,ARGVVLITDYYFDY,IGLV3-25,QSADSSGTR,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_73-P1369,IGHV4-34,AREGAVAGGDFDY,IGLV3-21,QVWDGTSDHPGWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_74-P1369,IGHV4-39,ARRPPGDYYYMDV,IGKV1-39,QQSYSIPQIT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_Plate2_HC_76-P1369,IGHV4-59,ARGRGLPPWFDP,IGLV6-57,QSYDSSNVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_18-P1369,IGHV4-59,ARPDMSSSSSPHYWYFDL,IGLV3-21,QVWDSSSGHFHVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_84-P1369,IGHV5-51,ARRGGSYYNNGDGMDV,IGLV3-1,QAWDSSTPHVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV072_P3_HC_4-P1369,IGHV6-1,ARSGSYYISHGMDV,IGKV3D-15,QQYNNWPPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_B4-1369,IGHV5-51,ARGVAVDWYFDL,IGLV1-40,QSYDSSLSALYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_F6-1369,IGHV5-51,ARGVAVDWYFDL,IGLV1-40,QSYDSSLSALYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_G8-1369,IGHV5-51,ARGVAVDWYFDL,IGLV1-40,QSYDSSLSALYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_A2-1369,IGHV5-51,ARGVAVDWYFDL,IGLV1-40,QSYDSSLSALYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_B2-1369,IGHV5-51,ARGVAVDWYFDL,IGLV1-40,QSYDSSLSALYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_B12-1369,IGHV5-51,ARGVAVDWYFDL,IGLV1-40,QSYDSSLSALYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_C10-1369,IGHV5-51,ARGVAVDWYFDL,IGLV1-40,QSYDSSLSVLYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_D10-1369,IGHV5-51,ARGVAVDWYFDL,IGLV1-40,QSYDSSLSALYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_E1-1369,IGHV5-51,ARGVAVDWYFDL,IGLV1-40,QSYDSSLSALYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_F3-1369,IGHV4-59,AREVVVQSAKDWSHYYYYMDV,IGKV3-11,QQRSSWFVT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_A6-1369,IGHV4-59,AREVVVSSPKDWSHYYYYMDV,IGKV3-11,QQRSTWFVT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_B11-1369,IGHV4-59,AREVVVQSAKDWSHYYYYMDV,IGKV3-11,QQRSSWFVT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_D11-1369,IGHV4-59,AREVVVQSAKDWSHYYYYMDV,IGKV3-11,QQRSSWFVT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_F10-1369,IGHV4-59,AREVVVQSAKDWSHYYYYMDV,IGKV3-11,QQRSSWFVT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_B11-1369,IGHV1-69,ARDSEYSSSWYSRGYYGMDV,IGKV2-28,MQALQTPPT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_A11-1369,IGHV1-69,ARDSEYSSSWYSRGYYGMDV,IGKV2-28,MQALQTPPT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_E2-1369,IGHV1-69,ARDSEYSSSWYSRGYYGMDV,IGKV2-28,MQALQTPPT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_B7-1369,IGHV3-7,ARQPESTIWYYFDY,IGLV3-25,QSADSSGSYVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_F5-1369,IGHV3-7,ARQPESTIWYYFDY,IGLV3-25,QSADSSGSYVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_H2-1369,IGHV3-7,ARQPESTIWYYFDY,IGLV3-25,QSADSSGSYVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_D12-1369,IGHV4-34,ARRRSFSRPSSIDY,IGKV2-28,MQALQTLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_B6-1369,IGHV4-34,ARRRSFSRPSSIDY,IGKV2-28,MQALQTLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_H7-1369,IGHV4-34,ARRRSFSRPSSIDY,IGKV2-28,MQALQTLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_E6-1369,IGHV1-58,AANHCSGGSCYDGFDI,IGKV3-20,QQYGSSPWM,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_H6-1369,IGHV1-58,AAPYCSGGSCNDAFDI,IGKV3-20,QQYGSSPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_A10-1369,IGHV3-15,TTDPHCSSTSCPIFYYYYMDV,IGLV3-21,QVWDSSSDQGV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_C4-1369,IGHV3-15,TTDPHCSSTSCPIFYYYYMDV,IGLV3-21,QVWDSSSDQGV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_E9-1369,IGHV3-30,AKSPMGYCTNGVCYPDS,IGLV6-57,QSYDINSRWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_G5-1369,IGHV3-30,AKSPMGYCTNGVCYPDS,IGLV6-57,QSYDINSRWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_F10-1369,IGHV4-34,ARAGFGVVITYGSGTDPLFDY,IGLV1-40,QSYDSSLSGSRV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_H3-1369,IGHV4-34,ARAGFGVVITYGSGTDPLFDY,IGLV1-40,QSYDSSLSGSRV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_A5-1369,IGHV1-2,AREYLERYFDGGQRWISYYYMDV,IGLV2-14,SSYTPNSTLVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_A9-1369,IGHV1-46,AREIPDILEVVAATGSLDD,IGLV2-8,SSYAGITNLV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_A11-1369,IGHV1-69,ARDSEYSSSWYSRGYYGMDV,IGLV2-8,YSYGGNNNAV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_B1-1369,IGHV1-69,ARDSGYSGYGSTYYMDV,IGLV1-40,QSYDSSLSGSV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_F11-1369,IGHV1-69,ARDSEYSSSWYSRGYYGMDV,IGKV2-28,MQALQTPPT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_G11-1369,IGHV1-69-2,ARSGPDYFDY,IGKV3-15,QQYNNWPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_C12-1369,IGHV3-13,ARGTTFNHYYYMDV,IGKV1-39,QQSYSTPPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_C3-1369,IGHV3-15,TTDVGADSSSAYYYYYMDV,IGKV3D-20,QQYGSSPYT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_E11-1369,IGHV3-21,ARDVASNYAYFDL,IGKV3-15,QQYDNWPL,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_H12-1369,IGHV3-23,AKDTGSMIVELLGY,IGLV1-40,QSYDTSLRVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_B8-1369,IGHV3-49,TRARSVTMVWYRYYMDV,IGKV2D-29,MQSIQLPYT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_C2-1369,IGHV3-64,AREGPFLPSLYSSSRDAFDI,IGLV3-21,QVWDSSSDPHYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_C8-1369,IGHV3-64,ARGPIAAAGSYFDY,IGLV3-21,QVWDSSSDPHWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_F9-1369,IGHV3-66,ARDLAVYGMDV,IGKV1-9,QQLNSYPPVT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_C3-1369,IGHV3-66,ARDGEGQRETDY,IGKV1-33,QQYDNLPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_G3-1369,IGHV3-74,TRDDSSWPHFFDN,IGKV1-39,QQSYSSPLWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_B7-1369,IGHV3-74,TRDDSSWPHFFDN,IGKV3-15,QQYDNWPL,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_H10-1369,IGHV4-34,ARAYVSSVSEDYFDY,IGKV1-39,QQSYTTPYT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P1_HC_B9-1369,IGHV4-34,ARHWMPRDYYYYGMDV,IGKV1-39,QQSYSTPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_E3-1369,IGHV4-34,ARGAKGDSDWYFDL,IGKV3-11,QQGDNWPRMYT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_F8-1369,IGHV4-59,ARHYDILTALSWFDP,IGLV1-51,GTWDSSLSAYWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_H11-1369,IGHV4-59,ARLLSTEWLFNWFDP,IGLV3-1,QAWDSSTAYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD57_P2_HC_A9-1369,IGHV5-51,ARGIAVDWYFDL,IGLV2-14,SSYRGSSTPYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_9-P1369,IGHV3-53,ARDWGEYYFDY,IGKV3-20,QQYGSSPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_36-P1369,IGHV3-53,ARDYGDYYFDY,IGKV3-20,QQYGSSPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_40-P1369,IGHV3-53,ARDWGEYYFDY,IGKV3-20,QQYGSSPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_13-P1369,IGHV3-53,ARDYGDYYFDY,IGKV3-20,QQYGSSPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_93-P1369,IGHV3-53,VRDYGDFYFDY,IGKV3-20,QQYGSSPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_11-P1369,IGHV4-34,ARKPLLYSDFSPGAFDI,IGKV3-20,QQYHTTPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_42-P1369,IGHV4-34,ARKPLLYSNLSPGAFDI,IGKV3-20,QQYGTTPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_84-P1369,IGHV4-34,ARKTLLFSDFSPGAFDI,IGKV3-20,QQYGTTPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_31-P1369,IGHV4-34,ARKPLLHSDLSPGAFDI,IGKV3-20,QQYVTTPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_53-P1369,IGHV4-34,ARKPLLYSDFSPGAFDI,IGKV3-20,QQYTTTPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_29-P1369,IGHV3-53,ARGEGWDLPYDY,IGLV2-8,SSYAGSNNFVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_35-P1369,IGHV3-53,ARGEGWDLPYDY,IGLV2-8,SSYAGSNNFVL,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_4-P1369,IGHV3-53,ARGEGWELPYDY,IGLV2-8,SSYEGSNNFVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_63-P1369,IGHV1-18,ARGEAVAGTTGFFDY,IGLV1-47,AAWDDSLSGFVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_68-P1369,IGHV1-18,ARGEAVAGTTGFFDY,IGLV1-47,AAWDDSLSGFVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_13-P1369,IGHV1-2,ARDVIVSMVRGVIFRMDV,IGLV1-44,AAWDDSLNGVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_27-P1369,IGHV1-2,ATAHPRRIQGVFFLGPGV,IGLV1-44,AAWDDSLNGVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_79-P1369,IGHV1-46,ARANHETTMDTYYYYYYMDV,IGLV2-14,SSYTSSSTSVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_91-P1369,IGHV1-46,ARANHETTMDTYYYYYYMDV,IGLV2-14,SSYTSSSTSVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_53-P1369,IGHV1-58,AAPHCSSTSCFDAFDI,IGKV3-20,QQYGNSPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_81-P1369,IGHV1-58,AAPYCSGGSCSDAFDI,IGKV3-20,QQYGSSPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_42-P1369,IGHV3-30-3,ARDPIWFGELLSPPFVHFDY,IGLV1-51,GTWDSSLSAGGVYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_89-P1369,IGHV3-30-3,ARDPIWFGELLSPPFVHFDY,IGLV1-51,GAWDSSLSAGGVYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_22-P1369,IGHV3-30-3,AREDYYDSSGSFDY,IGLV2-14,SSYTSSSTWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_88-P1369,IGHV3-30-3,AREDYYDSSGSFDY,IGLV2-14,SSYTSSSTWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_49-P1369,IGHV3-30-3,ASGYTGYDYFVRGDYYGLDV,IGLV4-69,QTWGTGILV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_84-P1369,IGHV3-30-3,ASGYTGYDYFVGGDYYGMDV,IGLV4-69,QTWGTGILV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_19-P1369,IGHV3-33,ARGVNPDDILTGVDAFDI,IGKV1-5,QQHNSSPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_38-P1369,IGHV3-33,ARGVNPDDILTGVDAFDI,IGKV1-5,QQHNSSPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_15-P1369,IGHV3-49,TRWDGWSQHDY,IGKV2-28,MQVLQIPYT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_69-P1369,IGHV3-49,TRWDGWSQHDY,IGKV2-28,MQVLQVPYT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_32-P1369,IGHV3-53,AREGMGMAAAGT,IGKV1-33,QQYDNLPQT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_73-P1369,IGHV3-53,AREGMGIAAAGT,IGKV1-33,QQYDNLPQT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_62-P1369,IGHV3-53,ARGDGELFFDH,IGLV1-40,QSYDSSLYAV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_73-P1369,IGHV3-53,ARGDGELFFDQ,IGLV1-40,QSYDSSLYAV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_46-P1369,IGHV4-4,VRDGGRPGDAFDI,IGLV2-14,NSYTSSSTRV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_57-P1369,IGHV4-4,VRDGGRPGDAFDI,IGLV2-14,NSYTSSSTRV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_36-P1369,IGHV4-59,ARVEDWGYCSSTNCYSGAFDI,IGLV1-36,AAWDDSLNGAWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_71-P1369,IGHV4-59,ARVEDWGYCSSTNCYSGAFDI,IGLV1-36,AAWDDSLNGAWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_77-P1369,IGHV4-61,ARERPGGTYSNTWYTPTDTNWFDT,IGLV3-21,QVWDSSRDHVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_72-P1369,IGHV4-61,ARERPGGTYSNTWYTPTDTNWFDT,IGLV3-21,QVWDSSRDHVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_75-P1369,IGHV5-51,ARSFRDDPRIAVAGPADAFDI,IGKV1-5,QQYNSYPYT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_90-P1369,IGHV5-51,ARSFRDDPRIAVAGPADAFDI,IGKV1-5,QQYNSYPYT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_52-P1369,IGHV1-18,ARAIAVAGTSGEFDY,IGLV1-44,AAWDDSLNGHVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_58-P1369,IGHV1-18,ARSQGWLQLNDY,IGLV6-57,QSYDSSTPNCV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_7-P1369,IGHV1-18,ARVGHARGVITGGDYFYYGMDV,IGKV3-20,QQYGSSPT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_18-P1369,IGHV1-2,AREPQINPYYDILTGYRAFDY,IGKV3-20,QQYGSSLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_45-P1369,IGHV1-2,ARGHDYVWGSYRYHNV,IGLV2-14,SSYTSSSTLL,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_60-P1369,IGHV1-2,ARDLAFSMVRAPGDY,IGLV2-23,CSYAGSSTWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_5-P1369,IGHV1-2,ARELIAVAGIFDY,IGLV3-21,QVWDSSWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_94-P1369,IGHV1-2,ARAPLFPTGVLAGDYYYYGMDV,IGLV2-23,CSYAGSSTLV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_83-P1369,IGHV1-2,ARYKGTTVNTNYYYGMDV,IGLV3-1,QAWDSSTVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_21-P1369,IGHV1-46,ARGPRSPSDWCSGGSCYDDQNWFDP,IGKV1-39,QQSYSTLIT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_24-P1369,IGHV1-46,ARDFELWFGELRGWFDP,IGKV3-15,QQYNNWPPIT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_40-P1369,IGHV1-46,ARDPSPIIARPGMGYWFDP,IGLV1-40,QSYDSSLSAVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_17-P1369,IGHV1-69,ASFHVAYGDYIPFDY,IGKV3-20,QQYGRSPTWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_78-P1369,IGHV1-69,ARAGLLTKNIVATIGCFDP,IGKV4-1,QQYYSTPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_28-P1369,IGHV1-69,ARDSSGYYYVSNWFDP,IGLV1-40,QSYDSSLSGVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_95-P1369,IGHV1-8,ARGGRYCSSTSCYSHVGFDP,IGKV1-9,QQLNSYPIT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_92-P1369,IGHV3-11,ATYRSYLPLVQVDY,IGLV6-57,QSYDSSKHAV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_38-P1369,IGHV3-13,ARVRYDSSGYFWSLDY,IGKV1-39,QQSYSTPQYT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_61-P1369,IGHV3-13,ARGVSGVVRGVIRSFYYYGLDV,IGKV1-39,QQSYITPGWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_55-P1369,IGHV3-21,ARGQLLPFADY,IGLV6-57,QSYDSSKSWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_47-P1369,IGHV3-21,TRGSRGYYDRSGYYTPLDPYYGMDV,IGLV1-40,QSYDSSLSGSYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_49-P1369,IGHV3-23,AKEEVLPAVEYFQH,IGLV3-21,QVWDGSSDHHVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_80-P1369,IGHV3-23,VETNLWFGEDNYYYYYGMDV,IGKV3-20,QQYGSSPPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_68-P1369,IGHV3-30,ATGGGSYFSPRIYFDY,IGKV1-33,QQYDNLPPYT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_51-P1369,IGHV3-30,AKQAGPYCSGGTCYPGTLDY,IGKV1-33,QQYDNVPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_43-P1369,IGHV3-30,AKAGYSYGYPQQYFDY,IGKV1-5,QQYNSYSYT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_3-P1369,IGHV3-30,AKSLGPYCSGGNCYSSYFDY,IGKV1-5,QQYNSYST,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_44-P1369,IGHV3-30,AKKGGGAYCGGDCYLGEFDY,IGKV3-20,QQYGTSPST,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_22-P1369,IGHV3-30,AKGGYYYYNSDSYQAEIDY,IGLV1-51,GTWDSSLSAFV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_76-P1369,IGHV3-30,AKSWWLSENWFDP,IGKV3-15,QQYNNWPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_16-P1369,IGHV3-30,AKGGLYDSSGYYPHYGMDV,IGKV1-33,QQYDNLPLA,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_91-P1369,IGHV3-30,AKDPLPFRDFFYYYMDV,IGLV2-14,SSYTSSSTLGV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_10-P1369,IGHV3-30-3,ARDQDLDTAMVTLFDY,IGKV1-39,QQSYSTPPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_65-P1369,IGHV3-30-3,ARDSPSQIVVVPVFDY,IGKV1-39,QQSYSTLALT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_35-P1369,IGHV3-30-3,ARETQGGYYGSGSYYASPFDP,IGLV3-21,QVWDSSSDHPVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_24-P1369,IGHV3-30-3,ARDFYHNWFDP,IGLV6-57,QSYDSSNQWVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_34-P1369,IGHV3-33,ARDRGLRLGGPKYYFDY,IGLV2-14,SSYTSSSVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_2-P1369,IGHV3-48,AREGARVGATYDTYYFDY,IGKV3-11,QQRNNWPPEWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_64-P1369,IGHV3-48,ARVAIRVVVPSATYYFDY,IGKV3-11,QQRSNWPQGFT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_41-P1369,IGHV3-48,ARDPQRDPADYFDY,IGLV3-21,QVWDSSRV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_11-P1369,IGHV3-48,ARDQGYCSSTSCYDGYYYYMDV,IGKV1-39,QQSYSAPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_44-P1369,IGHV3-53,ARDLRGPGTFDI,IGKV1-33,QQYDNLPRVT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_88-P1369,IGHV3-53,AREVAAFDI,IGKV1-9,QQLNSYPPG,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_18-P1369,IGHV3-53,ARDLSAAFDI,IGKV1-9,QQLNSYPPA,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_59-P1369,IGHV3-53,ARTMDGDYFDY,IGKV1-27,QKYNSAPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_30-P1369,IGHV3-53,ARTDIVVVPAARGFYFDY,IGKV1-5,QQYNSYGT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_15-P1369,IGHV3-53,ARESGDTTMAFDY,IGKV1-9,QQLNSDSYT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_23-P1369,IGHV3-53,ARDLGTGLFDY,IGKV1-9,QQLDSYPPGT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_82-P1369,IGHV3-53,ARDYGDFYFDY,IGKV3-15,QQYYNWPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_95-P1369,IGHV3-53,ARDYGDLYFDY,IGKV3-20,QQYGSSPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_86-P1369,IGHV3-53,ATDLTSGRGP,IGKV1-6,LQDYNYPKT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_78-P1369,IGHV3-53,ARDLVVWGMDV,IGKV1-9,QLLNSYPYT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_46-P1369,IGHV3-7,AIQLWLRGGYDY,IGLV2-8,SSYAGSNNYVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_32-P1369,IGHV3-7,AVQLWLRGNFDY,IGLV6-57,QSYDSSNHVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_9-P1369,IGHV3-73,TKPHAHCGGDCYSRDWFDP,IGKV1-39,QQSYSTPPFT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_50-P1369,IGHV3-9,AKGLIAELVGGGWYFDY,IGKV3-11,QQRSNWPPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_74-P1369,IGHV3-9,AKALSSTGFLVVYFDY,IGKV3-15,QQYNNWLSLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_25-P1369,IGHV3-9,AKDDREGFGDYFDY,IGLV3-21,QVWDSSSDHYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_54-P1369,IGHV3-9,AKDSLVRRNFYYYYMDV,IGLV1-40,QSYDSSLSGVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_93-P1369,IGHV4-31,AWRYSSSWYTVDNKKGDYYFDY,IGKV2-28,MQALQTPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_20-P1369,IGHV4-39,AGMYYDILTGYSEGAFDI,IGLV2-23,CSYAGSSTWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_25-P1369,IGHV4-39,AGGTNPQWLDSTFDY,IGLV2-14,SSYTSSSTYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_64-P1369,IGHV4-39,ASAPYLNWNDWIFDY,IGLV2-14,SSYTSSSTLV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_28-P1369,IGHV4-59,ARLQWLRGAFDI,IGLV6-57,QSYDSSNLV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_58-P1369,IGHV4-59,ARYGWGYDSSGYYFDY,IGLV2-23,CSYAGSSTWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_2-P1369,IGHV4-59,ARATTPFSGVDY,IGLV6-57,QSYDTSNWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_10-P1369,IGHV4-59,ARILRGVAENWFDP,IGLV3-21,QVWDNNSDHRGV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_48-P1369,IGHV4-61,ATRGGYYDSSGYYALAFDI,IGLV2-14,SSYTSSSTVWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_45-P1369,IGHV5-10-1,ARHISSGWYDY,IGKV1-33,QQYDNLPYT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_39-P1369,IGHV5-10-1,ARHRHPGITMIVALDY,IGKV1-33,QQYDNVPL,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_87-P1369,IGHV5-10-1,ATETNSETTDMFTGYSFDP,IGLV1-44,AAWDDSLSGYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate2_HC_1-P1369,IGHV5-51,ARGGPPGGVKLELTDY,IGLV1-44,AAWDDSLNGPVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_92-P1369,IGHV5-51,ARLHPTYYDILTGYYIDY,IGLV2-23,CLYAFSSIV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_37-P1369,IGHV5-51,ALTTVTTGRWFDP,IGKV2-30,MQGTHWLWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV107_Plate1_HC_26-P1369,IGHV5-51,ARRPSSYSGWFDP,IGLV1-44,AAWDDSLNGLV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_100-p1369,IGHV3-23,ARESDCGSTSCYQVGWFDP,IGKV1-39,QQSYSTPPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_164-p1369,IGHV3-23,ATERIAVAGTRMYNWFDP,IGKV1-39,QQSYSAPPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_25-p1369,IGHV3-23,ASEEDYSNYVGWFDP,IGKV1-39,QQSYSTPPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_91-p1369,IGHV3-23,ARESDCGSTSCYQVGWFDP,IGKV1-39,QQSYSTPPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_115-p1369,IGHV3-66,ARDTLGRGGDY,IGKV1-33,QQYDNLPRS,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_133-p1369,IGHV3-66,ARDTFGRGGDY,IGKV1-33,QQYDNLPRS,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_34-p1369,IGHV3-66,ARDTLGRGGDY,IGKV1-33,QQYDNLPRS,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_106-p1369,IGHV3-9,AKGVEYSSSSNFDY,IGKV1D-12,QQTNSFPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_132-p1369,IGHV3-9,VKGVEYSSSSNFDY,IGKV1D-12,QQTNSFPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_6-p1369,IGHV3-9,VKGVEYSSSSNFDY,IGKV1D-12,QQANSFPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_116-p1369,IGHV1-2,ARERYFDLGGMDV,IGLV2-23,CSYAGSSTRL,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_77-p1369,IGHV1-2,AREPYFDLGGMDV,IGLV2-23,CSYAGSSTRV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_138-p1369,IGHV1-8,ARGFSLTWYFDL,IGLV3-21,QVWDSTGGHPDVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_176-p1369,IGHV1-8,ARGFSLTWYFDL,IGLV3-21,QVWDSTSDHPDVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_104-p1369,IGHV3-21,ARVQVGARGWVDY,IGLV6-57,QSYDSINWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_111-p1369,IGHV3-21,ARVQVGARGWVDY,IGLV6-57,QSYDRINWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_158-p1369,IGHV3-23,AKEPIGQPLLWWDY,IGKV3-11,QQRSNWPRG,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_78-p1369,IGHV3-23,AKEPIGQPLLWWDY,IGKV3-11,QQRSNWPRG,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_130-p1369,IGHV3-9,AKGSSSGWTRPLDY,IGLV3-21,QVWDSSSDPVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_44-p1369,IGHV3-9,AKGSSSGWTRPLDY,IGLV3-21,QVWDSSSDPVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_72-p1369,IGHV1-18,ARRPRDYYDRSGYYYVPGYFDY,IGKV1-33,QQYDNLPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_90-p1369,IGHV1-18,ARRVEDNGDDGGDYYYYYGMDV,IGLV3-25,QSADSSGTLVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_71-p1369,IGHV1-2,ARDLEYCSSTSCYTSTTFDY,IGLV3-21,QVWDYGVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_52-p1369,IGHV1-2,ASGIGHNWNYVSTPNGMDV,IGLV6-57,QSYDSGVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_10-p1369,IGHV1-2,ARDFAMGTVTGTFVY,IGLV2-8,SSYAGSNNWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_4-p1369,IGHV1-2,AREKVATMFALPPYGMDV,IGKV3-11,QQRSNWPPIA,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_127-p1369,IGHV1-46,ARPLLPGETGSLNRLDY,IGKV1-39,QQSYSTLWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_2-p1369,IGHV1-46,AREGVGGTSYFDY,IGLV3-21,QVWDSSSDPYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_113-p1369,IGHV1-46,ARGPERGIVGATDYFDY,IGKV3-20,QQYVSSPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_153-p1369,IGHV1-69,ASEWEIFGFDY,IGKV1-39,QQSYSTPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_55-p1369,IGHV1-69,TSGQGAGVNRGVVITTLGY,IGKV4-1,QQYYSTPCS,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_42-p1369,IGHV1-69,ARDDGQQLWSYFDY,IGKV4-1,QQYYSTLPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_30-p1369,IGHV1-69,ARDGLSGHFPHNWFDP,IGLV1-40,QSYDSSLRGV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_136-p1369,IGHV1-69,ARREAYGPRDYYYYYGMDV,IGLV9-49,GADQGSGSNFVGV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_99-p1369,IGHV1-69,ARVLGYYDSSGSNDAFDI,IGLV1-40,QSYDSSLSGSV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_152-p1369,IGHV1-8,ARGGRYCSDVSCYSGTGFDY,IGLV1-47,AAWDDSLSGYWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_156-p1369,IGHV3-11,ARDLPPRRFDI,IGKV1-33,QQFDNLPIT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_137-p1369,IGHV3-13,ARGDSGSYLGVWYFDL,IGKV1-39,QQSYSSPPIT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_75-p1369,IGHV3-13,ARDRGSSGWYGWYFDL,IGKV1-39,QQSYSTPPIT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_123-p1369,IGHV3-13,ARGDYNILTGYYFDY,IGKV1-39,QQSYNTPQVT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_65-p1369,IGHV3-13,ARDRDSSWSFDY,IGKV1-39,QQSYSTPPIT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_81-p1369,IGHV3-13,ARGTFFYGSGSYNWFDP,IGKV1-39,QQSYSTPPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_166-p1369,IGHV3-15,TTLSDYGDLSSVY,IGKV1-39,QQSYSTPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_50-p1369,IGHV3-15,TTDLGYCSSTNCYYYY,IGLV3-21,QVWDSSSDHPV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_92-p1369,IGHV3-15,TTDDPGSYYYGMDV,IGLV7-46,LLSYSGARV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_140-p1369,IGHV3-21,AKEEYYGMDV,IGKV1-12,QQANRFPIT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_40-p1369,IGHV3-30,ARAGTTNSDYFDY,IGLV3-21,QVWDSSSALWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_43-p1369,IGHV3-30,AKQLYYYGSGSYVFDY,IGKV1-33,QQYDNLPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_149-p1369,IGHV3-30,AKGGYSYGYSLYYFDY,IGLV2-14,SSYTSSSTLV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_157-p1369,IGHV3-30,AKAQYSYGYVVYYFDY,IGLV6-57,QSYDSSNVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_21-p1369,IGHV3-30,AKDTPGGDDILTGWGLYGMDV,IGKV1-39,QQSYSTPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_122-p1369,IGHV3-33,ARDMGTLVTHFDY,IGKV1-39,QQSYSSPPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_98-p1369,IGHV3-33,ARDVGRVTTWFDP,IGKV1-39,QQSYSTPPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_48-p1369,IGHV3-48,ARASGLRSYYYYGMDV,IGKV1-39,QQSYSTPAT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_79-p1369,IGHV3-48,ARVVGSGSYYYYGMDV,IGKV1-39,QQSYSTPAT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_3-p1369,IGHV3-49,TRDLSYYYDSSGRGSHLFDY,IGKV3-15,QQYNNWWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_121-p1369,IGHV3-53,ARSLWLRGSFQH,IGLV6-57,QSYDSSSWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_134-p1369,IGHV3-53,ARDLMAYGMDV,IGKV1-9,QQLNSYPQGT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_68-p1369,IGHV3-53,ARDGGHYGMDV,IGKV1-9,QQLNSYPPA,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_183-p1369,IGHV3-53,ARESYGMDV,IGKV3-20,QQYVTSPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_74-p1369,IGHV3-66,ARDYGDFYFDY,IGKV3-15,QQYNNWPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_27-p1369,IGHV3-7,ARGDYDFWSGYYDY,IGLV3-25,QSADSSSWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_142-p1369,IGHV3-7,ATAPWLRGGFDY,IGLV6-57,QSFDSTNLWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_45-p1369,IGHV3-74,TRDDSSWPHFFDN,IGKV1-33,QQYDNLPPKLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_126-p1369,IGHV3-74,TRDDSSWPHFFDN,IGKV1-39,QQSYISPYT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_1-p1369,IGHV3-9,AKIADIVRAYDFWSGQHFDAFDI,IGLV1-44,AAWDDSLVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_15-p1369,IGHV3-9,AKDGGSGTTEYEAYYFDY,IGLV1-44,AAWDDSLNGVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_20-p1369,IGHV3-9,AKDMGRDDSSGSLLFDY,IGLV3-21,QVWDSSSDHVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_159-p1369,IGHV3-9,AKDIGSKRSTSENYGMDV,IGLV3-21,QVWDSSSDSVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_103-p1369,IGHV4-39,ASLRGAYYDFWSGPRDGGWFDP,IGLV2-23,CSYAGSSLWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_23-p1369,IGHV4-61,AREIPSTWYFDL,IGLV1-47,AAWDDSLSGYWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_101-p1369,IGHV4-61,ARDIPPTWYFDL,IGLV3-21,QVWDSTSDHLFWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_8-p1369,IGHV5-51,ARPVTYDWYFDL,IGKV1-12,QQANSFPIT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_124-p1369,IGHV5-51,ARVPSSSDYGDYGGFEY,IGKV1-39,QQSYSTPCS,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_28-p1369,IGHV5-51,ARMVTSGTYYYDNSGYSSSGPFDY,IGKV1D-13,QQFNN,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_12-p1369,IGHV5-51,ARLSDRWYSPFDP,IGKV3-15,QQYNNWPPGGFT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_174-p1369,IGHV5-51,ARLPSGRYNWFDP,IGLV1-44,AAWDDSLNGHVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV096_HC_189-p1369,IGHV5-51,ARLPQEEKRFLEWLPPANVRKQIPYYYGMDV,IGLV1-40,QSYDSSLSGPYWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_43-P1369,IGHV3-53,AREGEVEGYNDFWSGYSRDRYYFDY,IGLV2-14,SSYTSSSTRV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_57-P1369,IGHV3-53,AREGEVEGYYDFWSGYSRDRYYFDY,IGLV2-14,SSYTSSTTRV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_58-P1369,IGHV3-53,AREGEVEGYYDFWSGYSRDRYYFDY,IGLV2-14,SSYTSISTRV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_26-P1369,IGHV3-53,AREGDVEGYYDFWSGYSRDRYYFDY,IGLV2-14,SSYTSSSTRV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_41-P1369,IGHV3-53,AREGEVEGYYDFWSGYSRDRYYFDY,IGLV2-14,SSYTSSSTRV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_49-P1369,IGHV3-53,AREGEVEGYYDFWSGYSRDRYYFDY,IGLV2-14,SSYTSSTTRV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_16-P1369,IGHV3-66,ARDSSEVRDHPGHPGRSVGAFDI,IGLV2-23,CSYAGASTFV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_12-P1369,IGHV3-66,ARDSSEVRDHPGHPGRSVGAFDI,IGLV2-23,CSYAGASTFV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_65-P1369,IGHV3-66,ARDSSEVRDHPGHPGRSVGAFDI,IGLV2-23,CSYAGASTFV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_57-P1369,IGHV3-66,ARDSSEVRDHPGHPGRSVGAFDI,IGLV2-23,CSYAGASTFV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_10-P1369,IGHV1-18,ARDRGGHDFWSGYGFYYYYGMDV,IGKV1-27,QKYNSAPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_95-P1369,IGHV1-18,ARDRGGHNFWSGYGYYYYYGMDV,IGKV1-27,QKYNSAPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_34-P1369,IGHV3-21,ARERGYYGGKTPPFL,IGLV6-57,QSYDSSNYWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_24-P1369,IGHV3-21,ARERGYDGGKTPPFL,IGLV6-57,QSYDSSNYWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_91-P1369,IGHV3-30,AKNVGTGYNVMYYFDY,IGKV1-33,QQYDNLPIT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_87-P1369,IGHV3-30,AKQAGPYCSGGSCYSAPFDY,IGKV1-33,QQYDNLPIT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_69-P1369,IGHV3-30,AKVGLGYSSGWYGEEIDY,IGKV1-39,QQSYRTPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_68-P1369,IGHV3-30,AKVGMEYSSGWYGEEIDF,IGKV1-39,QQSYRTPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_64-P1369,IGHV3-30,AKDPFPLAVAGTGYFDY,IGLV3-21,QVWDSSSDPWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_77-P1369,IGHV3-30,AKDPWELRQGNYFDY,IGLV3-21,QVWDSSSDPWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_65-P1369,IGHV3-53,ARDYGDYYFDY,IGKV3-15,QQYNNWPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_27-P1369,IGHV3-53,ARDFGEFYFDY,IGKV3-15,QQYNNWPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_3-P1369,IGHV3-66,ARDSSEVRDHPGHPGRSVGAFDI,IGLV2-23,CSYAGASTFV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_90-P1369,IGHV3-66,ARDSSEVRDHPGHPGRSVGAFDI,IGLV2-23,CSYAGTSTFV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_24-P1369,IGHV3-66,ARIANYMDV,IGKV3-15,QQYNNWPPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_94-P1369,IGHV3-66,ARIANYMDV,IGKV3-15,QQYNNWPPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_8-P1369,IGHV5-51,ARLSDRWYSPFDP,IGLV7-46,LLSYSGARPV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_91-P1369,IGHV5-51,ARLSDRWYSPFDP,IGLV7-46,LLSYSGARPV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_77-P1369,IGHV1-18,ARVPRGYYDRSGYYYLPHYLDY,IGKV1-33,QQYDSLPGCS,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_78-P1369,IGHV1-18,ARDSAYSGYDFFEAPRDY,IGKV1-39,QQSYRTPPL,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_21-P1369,IGHV1-18,ARPSSSLTSYFDY,IGLV3-21,QVWDSSSDRHWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_53-P1369,IGHV1-18,ARVPASYGDDDYYYYYGMDV,IGLV3-25,QSADSSGTLWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_27-P1369,IGHV1-2,ARGPLFHRLVYDFWSGYHDGFDM,IGLV2-14,NSYTSSSTWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_10-P1369,IGHV1-2,ARTPRVYDPTLPNQWLVGEYYCDY,IGLV2-11,CSYAGSYTWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_60-P1369,IGHV1-2,ARGTEYNWNSAHFDP,IGLV2-14,SSYTSSSTSWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_29-P1369,IGHV1-2,VRGGTWNYVGGEV,IGLV2-14,TSFTSSSDSWI,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_61-P1369,IGHV1-46,ASSSSTPDYYGMDV,IGKV1-9,QQLNSYPLCS,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_48-P1369,IGHV1-46,ARASTSTTNWNDALSLGC,IGLV1-40,QSYDSGLSGSGVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_78-P1369,IGHV1-46,ARGGSSRYCSSTSCYSFGVDNFDY,IGLV3-21,QVWDSSSDHYYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_43-P1369,IGHV1-69,ARVGYGYYFDY,IGKV3-11,QQRSNWPS,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_89-P1369,IGHV1-69,ARDLRYCSGGRCLWWFDP,IGKV1-39,QQSYSTPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_15-P1369,IGHV1-69,ARYTYYYDRSGYYRPDYFDY,IGKV1-13,QQFNSYQLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_54-P1369,IGHV3-15,TTTNDYGDYSPAY,IGKV1-39,QQSYSTPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_72-P1369,IGHV3-15,TSQVWLRGPGDY,IGLV6-57,QSYDSSLNWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_17-P1369,IGHV3-21,AREAEWEAFDI,IGLV2-11,CSYAGSYTWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_84-P1369,IGHV3-21,ARDVASNYAYFDL,IGKV1-39,QQSYSTPPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_67-P1369,IGHV3-21,ARERYGDN,IGLV4-69,QTWGPWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_84-P1369,IGHV3-21,ARVVANWFDP,IGKV4-1,QQYYSTPQPSWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_40-P1369,IGHV3-21,AREAARRYDFWSGLNWFDP,IGKV4-1,QQYYSTMLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_36-P1369,IGHV3-23,AKSGGRHYYDSSGYYRLPLDDAFDI,IGLV1-40,QSYDSSLSGSWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_52-P1369,IGHV3-30,ARAEWLRGAFDI,IGLV6-57,QSYDSTNHWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_70-P1369,IGHV3-30,ARAGWELLRIRYYFDF,IGKV1-33,QQYDNLPPT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_31-P1369,IGHV3-30,YALFERGNWNDAEY,IGKV2-30,MQGTHWPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_30-P1369,IGHV3-30,AKDLGSSLYYDAFDI,IGKV1-39,QQSYSTPPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_20-P1369,IGHV3-30,AKVDGSYYYYYYGMDV,IGLV2-14,SSYTSSSTAWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_22-P1369,IGHV3-33,AREQEANYYDISGYYHWGESLGY,IGKV1-9,QKVNSHPPGLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_70-P1369,IGHV3-33,ARGGRYYDSSGYNGTYEFDY,IGKV3-15,QQYNNWPPVT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_50-P1369,IGHV3-33,ARDRKYSSGWSVVNFDY,IGLV1-36,AAWDDSLNGWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_59-P1369,IGHV3-33,ARDGLNWNVPHYGMDV,IGKV1-12,QQANSFPPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_58-P1369,IGHV3-53,ARVGGAHSGYDGSFDY,IGLV2-23,CSYAGSSTWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_8-P1369,IGHV3-53,ARDRVIYGMDV,IGKV1-33,QQYDNLPQT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_11-P1369,IGHV3-53,ARAISESPRYGVY,IGKV1-33,QQYDNLPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_14-P1369,IGHV3-53,ARVLPFGDYFDY,IGLV1-40,QSYDINLSAWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_91-P1369,IGHV3-66,ARDSSEVRDHPGHPGRSVGAFDI,IGKV4-1,QQYYSTPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_51-P1369,IGHV3-66,ARDSTPGYGDY,IGKV1-33,QQYDNLPIT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_47-P1369,IGHV3-66,ARDYGDFYFDY,IGKV3-15,QQYNNWPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_71-P1369,IGHV3-66,ARDLRDQDGYSYGAFDY,IGLV2-14,SSYTSSSSWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P5_IgG_16-P1369,IGHV3-74,ASAFWQRGNFDY,IGLV6-57,QSYDSSILWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_25-P1369,IGHV3-74,ARPTAVAAAGNYFYYYGMDV,IGLV2-14,SSYRSSSTLV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_86-P1369,IGHV4-30-2,ARFTNPNYYDSSGYYGFDY,IGLV2-8,TSYAGSNNWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_39-P1369,IGHV4-31,ARVKGWLRGYFDY,IGLV6-57,QSYDSGSHVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_83-P1369,IGHV4-4,ARVAAFLDY,IGKV1-NL1,QQYYSTRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_38-P1369,IGHV4-4,ARTWIQPHNWFDP,IGKV1-16,QQYNSYPLFT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_72-P1369,IGHV4-4,ARGPPRLLWFGESPPTYWYFNL,IGKV4-1,QQYYSTPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_38-P1369,IGHV4-59,ARYQLAPGSGSYYNWGGYPRESEYYFDY,IGLV2-11,CSYAGSYTWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_5-P1369,IGHV4-59,ARHDTIFGVGQYYFDY,IGLV2-23,CSYAGSSTWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_35-P1369,IGHV4-59,ARHSWLRGMADY,IGLV6-57,QSYDSSIWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P3_IgG_49-P1369,IGHV4-59,ARLKQQLVGFGWFDP,IGLV1-40,QSYDHSLNWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COV047_P4_IgG_23-P1369,IGHV6-1,ARDILRDTSWPHDAFDI,IGLV2-14,SSYTSSSTPFYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_A4-p1369,IGHV3-30,AKEGRPSDIVVVVAFDY,IGKV1-39,QQSYSTPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_B5-p1369,IGHV3-30,AKEGRPSDIVVVVAFDY,IGKV1-39,QQSYSTPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_C12-p1369,IGHV3-30,AKEGRPSDIVVVVAFDY,IGKV1-39,QQSYSTPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_E4-p1369,IGHV3-30,AKEGRPSDIVVVVAFDY,IGKV1-39,QQSYSTPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_F1-p1369,IGHV3-30,AKEGRPSDIVVVVAFDY,IGKV1-39,QQSYSTPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_B7-p1369,IGHV3-30,AKEGRPSDIVVVVAFDY,IGKV1-39,QQSYSTPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_B9-p1369,IGHV3-30,AKEGRPSDIVVVVAFDY,IGKV1-39,QQSYSTPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_E1-p1369,IGHV3-30,AKEGRPSDIVVVVAFDY,IGKV1-39,QQSYSTPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_E11-p1369,IGHV3-30,AKEGRPSDIVVVVAFDY,IGKV1-39,QQSYSTPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_F6-p1369,IGHV3-30,AKEGRPSDIVVVVAFDY,IGKV1-39,QQSYSTPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_A6-p1369,IGHV3-30,AKEGRPSDIVVVVAFDY,IGKV1-39,QQSYSTPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_B12-p1369,IGHV3-30,AKEGRPSDIVVVVAFDY,IGKV1-39,QQSYSTPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_C8-p1369,IGHV1-2,ASPASRGYSGYDHGYYYYMDV,IGKV1-33,QQYDNLPIT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_F12-p1369,IGHV1-2,ASPASRGYSGYDHGYYYYMDV,IGKV1-33,QQYDNLPIT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_H9-p1369,IGHV1-2,ASPASRGYSGYDHGYYYYMDV,IGKV1-33,QQYDNLPIT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_E5-p1369,IGHV3-11,ARRGDGSSSIYYYNYMDV,IGLV1-44,AAWDDSLNGPV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_F8-p1369,IGHV3-11,ARRGDGSSSIYYYNYMDV,IGLV1-44,AAWDDSLNGPV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_G5-p1369,IGHV3-11,ARRGDGSSSIYYYNYMDV,IGLV1-44,AAWDDSLNGPV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_A11-p1369,IGHV3-30-3,ARDGIVDTAMVTWFDY,IGKV1-39,QQSYSTPPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_D1-p1369,IGHV3-30-3,ARDQGMATTYFDY,IGKV1-39,QQSYNTPPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_H7-p1369,IGHV3-30-3,ARDGIVDTALVTWFDY,IGKV1-39,QQSYSTPPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_B5-p1369,IGHV1-2,ARDSPFSGLGASNDY,IGLV2-8,SSDAGSNNVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_B5-p1369,IGHV1-2,ARDSPFSALGASNDY,IGLV2-8,SSDAGSNNVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_F9-p1369,IGHV1-58,AAPHCSGGSCLDAFDI,IGKV3-20,QQYGSSPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_F10-p1369,IGHV1-58,AAPHCSGGSCYDAFDI,IGKV3-20,QQYGSSPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_E9-p1369,IGHV3-15,TTGPHYDSSGYSYTVDS,IGKV2-28,MQGLQTPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_G2-p1369,IGHV3-15,TTGPHYDDSGYSYTVDY,IGKV2-28,MQALQTPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_G4-p1369,IGHV3-30,AKASGIYCSGGDCYSYYFDY,IGKV1-5,QQYNSYST,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_B2-p1369,IGHV3-30,AKASGIYCSGGNCYSYYFDY,IGKV1-5,QQYNSYST,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_F2-p1369,IGHV3-9,AKGRVVYAIDPDSVSPFDY,IGLV2-14,SSYTSRSTLGV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_E2-p1369,IGHV3-9,AKPRKRGDYYGSGSYDY,IGLV2-14,SSYTSSSTVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_B10-p1369,IGHV4-39,ARHAAAYYDRSGYYFIEYFQH,IGKV1-5,QQYNNYRYT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_H11-p1369,IGHV4-39,ARHAAAYYDRSGYYFIEYFQH,IGKV1-5,QKYNSYRYT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_E4-p1369,IGHV1-18,ARTDGTPAEYFQY,IGLV2-14,SSYRGSSTPYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_G7-p1369,IGHV1-2,ARGGQDELTGAFDI,IGLV3-21,QVWDSGWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_D10-p1369,IGHV1-2,AKSPYYYDSSGYLGGFDY,IGLV2-23,CSYAASSTYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_C7-p1369,IGHV1-2,ARDLGYSYVQGYFDY,IGLV2-23,CSYAGSNTWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_B12-p1369,IGHV1-2,ARDLGFSRLQFLFDY,IGLV2-23,CSYAGSSIVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_F4-p1369,IGHV1-2,ASTGYYILTGYEFGAMDV,IGLV2-14,SSYTSSSTV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_D7-p1369,IGHV1-2,ARDRPLWFGVEYGMDV,IGLV2-14,SSYTSSSTLV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_C1-p1369,IGHV1-2,ATTEGQQLPHPPYYYYYYYMDV,IGLV2-14,SSYTSSSTYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_G5-p1369,IGHV1-46,ARDRAETEGSETYYYDSSGYYLLGY,IGKV1-39,QQSYSTPPS,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_D3-p1369,IGHV1-46,ARSSVTGTPPFDY,IGLV3-21,QVWDSSSDHVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_G8-p1369,IGHV1-46,ARVPREGTPGFDP,IGLV3-21,QVWDSSSDHVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_E4-p1369,IGHV1-46,LVGISTIVVVRPAVWTS,IGLV5-52,GTWHSNSRV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_F12-p1369,IGHV1-69,ARVLYYYDSSGYPNLEYFQH,IGKV1-33,QQYDNLPSFT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_B3-p1369,IGHV1-69,ARGNRLLYCSSTSCYLDAVRQGYYYYYYMDV,IGLV1-44,ASWDDSLNGPL,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_C11-p1369,IGHV1-69,ARVGYYYDRSGFPRTEDYFDY,IGLV1-40,QSYDSSLSGVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_G6-p1369,IGHV1-69,ARDEGYCSGGSCYGYYYGMDV,IGKV1-33,QQYDNLPMYT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_B2-p1369,IGHV1-69,ARGNRLLYCSSTSCYLDAVRQGYYYYYYMDV,IGKV3-11,QQRSNWPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_D2-p1369,IGHV3-11,ARGLVYTPYRFGY,IGKV1-33,QQHDNVVT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_B4-p1369,IGHV3-11,ARGRTWELVDY,IGLV2-14,SSYRGSSTPYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_A12-p1369,IGHV3-11,ARGKWLRGSFDY,IGLV6-57,QSYDSSNHWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_A10-p1369,IGHV3-13,ARVGYDSSGYSGWYFDL,IGKV1-39,QQSYSTPPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_A2-p1369,IGHV3-13,ARGGGETITTVFDY,IGLV2-14,SSYRGSSTPYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_D3-p1369,IGHV3-13,ARGSYSNYVGYMDV,IGKV1-39,QQSYSTPGLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_D10-p1369,IGHV3-15,TTDQIYGDYLRMPVPFDY,IGLV1-47,ATWDDSLSGPV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_H6-p1369,IGHV3-15,TTGPQYDDNGYSYTVDY,IGLV2-14,SSYRGSSTPYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_D12-p1369,IGHV3-21,AREVKRVVAAPEYYFDY,IGLV1-44,AEWDDSLSTWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_D11-p1369,IGHV3-21,AREVKRVVAAPEYYFDY,IGLV2-14,SSYRGSSTPYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_C3-p1369,IGHV3-21,ARDRNRYDFWSGYYRLVGFDP,IGLV2-8,SSYAGSNNHV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_F11-p1369,IGHV3-23,AKVWSISLDAFDI,IGLV3-21,QVWDSSSDL,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_C4-p1369,IGHV3-23,AKDGGRQWLVELLDY,IGKV1-39,QQSYSSPPT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_G9-p1369,IGHV3-23,AKDRAAAHWATDY,IGKV1-33,QQYDNRLFT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_F7-p1369,IGHV3-23,AKDDSSGYHYYFDY,IGKV1-39,QQSYNTPPIT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_D1-p1369,IGHV3-23,AKDSGTAMVEIFDY,IGKV1-39,QQSYSSTLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_E1-p1369,IGHV3-23,AKDLRSTTFYVYYFDY,IGLV2-14,SSYTSSSTPDV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_F8-p1369,IGHV3-23,AKVPIHYCSNGVCYFDY,IGLV6-57,QSYDSSNRWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_D4-p1369,IGHV3-23,AKVVGSGTPPDYYYYYYMDV,IGLV2-14,SSYRGSSTPYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_D4-p1369,IGHV3-30,ARATCSGGSCLFGQNAFDI,IGKV2-30,MQGTHWPPYT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_G9-p1369,IGHV3-30,ARDYGSSWYQVPDY,IGKV1-39,QQSYSTPPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_H9-p1369,IGHV3-30,AREFGDPEWYFDY,IGKV1-5,QQYNSYWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_G8-p1369,IGHV3-30,AKNQNSYGYLSYFDY,IGKV1-33,QQYDNLPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_E12-p1369,IGHV3-30,AKASGEYCGGGSCYRGVFDY,IGKV1-33,QQYDNLPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_H4-p1369,IGHV3-30,AKVMGPYCSGGSCYSGYFDY,IGKV3-11,QQRSNWPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_C4-p1369,IGHV3-30,AKAGGPYCSGGSCYSSYFDY,IGKV3-20,QQYGSSPAIT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_G2-p1369,IGHV3-30-3,ARDCGGDCYPTTDAFDI,IGKV1-39,QQSYSTPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_H10-p1369,IGHV3-30-3,ARDHDYGEIVDAFDI,IGKV1-39,QQSYSTLMYT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_B1-p1369,IGHV3-30-3,ARDSEDCSSTSCYLDY,IGKV4-1,QQYYSTPFT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_E6-p1369,IGHV3-30-3,ARGPGWQWPELDY,IGLV1-44,AAWDDSLNGPV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_A5-p1369,IGHV3-30-3,ATEDYYDSSGSFDY,IGLV2-11,CSYAGSFWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_C12-p1369,IGHV3-30-3,ARSKSYTSWGYYHMDV,IGLV2-14,SSYTSSSTWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_D8-p1369,IGHV3-33,ARDGTSITLITEGDAFDI,IGKV1-12,QQANSLPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_B11-p1369,IGHV3-33,ARDPSVVVTAIDFDY,IGKV2-30,MQGTHWPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_C9-p1369,IGHV3-33,AREHTPTDIVVVNVEY,IGKV2-30,MQGTHWPYT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_H8-p1369,IGHV3-33,AREKDIVATDFDY,IGLV1-40,QSYDSSLSGPYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_E10-p1369,IGHV3-33,AREYFYDSSDYYFEYYFDY,IGLV2-11,CSYAGSYTYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_A4-p1369,IGHV3-33,ARDHSLGVRGDGYGMDV,IGKV1D-13,QQFNNYPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_G11-p1369,IGHV3-33,ARDGAVVRFLEWPTVGYYYYYMDV,IGKV2-28,MQALQTPIT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_G10-p1369,IGHV3-33,ARDMMIRGVAWYYYMDV,IGLV2-14,SSYISSNTV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_H2-p1369,IGHV3-48,ARDSGGDIVVIPAVNGFDY,IGLV3-25,QSADSRGV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_A8-p1369,IGHV3-48,AREAHDGALTDYGDYLNWFDP,IGLV3-21,QVWDSSSDHLYWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_A3-p1369,IGHV3-53,ARDLYSSGGTDI,IGKV3-20,QQYGSSPGT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_G1-p1369,IGHV3-53,ARDLYSSGGTDI,IGLV2-14,SSYRGSSTPYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_A2-p1369,IGHV3-53,ARGYGDYYFDY,IGKV1-9,QHLNG,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_F7-p1369,IGHV3-53,ARDYGDFYFDY,IGKV1-NL1,QQYYSTPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_C8-p1369,IGHV3-53,ARDWGDYYFDY,IGKV3-20,QQYGSSPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_A10-p1369,IGHV3-53,ARDYGDFYFDY,IGKV3-20,QQYGSSPRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_B12-p1369,IGHV3-53,ARDLSVFGMDV,IGKV1-9,QQVNSYSH,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_C9-p1369,IGHV3-53,ARDLGERGMDV,IGLV2-14,SSYRGSSTPYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_H7-p1369,IGHV3-7,ARYCSGGSCHPPGQWLSDAFDI,IGKV1-39,QQSYSTWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_F1-p1369,IGHV3-7,ARLRWLRADFDY,IGLV6-57,QSYDSGNVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_C10-p1369,IGHV3-7,ARYYDILTGYYVDYYYMDV,IGLV3-25,QSADSSGTYVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_H10-p1369,IGHV3-74,TRDDSSWPHFFDN,IGKV1-39,QQSYSTRT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_D8-p1369,IGHV3-74,ARAWAMRQTTLTPEWIDY,IGKV3-20,QQYGSSPYT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_D9-p1369,IGHV3-74,ARAWAMRQTTLTPEWIDY,IGLV3-25,QSADSRKVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_G3-p1369,IGHV3-9,AKGGEGFRNWNDGLDYFDY,IGLV1-44,AAWDDSLNGYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_A5-p1369,IGHV3-9,AKDGRSGDQWPELYYFDY,IGLV3-21,QVWDSSSDHVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_E10-p1369,IGHV3-9,AKAGVRGIAAAGPDLNFDH,IGKV3-11,QQRIT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_F9-p1369,IGHV3-9,AKGSSSSYHNWFDP,IGLV2-14,SSYRGSSTPYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_D6-p1369,IGHV3-9,AKDGAGTENWFDP,IGLV3-21,QVWDSSSDPHVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_G3-p1369,IGHV3-9,AKDMLGNYYYYAMVV,IGLV2-14,SSYTSSSTLEGV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_E6-p1369,IGHV4-31,ARTMYYYDSSGSFDY,IGKV2-28,MQALQTPHT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_G1-p1369,IGHV4-31,ASGELSAFGELFPHDY,IGKV3-11,QQRSNWLFT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_G7-p1369,IGHV4-31,ARVHVVRGVANYPYFDY,IGLV2-11,CSYAGSYTPWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_D5-p1369,IGHV4-31,ARGSYSNYNGGLDY,IGLV2-8,SSYAGSNNWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_A9-p1369,IGHV4-31,ARVATDYGDSFDY,IGLV7-43,LLYYGGAWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_A8-p1369,IGHV4-4,ARAPPGDFYDSSGYFSAFDI,IGLV2-14,SSYRGSSTPYV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_B6-p1369,IGHV4-4,ARDNGYVWGSYRPDAFDI,IGLV6-57,QSYDSRNVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_D4-p1369,IGHV4-4,ARVVGYSSRGANYYMDV,IGLV1-40,QSYDSSLSDSL,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_H5-p1369,IGHV4-59,ARVPSVGDCSSTSCLYWYFDL,IGKV1-5,QQYNSYST,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_F4-p1369,IGHV4-59,ARYGMGELLTLRSEYYFDY,IGLV2-11,YSYAGSYTFV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P3_HC_C4-p1369,IGHV4-59,ARSYDSSGLSYNWFDP,IGLV1-40,QSYDSSLSGYVV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_E2-p1369,IGHV4-59,ARGGYYYDSSGYEYYYYYGMDV,IGLV1-47,AAWDDSLSGYWV,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_C5-p1369,IGHV4-61,ARETYYYDSSGYYISDAFDI,IGKV1-5,QQYNSFSYT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P2_HC_H4-p1369,IGHV5-51,ARQWRGYYDRSGYYHFDAFDI,IGKV3-15,QQYNNWLGT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
COVD21_P1_HC_C6-p1369,IGHV5-51,ARHWYYGDYGNYSYYYLDV,IGKV3-15,QQYNNWPLT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature. doi: 10.1038/s41586-020-2456-9.
81E8,IGHV2-70,ARVQVAAAGSPYDY,IGKV1-39,QQTYSTPRT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
81D2,IGHV3-53,ARFRYGDYPDY,IGKV1-33,QQYDNLPSFT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
81A2,IGHV4-34,GVPYCSSSSCYRYYGMDV,IGKV1-9,QQLNSYPQAT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
81C8,IGHV3-33,ARDGVDFGMVTLFDY,IGKV1-39,QQSYNTPPWT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
81A1,IGHV4-59,ARDQGYSSGWNDAFDI,IGLV2-23,CSYAGSRFWV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
81A11,IGHV1-69,AREAGTTDWYFDL,IGLV1-40,QSYDSSLSVVV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
81C3,IGHV4-39,ARHPRFSWRGNDSGYFDY,IGLV2-14,SSFTSSSTPYV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
81C7,IGHV2-5,AHSMVRGVLFGADFDY,IGLV1-36,AAWDDSLNGPV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
81D5,IGHV5-51,ARRWDGVGFDI,IGLV3-19,NSRDSSINHYV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
81F2,IGHV4-34,ARGWTVPPLWVLNWFDP,IGKV2-28,MQALQTPRT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
81G8,IGHV3-7,ARSPHYYGGFDY,IGLV6-57,QSYHNSVWV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
81E1,IGHV1-24,AITSVARGLRGYFDT,IGLV1-47,AAWDDSLSRVV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
81E10,IGHV1-24,AITSLARGLKGYFDS,IGLV1-47,AAWDDSLSGVI,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
81A6,IGHV3-9,AKDIGCSSTSCSYYHYYGMDV,IGKV2-28,MQALQTPT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
81B2,IGHV3-66,ARDGRAVAGTD,IGKV1-33,HQYDNLPRT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
81B7,IGHV1-18,ARDYGWFGELSTEGQFDY,IGKV3-11,QQRRDFT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
82A6,IGHV4-39,ARFITDGYSSGSDS,IGKV1-39,QQSYSTPRLT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
82C4,IGHV1-58,AADRMRIVGGKGYYYGMDV,IGKV1-5,QQYNSYSPGDT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
82G8,IGHV4-59,ARRSMGYCSGGNCYSGFDP,IGKV1-39,QQSYSTPLT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
82B6,IGHV4-61,AMTYYDYIWGRVDPQFDP,IGKV2-30,CMQGTHWPPT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
82B7,IGHV1-18,ARDYGWFGELSTEGQFDY,IGKV3-20,HQYASSPRT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
82C6,IGHV4-39,ARFITDGYSSGSDS,IGKV2-30,MQGTHWPMYT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
82F6,IGHV3-30,AKQASPYCSGGSCYSGNFDY,IGKV1-33,QQHDNVPLT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
82A5,IGHV1-18,ARVQWLRLDY,IGKV1-12,QQAKGFPLT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
82C12,IGHV2-5,AHRPAGFWSAHFDY,IGKV1-39,QQSYSTPAWT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
51D3,IGHV3-66,AREGLLVGPTGRGLGMDV,IGKV1-33,QQYADLPYT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
51D4,IGHV2-70,ARMVVRGVMLDY,IGKV1-39,QQSYSPPHS,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
51A3,IGHV1-18,ARDLAWFGELSESPIEY,IGKV3-11,QQRGNSIT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
51D2,IGHV2-5,AHRLAPDYDFLTGYYNGDDAFDV,IGKV1-39,QQSYNTLALS,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
51A1,IGHV3-66,ARDLNIAGGFDI,IGKV1-9,QHLNIDPIT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
51E12,IGHV3-7,ARLMYYYGNFDY,IGKV1-8,QQYYGYPT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
51D12,IGHV5-10-1,ARLPFCDSASCGRAHYYYGMDV,IGKV3-15,QQYNNWPET,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
51F11,IGHV1-69,ATGRYTYGYGYYFDY,IGKV3-20,QQYGSSRT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
51E10,IGHV1-18,ARARQLVLNWYFDL,IGKV4-1,QQYYITPQLT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
51E7,IGHV3-13,ARVGYYGSGSYPLYWYFDL,IGKV1-39,QQSYSAPPWT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
51D7,IGHV5-51,ATRTGWTNDAFDI,IGKV1-39,QQSYSTPCT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
51F5,IGHV2-70,ALGRAGTMDY,IGKV1-39,QQSYSPPYT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
51E3,IGHV3-9,AKDMVAGPHYYGMDV,IGLV1-44,AAWDDSLNGWV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
51B1,IGHV5-51,ARHPSNFYDSGGDYYAMDV,IGLV2-23,CSYAGSSSWV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
52C1,IGHV3-66,ARLASDGSGSYLDYFDY,IGLV1-40,QSYDSSLSGSWV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
52G1,IGHV3-9,AKDLSSGWDLFDY,IGLV3-21,QVWDTSGDPLV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
52C6,IGHV1-69,ATDGGGGSYYYAHYYYGMDV,IGLV8-61,VLYMGSGIVV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
52E7,IGHV5-51,VRSDGDYVIGHDY,IGLV1-44,ATWDDSLNGRV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
52B6,IGHV3-48,ARGRDDYGDYRGGDFDY,IGKV3-11,QQRSNWPPIT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
52F7,IGHV3-9,AKDIGVMVPGVTPYGMDV,IGKV2D-30,MQGTHWPPGT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
52B8,IGHV1-69,ARGPAYVSGTYYWNAFDI,IGKV3-15,QHYNNWPLYT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
52E9,IGHV3-30,ARDPPPGNMGSMAQHLVLLVVFDI,IGKV1-39,QQSYTTLALT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
52G9,IGHV3-66,ARDPMRPGMDV,IGKV1-33,QQYDNLPRT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
53H3,IGHV3-66,ARYYGPQGRAFDI,IGKV1-33,QQYDNLPLT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
53C5,IGHV1-69,ARGRYTYGTEGYFDN,IGKV1-5,QQYNNLYT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
53G1,IGHV3-33,AKGGFGYASGWYYLDY,IGKV1-33,QQYGNLPPIA,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
53B2,IGHV3-13,ARAYYDTSGYYNYFDH,IGKV3-15,QHYNNWPLYT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
53H5,IGHV3-53,ARGYGSGSYGWFDP,IGKV3-15,QHYNNWPLYT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
53H6,IGHV3-53,AREGLGMDV,IGKV3-15,QHYNNWPLYT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
53F9,IGHV3-53,AREGLVGTTLTFDY,IGKV2D-30,MQGTHWPPGT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
53G6,IGHV2-70,ARFLVGGFKAWFDP,IGLV1-51,GTWDTSLNVWV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
53C10,IGHV3-43,ARESPKLTGYFDY,IGLV3-21,QVWDSSSDPYV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
53E11,IGHV1-46,ARDQAFIVATLGPDY,IGLV8-61,VLYMGSGIWV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
53E12,IGHV3-53,AKMLWLRGWFDP,IGLV6-57,QSYDTSNHWV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
53F12,IGHV3-66,ARDAVGSYYYGMEV,IGKV3-15,QHYNNWPLYT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
54H2,IGHV5-51,ARQESGWSFDY,IGKV1-39,QQSYSTPRT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
54F10,IGHV3-53,ARDLEERGAMDV,IGKV3-20,QQYGSSLWT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
54G7,IGHV3-66,ARAGWLRGRFDP,IGLV3-21,QVWDSTTDLPHWV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
55G3,IGHV2-70,ARTRLGITAFDI,IGKV1-39,QQSYTTPRT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
55A8,IGHV1-69,ARGTEYGDYDVSHD,IGKV1-5,QQYNSYSHT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
55C9,IGHV3-53,AREGLVGTALAFDY,IGKV1-39,QQSYSTPPYT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
55G9,IGHV3-13,ARVGYDSSGYYWYLDL,IGKV1-39,QQSYTTPLFT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
55G11,IGHV3-30,GKGAGPYCGGGSCYPTKVDY,IGKV1-33,QQYDNLLWT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
56C3,IGHV3-33,AKDGSGSYYNSGALDY,IGKV1-33,QQYDNLPPYT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
56H3,IGHV3-66,ARDYGDYYFDY,IGKV3-20,QQYGSSPRT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
56B4,IGHV1-18,ATDDPDIVLVPAAMSLDY,IGKV1-39,QQSYNTLALS,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
56D7,IGHV3-66,ARDLDYYGMDV,IGKV1-9,QQLNSYPPIT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
56H7,IGHV4-59,ATDYYDSSGYRYGMDV,IGKV1D-12,QQANSFPLT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
56A8,IGHV1-69,ASFGSLWDLRDY,IGKV3-20,QQYGTSRT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
56E8,IGHV3-23,AKDVGSRLIYDVFDY,IGKV1-39,QQSYSTPPYS,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
56A10,IGHV2-70,TRTATVVKDY,IGKV1-39,QQSYSTPRT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
56B11,IGHV2-70,ARMIPIPALDY,IGKV1-39,QQSYSTPHT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
56B12,IGHV2-70,AREEAAGTKLDY,IGKV1-39,QQSYSTPRT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
56C12,IGHV3-30,AKDPTSLYCSGGSCYNNWFDP,IGKV1-39,QQTYSTPRT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
56E1,IGHV3-30,AGGGVLVTSDPDAFDI,IGLV1-44,AAWDDSLNGWV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
56A3,IGHV3-30,AKRGGTYCSGGICYGGYFDY,IGLV1-40,QSYDSSLSDWGV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
56F3,IGHV1-46,ARDYSRITMIRGAGDY,IGLV1-51,GTWDSSLSAQV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
56H9,IGHV3-53,ARGPYPSSSWA,IGLV2-14,SSFTSSSTPYV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
56H11,IGHV4-4,AGEQHIVTTIIDY,IGLV1-44,ATWDDSLNGRV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
57B2,IGHV3-30,AGGGVLVTSDPDAFDI,IGKV1-33,QQSDNVPVT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
57C4,IGHV3-15,STTNDYGDYSANY,IGKV1-39,QQSYSTPLT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
57E7,IGHV5-51,ARIEYYNDSSGYYQF,IGKV3-20,QQYGSSWT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
57H7,IGHV1-8,ARGLWFGDLTRTKYNWFDP,IGKV1D-13,QQFNNFLLT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
57A8,IGHV3-23,AKGQRGSPDFFDY,IGKV1-5,QQYNSYSPLT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
57B8,IGHV3-53,ARDLVTWGLDY,IGKV1-9,QLLNTDPIT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
57A9,IGHV1-3,ARAGWELNY,IGKV4-1,QQYYSFWA,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
57G9,IGHV2-70,ARITPHLVYDY,IGKV1-39,QQSYSIPRT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
57A6,IGHV5-51,ARQESGWSFDY,IGLV3-19,NSRDSSGNHWV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
57F7,IGHV4-34,ARDDSSSSGVGTGMDV,IGLV1-44,AVWDDSLNGWV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
57F8,IGHV2-5,AHTTWYYYGSGWFDP,IGLV1-44,AAWDDSLNGHV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
57A11,IGHV1-18,ARVQEFWLDP,IGLV3-21,QVWDSSSDHPL,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
57E11,IGHV1-8,ARGLWFGDLTRTKYNWFDP,IGLV1-44,AAWDDSLNGWV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
58G1,IGHV3-53,ARDLENGGLDV,IGKV1D-12,QQTNSFPT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
58D2,IGHV3-11,ASPLLSHNYGSGSYYNVYWYFEL,IGKV3-11,QQLGT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
58A4,IGHV4-59,ARTLGAYYDILTGFRTPGGWFAP,IGKV3-20,QQYGSSPWT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
58B5,IGHV3-23,AKEPSFGLWFGELSG,IGKV3-20,QQYGSSLPYT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
58G6,IGHV1-58,AAPNCNSTTCHDGFDI,IGKV3-20,QQYDNSPWT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
58G9,IGHV3-13,ARGSLRGGILSGYAFDI,IGKV1-39,QQSYSSPPWT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
58E2,IGHV4-39,ARYYGPGTYYDAFDI,IGLV2-14,SSYTSSSTWV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
58A3,IGHV3-30,ARDWVHYGSGSYPPDY,IGLV2-18,SSYTSSSTWV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
58H3,IGHV5-51,ARHPVLRGNIDY,IGLV1-40,QSYDSSLRGSV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
510H2,IGHV3-66,ARDKWEGTFDY,IGKV1-9,QQLNSYPRMT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
510A4,IGHV2-70,ARVQVAAAGSPYDY,IGKV2-28,MQALQMGT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
510G4,IGHV4-31,ARDYGGNSNYFHY,IGKV1-33,QQYDTLPLT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
510H4,IGHV3-66,AETGWDGMDV,IGKV3-11,QQRSNWPGT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
510A5,IGHV3-9,AKDRGYEILTPASFDY,IGKV1-39,QQSYSTPPYT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
510F6,IGHV2-5,AHSLPSKYSYSYGSFDY,IGKV1-39,QQSYSAPYT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
510D7,IGHV1-69,ATGRYTYGYGYYFDY,IGKV3-20,QQYGSSRT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
510E10,IGHV3-23,AKGELLWFGELLENWFDP,IGKV1-12,QQADSFPWT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
510H10,IGHV2-70,ARIQRGIAADY,IGKV1-39,QQSYSTPRT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
510B1,IGHV5-51,ARLPPHFGSGSYYGNAFDI,IGLV1-47,ATWDDSLTGPV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
510G2,IGHV7-4-1,ASTVGRGSGTYYYGNYYSYSMDV,IGLV2-14,TSYTGSSTSVV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
510H7,IGHV4-59,ARHCPWQQLVSNWFDP,IGKV1D-13,QQFNNFLLT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
510H6,IGHV1-46,ARTGFLIPSKGGGMDV,IGLV2-14,SSYTSSSSLQI,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
510C4,IGHV3-48,ARDPGEWESLDLDY,IGLV1-40,QSYDSSLSGNWV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
511A1,IGHV4-31,AREKIRSIAAAGTVYYYGMDV,IGKV3-15,QQYNNWPPWT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
511B4,IGHV4-59,ASTYWDSSGYYYGVDY,IGKV1D-12,QQANSFRLT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
511E7,IGHV5-51,ALAVGRGIPTSYFDY,IGKV1-33,QQYHNLPIT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
511G7,IGHV3-33,AKGGNYGDYLRGFDY,IGKV1-33,QQYHNVPPA,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
511E9,IGHV1-18,AREGAGLIIAYDY,IGKV6-21,HQSSSLPYT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
511D11,IGHV1-18,AVLDYCSGGSSSSGYYNYGMDV,IGKV3-20,QQYGRSPYT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
511H11,IGHV3-13,VRGDHSSGWYGTYYYYMDV,IGKV1-39,QQSYSSPPWT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
511D12,IGHV3-66,ARDLDIAGAFDI,IGKV1-9,QLLNSFPIT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
511A5,IGHV4-31,ARIYRGTMVVVFSDLHWYFDL,IGLV3-21,QVWDSSADHYV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
511E5,IGHV1-2,ARDSLFSRVDWYFDL,IGLV1-40,NSRDSSGNTVV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
511G5,IGHV1-46,ARDGALYSNSPTEFDY,IGLV1-47,TTWDASRGGWV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
511B7,IGHV1-46,ARGGLVPAVMPALDY,IGLV1-47,AAWDDSLSGPV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
511H7,IGHV3-23,ARGLQYYYDTSGYYKDSYYYGVDV,IGLV1-47,AAWDDSLSGPV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
511B11,IGHV3-7,AGLFWYGGYFDY,IGLV1-40,QSYDRSLSVLYV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
59B11,IGHV3-13,ARGTQDRVELMVGSPYYYYYMDV,IGKV1-39,QQSYITTMYT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
59D6,IGHV4-34,ARHRRDYITMIVRPTRLWAFDY,IGLV1-40,QSYDSALVV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
59A1,IGHV3-66,ARELGPVGGTDQ,IGKV1-39,QQSHSTPYT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
59A2,IGHV3-66,ARDLPLHGDYFDY,IGKV1-33,QQSDNVPVT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
59H6,IGHV3-30,ARETLGGYCNGGSCYDAGYFDY,IGKV3-20,QQYGSSPWT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
59G12,IGHV3-33,ARDGVDFGMVTLFDY,IGKV1-39,QQSYNTPPWT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B1E6,IGHV4-4,ARVQGLIDY,IGKV1-NL1,QQYYSTPPRT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B1B1,IGHV5-51,ASQAAAGYYYYMDV,IGKV1-39,QQSYNILWT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B1H12,IGHV3-23,AKQTDYGVGWFDP,IGKV1-33,QQYDNFSLT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B1E11,IGHV1-69,AVLPLHSSYNWYYFDY,IGKV3-11,QQRSNWPPGMYT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B2F2,IGHV2-5,AHQRHSNSWYVSAWFDP,IGLV1-40,QSYDSSLSGNFV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B5A6,IGHV3-33,AKGGWYSSKWYYFDY,IGKV2-28,MQALQMGT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B2D5,IGHV3-13,ARGSDTVTTAFDI,IGKV1-39,QQSYTTPGLT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B2H8,IGHV3-53,AREAPNSRGSGTNFDY,IGKV1-39,QQSYSTPPYT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B2D11,IGHV3-33,AKNGYSYAYPRQYFDY,IGKV1-33,QHYDNLKVT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B2E4,IGHV4-31,ARVSRYTMVRGVIFDY,IGLV2-23,CLYAGHSTYVV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B2G6,IGHV4-38-2,ARVGVATILGVDY,IGLV6-57,QSYDSSWV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B2E12,IGHV3-30,AKGGGYISAWSTRYYAMDV,IGLV2-14,SSYTSSSTWV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B3E9,IGHV3-23,AESSSLTGNFNY,IGLV3-21,QVWDTAWV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B5A1,IGHV3-13,ARGFDTTTGFYFDY,IGKV1-NL1,QQDYNFPWT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B5B6,IGHV1-69,ARTEYSYDSGSSRAYSMDV,IGKV1-39,QQTHSTPRT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B5E5,IGHV7-4-1,ARVGPSSSWPS,IGKV1-39,QQSYSTPRT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B5C1,IGHV3-33,AKGGWYSSKWYYFDY,IGKV2-28,MQALQMGT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B5F7,IGHV3-7,ARDLGVLWFGDPY,IGKV1-NL1,QQYYSAPRT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B4G4,IGHV2-5,AHSPDHRYFDVLTGYFNSERFYFDY,IGLV1-51,GTWDSSLSAGV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B4A7,IGHV4-39,ARIPRHLGQDHYYYVMDV,IGLV2-23,CSYAGIFV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B4D9,IGHV3-30,AKAAGGGYSYIYWGGDY,IGLV6-57,QSYDSSNLWV,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B4E1,IGHV4-61,AREYFVSLPAAQTLYYYGIDV,IGKV3-15,QQYKNWPPWT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B4H2,IGHV1-8,ARGLWFGDLTRTKYNWFDP,IGKV3-20,HQYDSSPLT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B4A3,IGHV1-46,ARDPPSGNYDNIDEWTRSENHYNYGMDA,IGKV3-11,QQRSNWPYLT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B4C5,IGHV3-11,ARDGSAVAGPMSYFDY,IGKV1-NL1,QQYYSIPRT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B4E5,IGHV2-70,AREVAGAVHLDY,IGKV1-39,QQSFSTPRT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B4B6,IGHV3-7,ARDLGVLWFGDLLF,IGKV1-NL1,QQYYSDPPRT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
8B4E11,IGHV4-59,ARGGYYYGPPRDFDY,IGKV3-20,QHYGSSPQYT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
13G9,IGHV1-58,AAPYCSSTSCRDGFDI,IGKV3-20,QQYGRSPWT,RBD,-,SARS-2_infection,Han et al. A rapid and efficient screening system for neutralizing antibodies and its application for the 2 discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD bioRxiv doi: 10.1101/2020.08.19.253369
HL CV01-101,IGHV3-74,ARGSSNLFDI,IGLV1-44,AAWDDSLNGWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-102,IGHV3-21,ARSGGYSGYDYSHRIDY,IGLV2-14,SSYTLDSTVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-103,IGHV1-69,ASGWGMEYSSSSADY,IGKV3-11,QQRSNWPPYT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-104,IGHV1-18,ARADETMVQGVIPNFDY,IGLV2-8,SSYAGSNNVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-107,IGHV3-74,ARGRDCGGSSCYGYPYYGMDV,IGKV2-28,MQALHTPYT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-109,IGHV3-7,ARAGSVGVVDY,IGKV2-30,MQGTHWPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-110,IGHV3-7,VRDRGYCVGDVCYTVLDY,IGKV1-6,LHDYNYPPT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-111,IGHV3-15,TTWFYYDIRDH,IGKV3-11,QQRSNWPPFT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-112,IGHV1-18,ARADDTMVQGVIPNFDY,IGLV2-8,SSYAGSNNVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-113,IGHV3-15,ASIYYDF,IGKV1-17,LHYNSVPYT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-114,IGHV1-2,ARGDAVARTLNLDY,IGLV1-44,AAWDDSLNGV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-116,IGHV3-7,ARAGNIGAVDY,IGKV2-30,MQGTHWPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-117,IGHV3-49,GLSYYYDNGGYYSVPPIDV,IGLV2-8,SSYADSNNLV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-118,IGHV3-9,AKNSPSCADAVCYFDV,IGKV4-1,QQYYSAPRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-120,IGHV4-30-4,AREGVLITIFGVARDAFDI,IGKV3-20,QQYGSSPRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-121,IGHV4-38-2,SIWGGVQGVLQDY,IGKV3-15,QQYNDWPRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-122,IGHV3-7,ARAGSIASVDY,IGKV2-30,MQGTHWPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-123,IGHV3-7,AKGGWRYFDY,IGKV3-11,QQRSSWPLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-124,IGHV3-23,AKYGSITIFGVVIIGYFYFDY,IGKV3-20,QQYGSSPAT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-125,IGHV1-18,ARADYTMVQGVIPNFDY,IGLV2-8,SSYAGSNNVL,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-126,IGHV5-51,AGHVRYCISTNCYHYGMDV,IGLV5-45,MIWHTSAWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-128,IGHV3-7,ARAGDRGAVDY,IGKV2-30,MQGTHWPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-129,IGHV1-18,ARADYTMVQGVIPNFDY,IGLV2-8,SSYAGSNNVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-130,IGHV3-7,ARPGYSGNNWGEAFDI,IGKV4-1,QQYYDTLWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-132,IGHV4-59,ARDRGYNWNYYYYYGMDV,IGKV3-20,QQYGSSPST,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-133,IGHV3-7,ARAGSRGSVDY,IGKV2-30,MQGTHWPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-134,IGHV3-30,AKEKLDCSSTSCYFGFIYYYYYMDV,IGKV1-12,QQANSFPLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-135,IGHV3-11,ARESYEGSSFDY,IGLV6-57,QSYDSSNRRV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-137,IGHV3-7,ARDYGRCGDY,IGKV3-11,QQGGNWPRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-138,IGHV4-39,ARHGYITIFGVVIIPGWFDP,IGKV3-15,QQYNNWPPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-139,IGHV4-39,ARHPDNELLPFDY,IGLV3-21,QVWDSSSDSYV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-140,IGHV3-30-3,ARDPRNYCHSNTCPVWYFDL,IGKV3-20,QQYGSSPRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-141,IGHV3-33,AREGNYGDYGGSFDY,IGLV3-10,YSTDSSGNHRV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-142,IGHV4-30-4,ARGPRITIFGVVIYWYFDL,IGLV1-40,QSYDSSLSGSGV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-144,IGHV3-30,ARRDRIFEFGATREALDF,IGLV1-40,QSYDSSLSGYV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-145,IGHV3-23,AKVTWTTTGDS,IGKV1-5,QQYNSYPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-146,IGHV3-7,ARAGDRGAVDY,IGKV2-30,MQGTQWPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-147,IGHV3-30-3,ARERVNGRWLQLLTP,IGKV1-5,QQYDAYLS,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-148,IGHV3-7,ARAGDRGAVDY,IGKV2-30,MQGTHWPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-149,IGHV1-18,AGYPRYNWNYDNRYYFDF,IGKV1-39,QQSYSAPIT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-151,IGHV1-18,ARADDTMVQGVIPNFDY,IGLV2-8,SSYAGSNNVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-152,IGHV1-3,ARGVGATIPYYYYYYMDV,IGKV1-5,QQYNSYSWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-153,IGHV4-4,AKVGGGNADHGPGYYYYYMDV,IGKV1-9,QELNRYPRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-154,IGHV3-9,AKNSASCADDLCYFDI,IGKV4-1,QQYYSGPRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-155,IGHV3-11,ARALPGGITIFGVVITEYYFDY,IGKV3-20,QQYGSSSYT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-158,IGHV3-21,ARGDDYGEYTGAFDA,IGLV3-1,QAWDSSTVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-159,IGHV1-46,ARGGETQQRLVWDQKTDD,IGKV1-17,LQYNSYPLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-163,IGHV3-7,ARAGSVGTVDY,IGKV2-30,MQGTHWPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-166,IGHV3-15,TTEKGRYHLGGVFAN,IGKV4-1,QQYYSTPLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-168,IGHV5-51,VWTSRGYFDH,IGLV7-43,LFYYGGAWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-169,IGHV3-30,ARDLSSGWSLDS,IGLV2-14,SSYTSSNTWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-170,IGHV4-4,ARYCSSTSCYGYYYYGMDV,IGLV2-8,SSYAGSISYV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-171,IGHV4-4,AKGGGSGWYYDAFDI,IGKV3-15,QQYNNWLRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-174,IGHV1-18,ARDDWNYARGNFDY,IGLV2-14,SSYTSSSSVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-175,IGHV3-7,ARAGGVGTVDY,IGKV2-30,MQGTLWPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-176,IGHV1-18,ARADHTMVQGVIPNFDY,IGKV2-28,SSYTGRKNVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-180,IGHV3-7,ARCDMAGTTDY,IGKV2-30,MQGTLWPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-181,IGHV3-21,ARDLEGVETIFGVVIIPAYWYFDL,IGKV2-28,MQALQTRLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-182,IGHV3-23,AKDLKIGTLGWYYDFWSGYLPDPSNKIFDY,IGLV1-40,QSYDSSLSGWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-183,IGHV3-73,TRVNPIQGAFYDALDI,IGLV1-51,GTWDSSLSVVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-184,IGHV4-59,ARFSSAAGVWALDH,IGKV4-1,QQYYTTPFT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-185,IGHV1-69,ACDMVQGVAVLDV,IGLV2-14,SSYTSSSTVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-186,IGHV4-59,ARHGKSIPYSNYDWFDP,IGKV1-39,QQSYSTLPFT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-188,IGHV3-72,ARDLGANGDRFGN,IGKV4-1,QQYYSTPLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-193,IGHV3-15,ATDLGDYGDYMRS,IGKV1-12,QQANSFPYT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-194,IGHV4-59,AKKADPHSAFDY,IGLV2-11,CSYAGSYTYV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-195,IGHV3-7,VRELVVGRAEYFQD,IGLV1-44,AAWDDSLNGRV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-196,IGHV3-30,AKDPGMLYPSAFDM,IGKV3-15,QQYNNWPPLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-197,IGHV3-23,AKDQDGHYGGNPDMDH,IGLV2-8,SSYAGSNKMV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-198,IGHV3-15,ATLTYGYSPY,IGLV2-14,SSYTSSTTYV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-199,IGHV3-74,ASNFNRNDGY,IGKV2-30,IQSTHWPPN,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-202,IGHV4-30-4,ARMGNMFGYSVVDF,IGKV1-39,LQTYSAPYT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-203,IGHV3-30,AKSEGKFYFYGVDV,IGLV1-47,AACDDSLSGHV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-205,IGHV5-51,AREARWSFPSWFDP,IGKV3-15,QQYNNWPRF,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-211,IGHV5-51,ARLSSGWYGGFNFDY,IGKV3-20,QQYGSSPVYT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-212,IGHV3-30,AKCSYTSICKGWDGAH,IGLV2-14,SSFTTSYTLV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-213,IGHV3-64,ARLQGTGYLDY,IGKV3-20,HQYGSSPRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-215,IGHV3-48,ARQWAVNWFVP,IGLV2-14,SSHTSSSTVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-220,IGHV3-48,ARDVGTYESTSTGMDV,IGKV3-11,QQRGNWPPAT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-221,IGHV3-30-3,ARGAPVDY,IGLV2-8,-,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-222,IGHV3-23,AKPGGEWYSSGWRFDY,IGLV1-47,AAWDDSLSGPV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-223,IGHV3-23,AKCGRTSCRVDAFDI,IGLV8-61,VLSMGGGVWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-225,IGHV3-53,ARDGGGSYPHRAFDI,IGLV2-14,SSYTSSSTSDVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-226,IGHV4-39,ARHATGTPPYYYYYMDV,IGLV3-1,QAWDSSTACV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-227,IGHV3-30,AKGSPLLGFGGVDY,IGLV5-39,AIWYSSSLV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-228,IGHV3-7,ARVGASDYDYVWGTRTLDS,IGKV4-1,QQCLTTPPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-229,IGHV5-51,ARPYGAGTAHYFDY,IGKV4-1,QQYYGTPHT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-231,IGHV4-39,ARHFHPGNYYYYYMDV,IGLV3-1,QAWDSSTYVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-232,IGHV4-39,ARKYGDLHFDY,IGLV8-61,VLYMGSGISV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-233,IGHV4-39,ARSDARFLEWLFPDAFDI,IGLV2-23,CSYAGSTTFVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-234,IGHV3-30,ARGSPFGGIRSGLGP,IGKV1-27,QKYNSAPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-238,IGHV4-39,ARHPTGSGSYQYYYYYIDV,IGLV3-1,QAWDSSTVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-241,IGHV3-66,ARDRGYDSSGYTAADAFDI,IGKV1-5,QQYNSYST,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-242,IGHV4-31,ARGGYRNWFDP,IGLV2-11,CSYAGSYTWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-244,IGHV5-10-1,ARLKGSVPPYYYNYMDV,IGKV2-28,MQGLQTPFI,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-249,IGHV3-30-3,ARHNRAQGPSFDV,IGKV1-39,QQTYSVPTT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-254,IGHV3-7,ASLLGGTVVNDY,IGKV4-1,QQYYSTQYT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-257,IGHV3-48,ARHPWDDYGDYYYYYMDV,IGKV3-20,QQYGSSLNT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-258,IGHV4-59,ARAVHGVDTGMVTYYYHYYMDV,IGLV3-21,QVWDNSIDHVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-260,IGHV1-8,ARGREYYDFWSGYYN,IGLV2-14,SSYTRSNTVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-266,IGHV3-15,TSERWLDAFDI,IGKV1-39,QQSYRSPPIT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-273,IGHV4-4,ARGWGKGPPLGY,IGLV2-23,YSYAGSSTWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV01-274,IGHV3-30,AKDNGDYACFDY,IGKV4-1,QQYYSTPLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV01-276,IGHV1-2,ARDPFEYYDFWSGYYRGGMDV,IGLV2-14,SSYTSSSTRV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-101,IGHV1-2,ARGLITWYYYYDSSAVDY,IGKV3-20,QQYGSSPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-103,IGHV3-21,ARDPDGHRSGWFDWFDP,IGKV1D-12,QQANSFPIT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-104,IGHV1-18,ARDSHYYDSSGYYYLYYYYGTDV,IGLV3-25,QSADSSGTYV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-106,IGHV4-31,ARGRTIFGVVSGAFDI,IGKV3-20,QQYGSSPLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-107,IGHV4-31,ARGRTIFGVVSGAFDI,IGKV3-20,QQYGSSPLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-108,IGHV3-15,TKTKNPPAYDFWSGYYRGRPPYYKYGMDV,IGLV1-40,QSYDNSLSEYDDV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-109,IGHV5-10-1,ARHVGVGATHSPPFDY,IGLV1-40,QSYDSSLSGPTV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-110,IGHV3-48,ARDLGSWYYLLDFDY,IGKV1-5,QQYNSYPRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-112,IGHV3-48,GRSSSWRYNWFDP,IGKV3-15,QQYNNWPPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-113,IGHV3-15,TTDPYYEISSGYSPDY,IGLV2-11,-,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-116,IGHV4-59,ARVQGRGSGSYYSAYYYGMDV,IGLV1-40,QSYDSSLSGV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-117,IGHV1-46,LRDGISTFGVVNHYYAMDV,IGLV2-14,SSYTSSSTVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-118,IGHV1-46,ARDGISTFGVVKHYYAMDV,IGLV2-14,SSYTTTTTLV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-120,IGHV3-21,ARDSLITIFGVVIEAPDDYGMDV,IGLV2-14,SSYTSSSTVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-121,IGHV3-23,AKDYFVIPPAALYDY,IGLV1-51,GTWDSSLSAGV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-123,IGHV3-23,VKELDDQLTLGGWFDP,IGLV2-23,CSYVGTATVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-124,IGHV5-51,ASSVRYFDWFDFDY,IGLV1-44,AAWDDSLNGYV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-129,IGHV1-69,ARARRPTYSSSWGTFDY,IGKV1-39,QQSYSTPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-130,IGHV4-59,ASGTYGGPYLFDY,IGKV1-5,QKYNTYPGT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-131,IGHV3-11,ARAGDMIVVAAFDY,IGKV3-20,QQYGSSPLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-132,IGHV3-7,ARGPQMVYALFPYYYYYGMDV,IGKV1-27,QKYNSAPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-135,IGHV3-64,VMELYGSDVFDL,IGKV1-39,QQSYSTSWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-138,IGHV3-74,ASYTWGRI,IGLV2-14,SSYTRSSTLVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-139,IGHV4-39,ASQGPLPPILYDILTGYYLGDYYYGMDV,IGKV2-28,MQALQTPLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-140,IGHV3-49,TRDAYYYGSGSYSEGGH,IGKV3-11,QQRSNWPPLFT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-141,IGHV4-38-2,ARDVTGYDNEDYYYYYGLDV,IGKV4-1,QQYYSSPRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-142,IGHV3-53,AREGPDSGYLDY,IGLV4-69,QTWGTGIRV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-143,IGHV3-48,ARDSGFWSGYYPGNFNY,IGKV1-33,QQYDNLPPLT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-144,IGHV1-18,ARDPWIELRPPRNYYYNGMDV,IGKV2-28,MQALQTPRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-145,IGHV1-46,ARDSSDCSGGSCYRFDY,IGLV1-44,AAWDDSLNGYV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-146,IGHV3-23,AKDRTVTKTGLFYLDDC,IGKV1-39,QQSYSTPIT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-147,IGHV3-23,ASQTGTGEVDY,IGLV3-1,QAWDSSTGV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-148,IGHV3-23,AKGPRLLWFGELSPFDY,IGLV1-51,GTWDSSLSALV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-150,IGHV3-23,VKGSGDIERMVSTLRYYFYGLEV,IGLV1-47,AVWDDSLSAWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-151,IGHV3-23,VKGSGDIERMVSTLRYYFYGLDV,IGLV1-47,AVWDDSLSAWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-152,IGHV3-30,AKSGEVFWFGRFRRDYLDY,IGLV1-44,AAWDDRLNGVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-153,IGHV3-74,ARDSCTSTSCYESMK,IGKV1-5,QHYNSYPWM,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-154,IGHV1-24,ATSTVIAAAGTVHYYYYYGMDV,IGKV2-24,MQATQFPYT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-155,IGHV3-33,ARDEKAYDFWSGYLSYYYYGMDV,IGKV2-30,MQGTHWPPYT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-156,IGHV5-10-1,ARLLYYYDSSGYYLPSPIDY,IGKV1-33,QQYDNLLLT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-158,IGHV3-23,VKGSGDIERMVSTLRYYFYGLDV,IGLV1-47,AVWDDSLSAWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-160,IGHV5-10-1,ARLGADSSGYYLPSGGIGY,IGLV1-40,QSYDSSLSGSKV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-161,IGHV4-39,ARQRKGWLQLRGNWYFDL,IGLV3-10,YSTDSSGNQVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-162,IGHV3-74,ARGGGTVVTPGPDY,IGLV4-69,QTWGIGTHDVI,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-163,IGHV3-23,VKGSGDIERMVDALRYYFYGMDV,IGLV1-47,AAWDDSLSAWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-166,IGHV4-4,TRLYCSSGACYLGP,IGKV3-20,QQYGRSPT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-167,IGHV1-46,ARGRDWFDP,IGLV2-23,CSYAGSSTWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-168,IGHV1-69,AREAFYDILTGYSSTPNHYYYGMDV,IGKV2-28,MQALQTPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-169,IGHV3-74,ARDFYYDSSGFDY,IGKV1-39,QQSYSTPPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-170,IGHV4-4,ARDTIGGHAFDI,IGLV3-21,QVWDSSSDHRV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-172,IGHV1-24,ATSTLFSSVVPASWFDP,IGLV2-14,SSYTSSSTPVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-173,IGHV1-2,ARILPSDYFWSGYYSIQETDAFDI,IGKV1-5,QQYNSYSSS,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-174,IGHV5-51,ARQVFIAVAGTGFDY,IGKV2-28,MQALQTPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-175,IGHV4-31,ARDFVSGPLMTENVPIYDSSGYYLTRYNWFDP,IGLV1-51,GTWDSSLSAVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-177,IGHV3-23,AKDSGSYLLN,IGLV3-1,QAWDSSTYV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-179,IGHV1-2,AREDGSSPLGGGMDV,IGLV3-1,QAWDSSTYV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-180,IGHV3-23,VKGSGDIERMVSSLRYYFYGLDV,IGLV1-47,AVWDDSLSAWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-181,IGHV1-69,ASTGHHQDASDY,IGKV3-11,QQRSNWPPRVT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-182,IGHV1-2,ARERLAAAGTDFDY,IGLV1-40,QSYDSSLSDYV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-183,IGHV3-23,VKGSGDIERMVSSLRYYFYGLDV,IGLV1-47,AVWDDSLSAWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-185,IGHV4-4,ARRGHTLLWYYYYGMDV,IGLV1-51,GTWDSSLSAGAV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-186,IGHV3-48,ARGQRGLPFYYYYGMDV,IGLV1-40,QSYDSSLSGSV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-188,IGHV3-23,VKGSGDIERMVSTLRYYFYGLDV,IGLV1-47,AVWDDSLSAWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-190,IGHV4-4,ARGMGYDFWSGYSSYYGMDV,IGKV1-16,QQYNSYPLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-191,IGHV3-11,ARDLGYNRRFDY,IGKV1-33,QQYDNLPLT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV03-192,IGHV3-15,TTDPLRYYDSSGYLYYGMDV,IGKV2-28,MQALLTPST,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-193,IGHV3-53,ARGGSWPNVFDI,IGLV8-61,VLYMGSGIWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV03-195,IGHV1-18,ARDRLRVRGVIKYYYYGMDV,IGLV3-25,QSADSSGTHWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-101,IGHV3-30,AKDRGYSSSWFSYLDS,IGKV3-20,QQYGSLRLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-102,IGHV1-3,AREDTFSVFGVVTRGNAYDV,IGKV3-20,QQYGVSPRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-104,IGHV5-51,ARLGRSLQPNLGFDL,IGKV2-30,MQGSHWPLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-107,IGHV3-21,ARDSESAWNRIGNFYFDL,IGKV3-15,QQYNDWLIT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-108,IGHV5-10-1,ARHHLKRGYATRYGMDV,IGKV1-39,QQSYSTPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-109,IGHV4-31,ASLEGPYCSDTTCYEGGQGLDY,IGKV3-11,HQRGNWWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-110,IGHV1-3,AREDTFSVFGVVTRGNAYDV,IGKV3-20,QQYGVSPRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-111,IGHV3-33,ARDLDGDYVTYYYGMDV,IGLV2-14,SSYTSSSTPVV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-113,IGHV3-30,ASGDGYRNFWYFDI,IGKV2-28,MQALQTPT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-114,IGHV3-30-3,ARTVGDYGDY,IGLV3-1,QAWDSSTVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-115,IGHV3-48,ARDRGGYSGYGPYYYGMDV,IGKV1-39,QQSYSTPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-116,IGHV4-38-2,-,IGLV2-23,CSYAGAGSSNVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-117,IGHV3-23,AKEKTSWLVAYYYGLDV,IGKV1-9,QQVNSHPHT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-118,IGHV4-31,ARDYPFCGADCPWVDVFDI,IGKV3-15,QQYSNWPRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-119,IGHV3-30,AKPVGSSGYYEGGKPIDY,IGKV1-5,QQYNSYWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-119,IGHV3-30,AKPVGSSGYYEGGKPIDY,IGLV3-21,QVWDSSSDHWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-120,IGHV5-51,ARNRAGVIDY,IGLV6-57,QSYDSSNLWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-121,IGHV1-8,VRERIDYDHSGVSTSAFEF,IGLV1-44,GGWDDSLNGYV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-122,IGHV3-23,AKGGYCSGGNCKMAHSYYGLDV,IGLV1-47,AAWDDSLSGHWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-125,IGHV4-39,ASSNTASTMIVVVVQRNWFDP,IGKV3-15,QQYNNWPPIT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-126,IGHV3-48,ARDRARAKWLAYSNYFDY,IGKV3-15,QQYNNWPL,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-127,IGHV3-33,ARDRVSSWEYYFDY,IGLV3-10,YSTDSSGNHRGV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-129,IGHV4-59,ARDRVSGGMDV,IGLV3-21,QVWDSSSDHVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-131,IGHV3-23,ARGYIGYCSGSTCTTNGGGDY,IGLV1-51,VTWDSSLSAGV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-134,IGHV3-23,AKAGIRGGISMVRAHFDI,IGLV2-8,SSYAGSNNFV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-135,IGHV3-33,AREDTAMVQRFDY,IGKV1-39,QQSYSTHT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-135,IGHV3-33,AREDTAMVQRFDY,IGLV3-1,QAWDSSNVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-136,IGHV1-69,ARGRDIVVESTDQDPMDV,IGKV4-1,QQYYSTSSIT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-138,IGHV4-31,ARDYPFCGADCPWVDVFDI,IGKV3-15,QQYNNWPRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-139,IGHV3-23,AKDFSGANGDYYYYGMDV,IGLV3-25,QSADSSGTWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-140,IGHV4-59,AAGGGSGFYYF,IGKV1-5,QQYKSSSST,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-143,IGHV4-59,ARDRVAAGVDY,IGLV3-21,QVWDSSSDHVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-144,IGHV3-30-3,ARTPGDGMDV,IGLV3-10,-,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-145,IGHV5-10-1,ARHAIYCSGGSCYAYFDY,IGLV1-41,-,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-146,IGHV4-31,ARDYPFCGADCPWVDVFDI,IGKV3-15,QQYNNWPRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-148,IGHV4-39,ARQRTHTIFGVVVHFDY,IGKV4-1,QQYYSTPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-149,IGHV4-59,ARGWGFPGSTNVHFYFYGLDV,IGKV1-9,QQLNSYRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-151,IGHV4-59,AAGEVVTAISYYYYGMDV,IGLV3-1,QAWDSSSVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-152,IGHV3-15,TTERIYDYVWGSYRYSDY,IGKV3-20,QQYGSSPVT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-153,IGHV4-4,ARDLNV,IGKV3-15,QQYVNWPFT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-155,IGHV1-2,ARALRITMIVVVTHYGMDV,IGKV3-20,QQYGSSPYT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-157,IGHV3-48,ARDKSDFWSGNFDY,IGKV1-33,QQYDNLLVT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-159,IGHV4-38-2,ARDKVDYYPYYFDY,IGLV3-21,QVWDSSSDHRV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-162,IGHV3-21,ARDQWSGTTVTSMGH,IGKV1-5,QQYDSNWYT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-163,IGHV1-2,AREVMVRGALPPYGMDV,IGKV3-11,QQRSNWPPVT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-164,IGHV4-31,ARDYPFCGADCSWVDVFDI,IGKV3-15,QQYNNWPRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-165,IGHV3-74,AREGGDGFDY,IGKV1-5,QQYQSYPLA,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-167,IGHV1-69,ARGVEMATILPDDAFDI,IGKV3-15,QQYNNWPPVT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-169,IGHV1-69,ARGSTHNNLFVMDY,IGLV7-46,FLSYSGVRGLFVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-170,IGHV1-2,ARVDTTGTTFWLYYYYGMDV,IGLV3-1,QAWDSSTALVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-171,IGHV4-30-4,ARLHGDYYYFDY,IGKV1-39,QQSYSTHT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-171,IGHV4-30-4,ARLHGDYYYFDY,IGLV3-1,QAWDSSVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-172,IGHV4-30-4,ARLSMTTVTRGNWFDP,IGKV1-39,QQSYSTHT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-174,IGHV1-2,ARDLSNSGSSFDY,IGLV3-1,QAWDSSTADVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-175,IGHV1-46,VQDLGVRGGRRALDV,IGKV2-28,FQALQTPYT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-176,IGHV3-53,ARGYPGGP,IGKV1-33,QQYDNLLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-178,IGHV3-23,AKDALGFCSGTSCYGEGAFDI,IGKV1-5,QQYNSYPYT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-178,IGHV3-23,AKDALGFCSGTSCYGEGAFDI,IGLV2-23,CSYAGSSTWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-181,IGHV3-30-3,ARDLQYYDFWSGYLGTPGRYYYYGMDV,IGKV3-20,QQYGSSPPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-182,IGHV4-59,ARDRVSGGMDV,IGLV3-21,QVWDSSSDHVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-183,IGHV3-30-3,ARDLRFLEWLFNVPYYYYYGMDV,IGKV1-9,QQLNSYPYT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-183,IGHV3-30-3,ARDLRFLEWLFNVPYYYYYGMDV,IGLV2-23,CSFAGGITLV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-185,IGHV3-15,TTDRTYDYVWGSYRYRDY,IGKV1-39,QQSYSTLPRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-187,IGHV3-73,TTIGSGYGFGH,IGKV1-39,QQSYSTHT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-187,IGHV3-73,TTIGSGYGFGH,IGLV2-11,CSYGGTYVL,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-189,IGHV3-9,AKAHSDPNYDFWSPDYYGMDV,IGLV2-14,SSYSTSSTKEV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-190,IGHV3-30-3,ARGVYGDSGVDY,IGLV3-21,QVWDSSSDHLYV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-191,IGHV3-11,ARDTSQSHMDV,IGKV2-30,MQGTHWPPYT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV05-192,IGHV1-3,AREDTFSVFGVVTRGNAYDV,IGKV3-20,QQYGVSPRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-194,IGHV3-74,ARDRHTYSLEYFQH,IGLV6-57,QSYDSSNQV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV05-195,IGHV3-30,AKEGSKGWLQSSCYFDY,IGLV3-25,QSADSSGTYQV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-102,IGHV1-18,ARDLARVGWTWWYYYYGMDV,IGKV2-30,MQGTHWPRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-103,IGHV3-23,AKVYGSNTHTPVDY,IGLV2-8,SSYAGSNNVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-104,IGHV3-7,ARDAARYYGMDV,IGKV1-39,QQSYSTPRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-107,IGHV3-23,AKDRRTMIVVVITNKYYYGMDV,IGKV1-5,QQYNSYPLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-108,IGHV3-15,TTDADTSPVV,IGLV4-69,QTWDTGIRV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-110,IGHV3-48,ARSLRMG,IGKV3-20,HQYGSIPRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-113,IGHV4-59,ARASFKMGTNYHYGMDV,IGKV1-27,QNYNSVPFT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-114,IGHV1-2,TTLTAVVTPLGY,IGKV2-30,MQGTHWPRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-118,IGHV3-15,TTDEQRNYCTSPNCRGGAFDI,IGLV4-69,QTWGTGIRV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-121,IGHV4-39,MRQGDWNYSYYFDA,IGKV2-30,VQGTLWPLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-127,IGHV4-39,ARHPLALITIFGVSRQYGMDV,IGKV1-12,QQANSFPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-128,IGHV3-30-3,ARELGTSGTLDS,IGLV2-14,LSHSTFTTPQWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-129,IGHV3-48,ASIASYDYVWGTNRPNDAFDI,IGLV2-23,CSYGGPRNLYV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-132,IGHV4-4,ARDRQYRGSDYNYYFDY,IGLV1-44,ATWDDSLNGRV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-133,IGHV4-39,ARHQRPVTTFIDY,IGKV3-15,QHYKDWPPFFT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-134,IGHV3-23,AKVMRDDFWSGYYNDYYYGMDV,IGKV3-20,QQYGRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-136,IGHV4-59,ARDNYSSRRYYYYYGMDV,IGKV3-20,QQYGSSPTWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-137,IGHV4-30-4,ARLSMTTVTRGNWFDP,IGLV1-47,AAWDDSLSGWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-138,IGHV3-23,VKDFPFGGCTSTTTNCDLFFAL,IGKV2-24,MQATQFPRA,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-139,IGHV4-59,AGYLRNDNLDP,IGKV3-11,QQRSDWPLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-140,IGHV3-64,AREYYGLLTGYYLDL,IGKV1-39,QQSYSIPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-143,IGHV3-23,AKEFSIGWGLFDS,IGKV3-11,QQRNNWPVT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-147,IGHV1-2,ARDLYYDILTGYYMPMDV,IGKV3-11,QQRGNWPPIT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-151,IGHV1-58,AADPGGVGYCSGGSCYRAFDI,IGKV3D-15,QQYNNWPPALT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-152,IGHV1-69,ARLRVPLTAHDAFDI,IGLV1-40,QSYDSSVGV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-154,IGHV1-69,ARAYCSGGSCYSYYYGMDV,IGLV3-1,QAWDSSTA,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-155,IGHV4-59,ARVPREWLSPLYYG,IGKV1-5,QQYNSYQWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-156,IGHV3-9,VKDNARTRRGSFDY,IGLV2-23,CSYAGSNTYV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-159,IGHV3-48,AREGELSNYDAFDI,IGLV2-11,CSYAGTHSYV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-161,IGHV3-30,AKEGSKGWLQSSCYFDY,IGKV2-28,MQAFEPPAIT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-163,IGHV3-33,ARDWAVAGNFDY,IGKV3-20,QQYGASPPTT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-164,IGHV1-46,ARDGSHWDFDY,IGLV2-14,SSYVSSDAWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-165,IGHV3-53,ARRAASGWNFDY,IGLV2-23,CSYLGSATYV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-166,IGHV1-18,ARDTWDIVIVPAASAYYGMDV,IGKV2-28,MQALQTHT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-172,IGHV3-15,TTDRTYDYVWGSYRYRDY,IGKV1-39,QQTFSSPPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-173,IGHV3-30,SKGFLEWLLRRYYYGMDV,IGKV1-9,QQLNSYPFT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-176,IGHV5-51,ARHFGGSGSYYNGHWIPAYYYHGMDV,IGKV2-28,MQARQTPPLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-176,IGHV5-51,ARHFGGSGSYYNGHWIPAYYYHGMDV,IGLV2-8,SSYAGSTNLV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-178,IGHV4-31,ARDRTMVVWNAFDI,IGKV1-39,QQSHSPSRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-179,IGHV3-7,ARESRLGIAIFDRRLRSWFGA,IGLV2-14,SSYTSSSTRV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-180,IGHV3-15,TTQHYDFWSGNYKPFAF,IGKV2-28,MQALQTLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-181,IGHV3-33,ARDEAAEYYFDY,IGLV3-25,QSADSSGTFWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-183,IGHV3-30,AKEGSKGWIQNSCYFDY,IGKV4-1,QQYYSTPPT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-185,IGHV3-23,VKDPNWANGY,IGKV2-30,VQGTHWPLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-186,IGHV1-46,AKGRSTIFGVIVNQGDCYDY,IGKV1-27,QKYNSAPLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-189,IGHV3-23,AKDPHFDFWSGNYFDY,IGKV1D-12,QQANSFPLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-190,IGHV4-31,ARDRGVTIFGVVIIDAFDI,IGKV3-20,QQYGSSPLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-191,IGHV1-18,SREGDLTIFGSVTNAYYYFGMDF,IGKV1-39,QQSYSTPIT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-196,IGHV1-2,ARDLGIGVAGNLDH,IGLV2-8,SSYAGSNNWV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-199,IGHV4-59,ARDRDSSGWYPNWFDP,IGKV1D-16,QQYNSYPRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-200,IGHV1-2,ARGPFYYDNSGTLGGLDV,IGLV2-14,SSYTSSSTYV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-201,IGHV1-2,ATDRLVNTGVYTTGSMDV,IGLV2-23,CSYGGSSDYV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-202,IGHV3-53,ARDLYYYGMDV,IGKV1-9,QQLNNYSVT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-203,IGHV1-2,ARKQQPSSLSYYYYGMDV,IGLV1-40,QSYDSSLSGSWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-204,IGHV4-39,ALCGYSYGSNYYYYGMDV,IGLV6-57,QSYDSSIWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-205,IGHV3-23,AKEYGYDSSGSGGDY,IGKV1-39,QQSYSTPNT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-205,IGHV3-23,AKEYGYDSSGSGGDY,IGLV2-23,CSYAGSSTWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-206,IGHV1-2,AREGYYDFWSGYYTVYYYGMDV,IGKV1-5,QQYNSYWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-206,IGHV1-2,AREGYYDFWSGYYTVYYYGMDV,IGLV2-14,SSYTSSSTRV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-208,IGHV1-2,ARGPFYYDSSGTLGGMDV,IGLV2-14,SSYTSRNTYV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-209,IGHV3-11,ARDGVIPPRFDY,IGKV1-33,QQYDNLPLT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-210,IGHV3-21,VSSGNYRFHY,IGLV2-14,SSYMSSSTPYV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-213,IGHV1-8,ARGPSWNGYYYYFDY,IGLV1-44,ASWDDRLNGVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-214,IGHV6-1,AREENAFDI,IGKV3-15,QQYSNWLLYT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-215,IGHV3-48,AREGHAFDI,IGKV3-20,QQYGSSPSWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-216,IGHV3-7,VAWGTTPLGTSENN,IGKV2-30,MQHTHWPHT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-217,IGHV1-8,ARGPSWNGYYYYFDY,IGLV1-44,ASWDDSLNGVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-218,IGHV3-23,AKRMGGNRFNPPVEY,IGLV1-40,HSYDSSLSASV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-219,IGHV3-11,ARDGIGQLWDDSYYYGLDV,IGKV2-30,MQGAHWPPYT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-221,IGHV3-30,AKKAGYSSGWYTDYYYNGMDV,IGLV1-40,QSYDSSLRGV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-222,IGHV1-2,ARGPYYYDSSGSLGAFDI,IGLV2-23,CSYAGGSTSYV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-223,IGHV1-8,VRGPSWNGYYYYFDY,IGLV1-44,ASWDDSLNGVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-224,IGHV5-51,ARLGPYYSSSSNGMDV,IGLV2-23,CSYAGSSTRV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-225,IGHV4-31,ARDTPPGYNWNYGPYGMDV,IGKV3-15,QQYNNWPPGYT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-226,IGHV3-30,AKKAGYSSGWYTDYYYNGMDV,IGLV2-8,SSYTASNRG,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-230,IGHV3-9,AKEISGYYFDY,IGLV4-69,QTWGTGIHWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-231,IGHV3-30,AKKAGYSSGWYTDYYYNGMDV,IGLV1-40,QSYDSSLRGV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-235,IGHV3-23,AKSTYGDYYYYYGMDV,IGLV2-14,NSYTSNSSLGV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-236,IGHV3-53,AREYSSGWYDY,IGKV3-15,QQYNNWPLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-237,IGHV1-2,ARGPFYYDSSGTLGGMDV,IGLV2-14,SSYTSSSTYV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-238,IGHV1-8,ARTNWNYYYYYYGMDV,IGLV1-44,AAWDDSLNGYV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-239,IGHV4-34,ARGRWYHDNNGYRSDAFDV,IGLV1-44,AAWDDSLNEV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-241,IGHV3-74,ITSMFNNGFY,IGLV2-11,SSYAGSYTV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-242,IGHV3-15,TTLWRLDP,IGLV7-46,LLTHTDSRV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-249,IGHV1-2,ARDLGIGVAGNLDH,IGLV2-8,SSYAGSNNWV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-250,IGHV1-18,AGSDNYGFPYNGMDV,IGLV2-8,SSYAGNNDFV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-251,IGHV3-23,AKEFSIGWGLFDY,IGKV3-11,QQRNNWPVT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-252,IGHV1-46,ARDKHWNNANYYYYGMDV,IGKV1-5,QQYNSYL,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-254,IGHV1-2,ARDQGGAALVGHSNY,IGLV2-23,CSYAGSSTWV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-255,IGHV1-2,ARDSRFSYVNGEFDY,IGLV2-23,CSYAGHSTWV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-262,IGHV1-2,ARVGWYDFGTPGDYYYYYGMDV,IGLV2-23,CSYAGTSTFV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-263,IGHV1-2,ADSGYWGSHYYYGMDV,IGKV2D-29,MQSIQLPLT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-264,IGHV1-2,ARDLGIGVAGNLDH,IGLV2-8,SSYAGSNNWV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-265,IGHV3-48,ARRRYSSSWYYYYGMDV,IGKV1-9,QQLNSYPLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-266,IGHV1-2,ATDRLVNTGVYTTGSMDV,IGLV2-23,CSYGGSSDYV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-267,IGHV1-2,ARVFGPGLDCSSTSCYTYGMDV,IGLV2-23,CSYAGSSSWV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-270,IGHV3-11,ARARGSSGWYRIGTRWGNWFDP,IGLV2-14,SSYTSSSNVV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-271,IGHV1-2,ARVPFAYCSSTSCDRGTPYYYYYGMDV,IGLV2-14,SSYTSSSTLV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-272,IGHV3-64,ARGLDNNGYYSGY,IGKV3-20,QQYGSSPRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-274,IGHV1-2,ARDQKNDILTGLGDY,IGLV2-8,SSYAGSNNWV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-275,IGHV3-66,ARDYYDSSGYYSSGGLGY,IGLV2-8,SSYAGSNNFV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-280,IGHV1-2,ARGPFYYDSSGTLGGMDV,IGLV2-14,SSYTSSSTYV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-281,IGHV1-2,ARGPFYYDSSGTLGGMDV,IGLV2-14,SSYTSSSTYV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-283,IGHV1-2,VRGPFYYDSSGPLGGMDV,IGLV2-14,SSYTSSSTYV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-284,IGHV5-51,ASGGDYPYGMDV,IGLV1-44,AAWDDSLSAWV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-285,IGHV1-2,ARGPFYYDNSGTLGGLDV,IGLV2-14,SSYTSSSTYV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-286,IGHV3-9,AKGGRYCSGTNCYEYYFFAMDV,IGLV2-8,SSYAGSNNNVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-287,IGHV1-58,AAPYCSSTNCYDAFDI,IGKV3-20,QQYGSSPWT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-289,IGHV1-2,ARGAAMVTGYTYYYGLDV,IGKV3-20,QQYGSSPIT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-290,IGHV1-2,ARDQKNDILTGLGDY,IGLV2-8,SSYAGSNNWV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-292,IGHV1-2,ARDQKNDILTGLGDY,IGLV2-8,SSYAGSNNWV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-293,IGHV3-11,ARCNGGGACFYGMDV,IGKV4-1,QQYYSTLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-293,IGHV3-11,ARCNGGGACFYGMDV,IGLV2-14,SSYTISSTWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-294,IGHV1-2,ARGPFYYDSSGTLGGMDV,IGLV2-14,SSYTSSSTYV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-297,IGHV3-53,ARRSASGWNFDY,IGLV2-8,SSYAGSNNLV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-299,IGHV5-51,ATSHGYSGYELGY,IGLV2-14,SSYTSSSTVWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-301,IGHV1-2,ARVDTTGTTFWLYYYYGMDV,IGKV2D-29,-,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-301,IGHV1-2,ARVDTTGTTFWLYYYYGMDV,IGLV2-23,CSYAGSSTWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-302,IGHV3-9,AKDKGPYYYYGMDV,IGKV2D-29,MQSIQLPQT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-303,IGHV1-2,ARDLGIGVAGNLDH,IGLV2-8,SSYAGSNNWV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-304,IGHV1-2,ARVFGPGLDCSSTSCYTYGMDV,IGLV2-23,CSYAGSNSWV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-305,IGHV1-2,ARDLGIGVAGNLDH,IGLV2-8,SSYAGSNNWV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-306,IGHV1-2,ARGTLYYDILTGSPNPPKLDY,IGKV1-39,QQSYSTPWT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-307,IGHV1-2,ARGPFYYDNSGTLGGLDV,IGLV2-14,SSYTSSSTYV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-309,IGHV1-2,ARGPFYYDNSGTLGGLDV,IGLV2-14,SSYTSSSTYV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-310,IGHV1-2,ARGPFYYDSSGTLGGMDV,IGLV2-14,SSYTSSSTYV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-312,IGHV1-2,ARIPIFGVVSTPGQYYYYGMDV,IGLV2-14,ISYTSSSTWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-313,IGHV1-2,ATDRLVNTGVYTTGSMDV,IGLV2-23,CSYGGSSDYV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-315,IGHV3-9,AKDFLWDLHPPRYYGMDV,IGKV1-39,QQSYSTHA,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-315,IGHV3-9,AKDFLWDLHPPRYYGMDV,IGLV1-51,GTWDSSLNGV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-316,IGHV1-2,ARGPFYYDSSGTLGGMDV,IGLV2-14,SSYTSSSTYV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-317,IGHV1-2,ARDQKNDILTGLGHY,IGLV2-8,SSYAGSNNWV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV07-319,IGHV1-2,ARGPFFFEVVVAEGFGWFDP,IGKV3-15,QQYNNWPPIT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-319,IGHV1-2,ARGPFFFEVVVAEGFGWFDP,IGLV2-8,SSYAGSNVYV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-323,IGHV1-2,ARVFGPGLDCSSTSCYTYGMDV,IGLV2-23,CSYAGSSSWV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV07-324,IGHV1-2,ARGPFYYDSSSTLGGMDV,IGLV2-14,SSYTSSSTYV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV23-101,IGHV3-30,ARDWEYYGSGTKAFDY,IGKV1-13,QHFNSYPLT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV23-103,IGHV1-2,-,IGLV2-14,SSYTRSTAVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV23-113,IGHV5-51,ATTRGYSDYEFAY,IGLV2-8,SSYAGSNNFPWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV23-114,IGHV4-31,ARDLGPRSDFGSGSGVGVIDP,IGKV3-15,QQYHNWPPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV23-115,IGHV1-2,ARGYYDILIGYATTHDAFDL,IGLV2-14,SSYTDSSTWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV23-116,IGHV3-21,ARASLVTMVRGAGNYMDV,IGKV3-11,QQRSNWPLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV23-116,IGHV3-21,ARASLVTMVRGAGNYMDV,IGLV2-23,CSYAGSRV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV23-121,IGHV1-2,ARELGSWDGRFDY,IGLV2-23,CSYAGSSTWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV23-126,IGHV4-59,ARDTTSYCSGGSCYYNYGMDV,IGKV2-28,MQALQTPRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-198,IGHV1-2,ARDLAYSMVRGISGI,IGLV2-23,CSYAGSNTWV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-201,IGHV1-2,ARDLAYSMVRGISGI,IGLV2-23,CSYAGSNTWV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-220,IGHV3-48,ARDRGSGWSLDESYFDH,IGKV1-39,QQSKSIPYT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-223,IGHV4-39,ARLRWLRGEFDY,IGLV6-57,QSYDSSTYWV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-226,IGHV4-39,ARLRWLRGEFDY,IGLV6-57,QSYDSSTYWV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-236,IGHV3-49,IRGGYGGNSGFDY,IGLV1-51,GTWDSSLSAVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-243,IGHV3-7,ARLYSGNYFDY,IGLV4-69,QTWDTAIWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-247,IGHV3-48,ARGFYDILTGYYSFHFDL,IGKV1-5,QQYNTYWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-248,IGHV3-33,ARREGVADYYYYYGMDV,IGKV1-6,LQVYNYPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-249,IGHV1-18,AREYDYSNPNYYYYYGMDV,IGLV3-27,YSAADNMGV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-252,IGHV3-74,VRVSGPFHDYFLYAMDV,IGKV3-20,QHYSAATWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-253,IGHV1-2,ARVFHGVITPFDY,IGLV5-37,MIWPSSAVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-255,IGHV4-34,ARGRLGFEELFRGVFFYYFDY,IGKV1-39,QQTFNSPRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-256,IGHV3-49,TRAQEEKITMIRRIISWFDP,IGKV3-20,QQYGSSPIT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-260,IGHV4-59,ARLLKSCTGGICQTYFYYAMDV,IGLV1-40,QSYDGSLSESAV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-262,IGHV4-31,ARGTTYTIFGVVISPFDY,IGKV3-20,QQYGSSPLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-265,IGHV4-34,ARGAPGT,IGKV1-5,QHYSTFPYT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-268,IGHV3-9,TTGYCRSNNCLTFYAF,IGKV1-39,QQSYRAPVT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-269,IGHV4-31,ARDYFGRSGSGSSLYYYYGMDV,IGLV3-1,QAWDSSTV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-271,IGHV3-21,ARVAAAGQKYYFDY,IGKV1-9,QQLNS,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-275,IGHV3-30,AKVANVFMLYPRGSWGMDV,IGLV1-47,AAWDDSLSGWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-280,IGHV3-48,AAGSSTSPSPV,IGKV3-15,QQYNNWPRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-282,IGHV3-23,AKDRGRRLTHLGVAPDV,IGKV1-39,QQSYTTPYT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-283,IGHV3-66,CGGYGSSWYLDY,IGKV3-11,QQRSNWPYT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-284,IGHV4-31,ARGGLSSRNGGNRSYSSSSFPLGRQDY,IGLV2-14,SSYTSSSTLYV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-285,IGHV5-51,ARFLSFVTSPTRYDY,IGLV2-14,SSYTSSSTLV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-286,IGHV1-69,ARHLPLSGYYAFDV,IGKV3-20,QQYGSSPYT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-287,IGHV3-23,AKDRSGGILAGGSGGALDI,IGKV1-5,QQYSSYSRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-290,IGHV4-39,ARASEDISLERAYNYGLTIDF,IGLV3-9,QVWDSSTVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-293,IGHV3-7,ARENYDSSGYYYAYYYYGMDV,IGLV3-25,QSADSSGTYV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-294,IGHV3-9,ARGDLGIRYFDY,IGKV3-15,QQYNNWPPIT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-294,IGHV3-9,ARGDLGIRYFDY,IGLV2-23,CSYAGSSTWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-296,IGHV1-18,-,IGKV4-1,QQYHSTPPA,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-296,IGHV1-18,-,IGLV2-23,CSYAGSSTWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-298,IGHV3-33,ARGWGGDGYTVDAFDV,IGKV2-28,MQALQPPYI,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-301,IGHV1-46,ARSLYSGSYGAYNWFDP,IGKV3-11,LQRINWLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-309,IGHV4-61,AREQVLDPGLYYGIDV,IGKV1-39,QQSYSTHT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-309,IGHV4-61,AREQVLDPGLYYGIDV,IGLV3-1,QAWDSDTVI,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-310,IGHV1-2,ARVFHGVITPFDF,IGLV5-37,MIWPSSDVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-311,IGHV1-2,ARGADIFITIFGVVIKENDY,IGLV2-18,SSYTSSSTLV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-314,IGHV3-30,ARGKNYGYSDDDLFQHFDY,IGLV7-43,LLHYGSSQLGV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-316,IGHV1-69,ARALGLSGHGMDV,IGKV1-39,QHSYSTPHT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-317,IGHV4-4,AKESWLELWLQGAGFDI,IGLV2-11,CSYGGSYTFVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-319,IGHV1-46,ARDLWMEYEYNDSGIQKTADQGMDV,IGLV3-1,QAWDINTVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-321,IGHV3-33,ARDMVRGPNDASDI,IGKV1-12,QQANSFPLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-322,IGHV4-39,ARQRTHTIFGVVVHFDY,IGLV3-25,QSADSSGTYDV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-323,IGHV3-49,TRAQEEKITMIRRIISWFDP,IGKV3-20,QQYGSSPIT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-325,IGHV3-49,TRAQEEKITMIRRIISWFDP,IGKV3-20,QQYGSSPIT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-329,IGHV3-33,ARDMVRGPNDASDI,IGKV3-15,QQYNNWPPVT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-330,IGHV3-49,TRAQEEKITMIRRIISWFDP,IGKV3-20,QQYGSSPIT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-331,IGHV3-23,AKEVPDIIVVAVAVGMDV,IGLV1-47,ASWDDSLSGVL,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-332,IGHV1-2,ARETRETYYDILTGYPFYYYFGMDV,IGLV1-51,GTWDGSLSAAV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-333,IGHV3-15,SSDLPKWGSGMADY,IGLV8-61,VLYMGSDIWA,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-336,IGHV3-49,TRAQEEKITMIRRIISWFDP,IGKV3-20,QQYGSSPIT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-344,IGHV3-33,ARREGVADYSYSCGMDV,IGKV1-6,LQVYNYPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV24-346,IGHV1-69,ARSDDSSGYYYLKEENDAFDI,IGKV2-30,MQGTHWREYT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV24-347,IGHV1-2,ARDRLYCSSTSCYTPYYYYYYGMDV,IGLV3-25,QSADSSGTYGV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-102,IGHV3-23,AKVETRGVGFDL,IGLV3-1,QAWDSSTVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-103,IGHV3-11,ARDWNLSGYYGGGR,IGKV1-16,QQYNSYPLT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-105,IGHV3-74,ARQRVARRRGFGESPFYYGLDV,IGKV1-6,LQNYNFPRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-107,IGHV1-2,ARDGAQYILTGDFDY,IGLV2-8,SSYAGSNNYV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-113,IGHV3-53,ARGGRLADAAGDY,IGKV1-33,QQYDNLPSWT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-114,IGHV5-51,ARAGNDNSLDY,IGKV1-39,QQSYTTPYT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-114,IGHV5-51,ARAGNDNSLDY,IGLV9-49,GADHGSGSNFVQKV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-115,IGHV3-7,ARDLYYYDSSGNGVNWFDP,IGLV1-40,QSYDSSLSGSYV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-117,IGHV4-30-4,ARVTRIYGSGSYCFDY,IGLV2-23,CSYVGSSTFVV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-118,IGHV4-59,ARAWSSSWYLDY,IGKV3-11,QQRSNWPPVT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-119,IGHV4-4,ARAWNFDY,IGLV2-23,CSYAGSSNWV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-122,IGHV3-23,AKVLDI,IGLV2-14,SSYTSSSTPYV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-124,IGHV4-59,ATYYYDSSGYPYGMDV,IGKV1-9,QQLNSYPG,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-125,IGHV5-51,ARHQGYSSSSLGY,IGLV9-49,GADHGSGSNFVYM,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-127,IGHV3-33,ARDPEIVVGGVDY,IGKV2-30,MQGTHWPYT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-128,IGHV3-11,ARDWNLSGYYGGGR,IGKV1-39,QQSYTTPYT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-129,IGHV4-31,ARDQGASASWDAFDI,IGKV3-20,QQYGSSLT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-131,IGHV3-11,ARDHSVRFLEWLLPY,IGKV1-9,QQLNSYPWT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-132,IGHV4-31,ARAERSITIFGVVTSAFDY,IGKV4-1,QQYYSTPYT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-134,IGHV4-34,ASSGWYYPDY,IGKV3-20,QQYGSSPNT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-135,IGHV3-23,AKVTGLGNAFDI,IGLV3-1,QAWDSSTVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-136,IGHV4-4,ARSSGRGRVVALGSFDP,IGLV2-23,CSYAGSSTWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-139,IGHV3-53,ARGHYDLFDY,IGKV1-9,QQLNSYPPGT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-140,IGHV4-31,ARAYDSSGYYPDY,IGKV1-39,QQSYSTLT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-142,IGHV5-51,ARIRGVYSSGWIGGDY,IGKV1-39,QQSYSTPRQWT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-143,IGHV1-2,ARDGAQYILTGDFDY,IGLV2-8,SSYAGSNNYV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-146,IGHV1-69,ARAATYYYDSSGYTPNWFDP,IGKV1-39,QQSYSTLYT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-147,IGHV3-9,AKDRRIAVAGTGEDYYFDY,IGLV3-21,QVWDSSSDQVV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-148,IGHV3-66,ARSAPLVGAYSGIYFDY,IGLV9-49,GADHGSGSNFVV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-149,IGHV1-69,ARAATYYYDSSGYTPNWFDP,IGKV1-39,QQSYSTLYT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-150,IGHV3-30,AKSQWLVLRHAFDI,IGKV2D-29,MQSIQLWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-156,IGHV4-59,ARFSQYYYDSSGYDFDY,IGLV2-23,CSYAGSSSWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-158,IGHV3-15,TTDRWFGELFSAYYYYYGMDV,IGKV3-11,QQRSNWPPIFT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-159,IGHV1-2,ARGNTVFWSGPPLDY,IGLV2-14,SSYTSSSTYV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-160,IGHV3-23,AKVAGRGNAFDI,IGLV7-43,LLYYGGAL,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-165,IGHV4-4,ARRSLGNYDSSGYDH,IGKV3-15,QQYNNWPPAIT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-165,IGHV4-4,ARRSLGNYDSSGYDH,IGLV1-44,AAWDDSLNGYV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-173,IGHV3-30-3,ARDYGGYNYN,IGLV3-1,QAWDSSTVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-177,IGHV3-9,AKDMVVVAIFGVGPFDY,IGKV1-6,LQDYNYPLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-179,IGHV5-51,ARQRRPPGKRVLTMIVVVYNDAFDI,IGKV1-33,QQYDNLLFT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-179,IGHV5-51,ARQRRPPGKRVLTMIVVVYNDAFDI,IGLV1-40,QSYDSSLSGSV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-180,IGHV4-4,ARRAAAGPRPYDY,IGLV2-23,CSYAGFSTWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-181,IGHV1-2,ARDLGYSYLYGAFDI,IGKV3-11,QQRSNWPT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-182,IGHV1-69,AKELGYSGYGAHRYFDL,IGLV1-40,QSYDSSLSGVV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-183,IGHV3-53,ARGDGWDNYYYGMDV,IGLV1-40,QSYDSSLSGSV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-184,IGHV4-39,ARGLGWFDP,IGKV1-NL1,QQYYSTPPRT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-186,IGHV1-2,ARDQSPDILKSPFDY,IGLV2-23,CSYAGSSTFG,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-193,IGHV3-11,ARDISRNLHDFRPYYFDY,IGLV7-46,LLSYSGARV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-194,IGHV4-59,ARHDVYSSGWYGEGAFDI,IGLV1-40,QSYDSSLSGSWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-199,IGHV4-59,ARYYQDFDY,IGLV1-44,AAWDDSLNGPYV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-201,IGHV3-30,AKDIVLVPAAIPVPIFDY,IGKV3-11,QQRSNWPPT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-202,IGHV3-33,ARDSSQQQLAYAFDI,IGLV3-1,QAWDSSIVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-205,IGHV4-30-2,ARDHYPYYYYGMDV,IGLV6-57,QSYDSSTVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-206,IGHV3-7,ARKGNAIDV,IGKV1-5,LQYNSYSWYT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-207,IGHV4-30-4,AKIRVRAGFRWAFDI,IGLV2-14,SSYTNTNTLV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-208,IGHV4-39,AHQSGNSGPWYFDL,IGLV8-61,VLYMGSGIVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-210,IGHV4-39,ARHVEPDYGGNSFDY,IGLV1-40,QSYDSSLSGYV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-211,IGHV3-9,AKDISNKWLRLTQPYSYYGLDV,IGLV2-8,SSYAGSNIPYV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-213,IGHV3-23,AKVLIRNGYDILTGYPYDAFDI,IGLV2-14,SSYTSSSTLV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-215,IGHV3-30-3,ARDGYSAYDFGY,IGLV8-61,VLFMGSGTWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-217,IGHV4-30-2,ASGPAWELFDY,IGKV3-15,QSYHNWPL,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-219,IGHV4-39,ARQMRIGTIVVVPAALDY,IGKV3-20,QQYYSSPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-221,IGHV3-66,ARGFGDYYFDY,IGKV3-20,QQLYT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-222,IGHV4-30-4,ARDPWQVTIFGVVIRYGMDV,IGKV1-9,QQLNSYPRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-225,IGHV3-11,ARDLWFGRYWGNWLDP,IGLV1-51,GTWDNSLSAAV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-227,IGHV3-66,ASEGRTTGTIVAYYYFAMDV,IGLV2-8,SSYAGRSNVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-228,IGHV4-31,AREKGTGDYYLDY,IGKV3-15,QQYNSWPRA,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-229,IGHV4-30-4,AKIRVRAGFRWAFDI,IGLV2-14,SSYTNTNTLV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-230,IGHV3-53,ARDNSSNWYYFDS,IGLV3-25,QSADSSGTYV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-231,IGHV3-33,ARDGLDDDYIWGSFKIRYYYMDV,IGLV2-8,SSYSGTTNFAQ,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-232,IGHV3-23,ASGTYRLGDY,IGLV1-44,AAWDDSLDGPV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-233,IGHV4-4,VTGGRWRFDP,IGLV2-11,CSYAGTYTYWL,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-235,IGHV3-23,VRDLSSSDPWYFDF,IGKV3D-20,QQYGDSPRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-236,IGHV3-64,ARGGYEIVVVPDYYYYGMDV,IGKV3-20,QQYKD,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-238,IGHV3-30,AKDPLNCSSTRCYTAWIYYYYGMDV,IGKV2D-29,MQSIQLPLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-240,IGHV3-30,AKDSVKGYSSGWYYYYYGMDV,IGKV2D-29,MQSIQLPLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-242,IGHV3-23,ARDLSSSDPWYFDF,IGKV3D-20,QQYGDSPRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-243,IGHV3-21,ARDRSGWYRNLFDY,IGKV2-28,MQALQASIT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-245,IGHV3-49,TRDFDHADSFDI,IGKV2-28,MQALHTPRYT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-248,IGHV3-30,AKGFYDSGP,IGKV2-30,MQGTHWKT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-251,IGHV3-23,AKDQTVSFFYYGMDV,IGLV1-47,ATWDDSLSGYV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-252,IGHV1-3,ARDNTNTWFGSIEY,IGKV4-1,QQNYATPLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-255,IGHV3-9,VREATRGAHFDC,IGLV2-8,SSYVGFNNLDNFV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-257,IGHV4-34,ARRIYYGDLGNWNFDL,IGKV1-16,QQYNSYPLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-259,IGHV1-69,ATLGYCSGGSCFPTGVFGY,IGLV7-46,LLSYSGARSWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-263,IGHV4-31,AREKGTGDYYLDS,IGKV3-15,QQYNSWPRA,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-265,IGHV3-23,AKDGHSMVRGVTMWGEFYYYYGMDV,IGKV3-15,QQYNNWPPYT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-270,IGHV3-9,VRSRWQLTSSAFDM,IGKV1-9,QQLNKYPIT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-271,IGHV4-31,AREKGTGDYYLDP,IGKV3-15,QQYNSWPRA,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-273,IGHV1-2,ARTYYYDSSGYRNYYYYGMDV,IGLV2-18,SLYTSSSTYV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-275,IGHV3-15,TTDRGNSITIFGVVIIDRPY,IGKV3-20,QQYGSS,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-276,IGHV3-21,ARDEGSPGLDYYGMDV,IGLV2-14,SSYTSNTTLVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-278,IGHV4-30-4,AKIRVRAGFRWAFDI,IGLV2-14,SSYTNTNTLV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-281,IGHV3-11,ARDMNYKYYYDSSGYPLLDY,IGLV1-44,AAWDDSLNGWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-284,IGHV3-49,IRARYYYDSSATFDY,IGKV1-39,QQCYSLPST,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV38-286,IGHV3-30,AKDASSPVYDFWSGYYNHLGMDV,IGLV3-21,QVWDSSSDQGV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-288,IGHV3-66,ARDYTVTTGGVDGMDV,IGKV3-11,QQRSNWPPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV38-289,IGHV3-23,VSRAAVGQPEY,IGKV1D-12,QQAYTLPRVT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV48-103,IGHV3-49,SRFYDYWNTFGLLLGSGLTFYHMDV,IGKV4-1,QQYCYTPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV48-104,IGHV1-69,ARDGQQLVRGWFDP,IGLV2-14,SSYTSSSTLYV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV48-107,IGHV4-39,ASENDYGEHDY,IGKV4-60,ETWDSNTRKVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV48-109,IGHV3-30,VKGDTSAYWPSSLLIS,IGLV2-14,GSYATGSSPVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV48-110,IGHV3-33,ARDARYSAYELPDYFFDL,IGKV1-5,QQYKGSSWAT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV48-113,IGHV3-33,ARDGLDDDYIWGSFKIRYYYMDV,IGLV4-69,QTWGTGINVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV48-119,IGHV3-23,AKTDRHWNHCD,IGLV2-14,SSYTGSSTLVA,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV48-123,IGHV1-3,ARNGGGLDQ,IGLV2-14,CSSTTSSTAV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-102,IGHV1-69,ARSPRPLIVVAEDGMDV,IGKV3-20,QQYGSSPFT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV-X1-109,IGHV1-2,ARGPLFWDTAMANFDY,IGLV2-14,-,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-111,IGHV3-49,NRELHNSVVVGVMGY,IGKV4-1,HHYYSPPYA,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-112,IGHV3-23,AKVGSGWYAFDY,IGKV3-15,QQYNKWPRT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV-X1-119,IGHV4-59,ARDRIMPLSYYYYYGMDV,IGLV1-44,AAWDDSLNGWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-126,IGHV3-53,ARDLSEGGMDV,IGKV1-12,QQANGFPPL,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-128,IGHV5-51,ARTYDFWSGFDYYGMDV,IGKV3-11,QQRSNWPT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV-X1-131,IGHV3-30,ARMATTYPEHDPSLY,IGLV3-21,QVWDSSSDHWV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-136,IGHV4-31,AAWRGFAATGFDS,IGKV1-9,QQLKSYPLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-137,IGHV1-8,ATEGTILTTMTAGAFDL,IGKV1-12,QQTDNFPYT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-140,IGHV1-69,ARFGGTSQSSGYYGFDN,IGKV2-28,MQPLQTPYT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV-X1-141,IGHV3-23,VTHDFPDWPPGGGMDV,IGLV6-57,QSYDWSNQGV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-142,IGHV1-18,STRGMAPHDY,IGKV1-39,HQTYDTWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-143,IGHV3-11,ARDLGYSTRFDY,IGKV1-33,QQYDNLPLT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-145,IGHV5-51,AREDLTGPDY,IGKV2-30,MQGTHWPNT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV-X1-146,IGHV3-23,ANNYYDNSGPDY,IGLV6-57,QSNDGSPSWV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV-X1-150,IGHV5-51,ARHLVCGGSCYPFDY,IGLV3-21,QVWDSSSDHQV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV-X1-153,IGHV3-33,ARDWFWRLGGVDY,IGLV8-61,VLYMGSGLVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV-X1-157,IGHV3-48,ATSYYDPSSAYSAHYAMDV,IGLV2-14,TSYTSLSPVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-164,IGHV1-2,ARSFGGFGGNYGMDV,IGKV1-39,QQSYSTPIT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV-X1-165,IGHV3-48,ARDPIGTGSDY,IGLV1-51,GTWDSSLNAGV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-167,IGHV3-74,ARAHSTTLYGWFDP,IGKV3-20,QHYVSSPLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV-X1-171,IGHV4-34,ARGFRKGSTFN,IGLV2-14,SSYTTSNTRE,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-172,IGHV3-48,ARDRLTIFGVAIDYYGMDV,IGKV1-12,QQANSFPALT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-173,IGHV3-30,AKDYDSALCTGGTCTFDAFDF,IGKV1-27,QNYNSAPPWT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV-X1-174,IGHV3-21,ATVQGDYVAGRAYYYGMDV,IGLV3-1,QAWDSSTAV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-175,IGHV1-69,ARGLQGTHLDC,IGKV4-1,QQYYSTGFT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV-X1-177,IGHV3-30,ARAETPASEIDY,IGLV3-1,QAWDSSHVV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-178,IGHV3-49,TRDRPIDYGDLHIYYYGLDV,IGKV2-28,MQALQTPPT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-180,IGHV4-39,LKDRTLQGNWFDP,IGKV3-11,QQRRDWPPVT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV-X1-183,IGHV3-30,ASKSPERGSFDY,IGLV2-14,SSYTNGSSLYV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV-X1-188,IGHV4-4,AKGGGPIVA,IGKV4-60,ETWDSNTRL,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV-X1-189,IGHV3-23,AKGRRYYDFWSGPMPYGMDV,IGLV2-14,SSYTSSSTLGV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV-X1-190,IGHV3-30,ANTSPGRGSFDY,IGLV2-14,SSYTNSSTLYV,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-191,IGHV4-31,ARQLRFLEWQYFDY,IGKV1-33,QQYDNLLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X1-195,IGHV3-64,VKGWGVKASSLGGDY,IGKV3-11,HQRSDWPRLT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X2-103,IGHV3-15,TTWRLGQDWFDP,IGKV1-39,QQSYSAPLT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HL CV-X2-105,IGHV3-73,TRRFDPNQRNDYYYALDF,IGLV1-44,SAWDDSLNGYV,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X2-106,IGHV1-69,ATRKETTVTTSLVYGMDV,IGKV1-39,QQSYSTPYT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X2-107,IGHV3-66,ARGKVGATGFEY,IGKV3-20,QQYGSSPPMYT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X2-108,IGHV3-66,ARGKVGATGFED,IGKV3-20,QQYGSSPPMYT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X2-109,IGHV5-51,ARLAHYYDRSGYSRADDAFDV,IGKV3-15,QQYNNWPPVYT,RBD,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X2-117,IGHV3-66,ARGKVGATGFED,IGKV3-20,QQYGSSPPMYT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X2-118,IGHV3-30,AKTGGPYCSGGSCYSALMDY,IGKV1-33,QQYDNLPPT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
HK CV-X2-123,IGHV4-4,ARDRTREGYHDTLTGEFYFYGTDV,IGKV3-20,QQYAMSPVT,S1,-,SARS-2_infection,Kreye et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model bioRxiv doi: 10.1101/2020.08.15.252320
COV2-2997,IGHV1-46,ARGAIPPNSRAEIDY,IGKV3-15,QQYYNWPLT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-3012,IGHV3-13,ARVLYDSSGFYNWFDP,IGKV1-39,QQSYEIPPWT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2961,IGHV1-58,AAPYCSSISCNDGFDI,IGKV3-20,QHYGSSRGWT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-3025,IGHV1-58,AAPYCSSISCNDGFDI,IGKV3-20,QHYGSSRGWT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2046,IGHV3-9,AKAHSTGHQYYYGMDV,IGKV1-39,QQSYNTPYT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2196,IGHV1-58,AAPYCSSISCNDGFDI,IGKV3-20,QHYGSSRGWT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2901,IGHV3-53,ARSYDILTGYRDAFDI,IGLV1-40,VAWDDSRNGLV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2070,IGHV4-34,ARVGYSQGYYYYYMDV,IGKV1-39,QQSYTTLLT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2132,IGHV3-53,ARDFLRWHDL,IGKV1-33,QQYDNLPPV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2911,IGHV4-39,ARMSRGYNYAYTFDI,IGLV2-23,CSYAGSVL,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2098,IGHV3-23,VKGLFDWFPL,IGKV3-15,HQYNNWPQT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2108,IGHV3-9,AKGVDYGGKLAYFDS,IGKV2-28,MQALQTPLT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2114,IGHV1-69,ARGRGYSNYGASYYMDV,IGLV1-40,QSYDSSLSGSV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2304,IGHV3-21,ARDPVWVDGELLSGGIPFDY,IGLV1-44,AAWDDSLNGVV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2078,IGHV1-69,ARVGVSGFKSGSNWYFDL,IGLV1-40,QSYDSSLSDSV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2299,IGHV3-30-3,ARDIDSGYDPTPVFDY,IGKV1-39,QQSYSTPWT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2351,IGHV5-51,ARRFYGPSSFDY,IGLV3-19,SSGDSSTDHHVV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2318,IGHV2-70,ARGVVTYDY,IGKV1-39,QQSYSTPGT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2703,IGHV3-13,ARARGGYNWNFDY,IGKV1-39,QQSYSTPPIT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2277,IGHV3-30,ARDVPTTVTAFTVFTY,IGKV1-39,QQSYSTPGLT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2068,IGHV3-53,ARSYDILTGYRDAFDI,IGLV1-40,QSYDSRLSGFVV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2504,IGHV1-2,ARVVVLGYGRPNNYYDGRNVWDY,IGLV1-44,AAWDDSLNALV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2510,IGHV7-4-1,ARWGPDYGDYASNDY,IGLV3-27,YSAADNNRV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2308,IGHV3-23,VKGLFDWFPL,IGKV3-15,HQYNNWPQT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2391,IGHV1-8,ARMRSGWPTHGRPDDF,IGLV1-44,AVWDDSLNGLV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2767,IGHV3-53,ARSYDILTGYRDAFDI,IGLV1-50,VAWDDSRNGLV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2081,IGHV1-46,ARGAIPPNSRAEIDY,IGKV3-15,QQYYNWPLT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2113,IGHV3-53,ARDFLRWHDL,IGKV1-33,QQYDNLPPV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2290,IGHV1-8,ARMRSGWPTHGRPDDF,IGLV1-44,LVWDDSLNGLV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2130,IGHV3-15,TTAGSYYYDTVGPGLPEGKFDY,IGKV4-1,QQYYSTLT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2050,IGHV1-2,ARVVVLGYGRPNNYYDGRNVWDY,IGLV1-44,AAWDDSLNALV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2064,IGHV1-8,ARMRTGWPTHGRPDDF,IGLV1-44,LVWDDSLNGLV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2684,IGHV1-58,AAPHCNRTSCYDAFDL,IGKV3-20,QQYNNWWRT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2072,IGHV1-58,AAPHCNRTSCYDAFDL,IGKV3-20,QQYGSSPWT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2539,IGHV1-8,ARMRTGWPTHGRPDDF,IGLV1-44,LAWDDSLNGLV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2389,IGHV3-9,AKDIIRQGEDGMDV,IGKV1-39,QQSYSTPWT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2532,IGHV1-46,ARGFHVPAALRNWFDP,IGLV1-44,VAWDDSRNGLV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2096,IGHV1-8,ARMRSGWPTHGRPDDF,IGLV1-44,AVWDDSLNGLV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2051,IGHV2-70,ARGVVTYDY,IGKV1-39,QQSYSTPGT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2759,IGHV5-51,ARTPTLYNWFHP,IGLV1-44,AAWDDSLNGSWV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2240,IGHV3-9,AKVGYTISRQWLVGEFDY,IGLV2-8,SAYAGSNNLV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2413,IGHV1-8,ARMRSGWPTHGRPDDY,IGLV1-44,AVWDDSLNGLV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2416,IGHV4-31,ASAKLVATISYFDY,IGLV1-36,AAWDDSLNGVV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2399,IGHV3-66,ARDYRDWI,IGKV1-33,QQYHNLPRT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2756,IGHV3-23,AKWAGPIVMKYYLQY,IGLV1-40,QSYDISLGGWV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2819,IGHV4-31,ARVVPTRGPVAWFDP,IGKV1-39,QQSYSTLLYT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2381,IGHV1-58,AAPYCSRTSCHDAFDI,IGKV3-20,QHFGSSSQWT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2628,IGHV3-9,AKDIIRQGEDGMDV,IGKV1-39,HQSYFTPQT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2909,IGHV1-69,ARGRGYSNYGASYYMDV,IGLV1-40,QSYDSSLSGSV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2353,IGHV5-51,ARLGVSKYCSGGRCLSGGSNWFDP,IGKV3-15,QQYNNWPPMYT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2589,IGHV2-70,ARIQYQLNGMDV,IGKV1-39,QQSYSTPYT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2485,IGHV1-69,ARVGVSGFKSGSNWYFDL,IGLV1-40,QSYDSSLSDSV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2693,IGHV1-8,ARMRSGWPTHGRPDDL,IGLV1-44,AVWDDSLNGLV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2762,IGHV4-39,ARHQRYCSSSSCHVWDY,IGLV2-23,CSYAGSSTWL,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2080,IGHV3-66,ARDLVTYGLDV,IGKV1-9,QLLNSHPLT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2527,IGHV4-30-4,ARFRRSYGSGSYYNISFDY,IGLV2-23,CSYVGSSTYVV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2618,IGHV3-20,ASVITFGGVIVRSY,IGLV1-44,AVWDDSLNGVV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2531,IGHV4-59,ARATWLRDAFGI,IGLV6-57,QSFDSGNVV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2919,IGHV2-70,ARTMATINAFDI,IGKV1-39,QQSFSTPRT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2037,IGHV3-53,ARDLNEHGLDV,IGKV1-12,QQTNSFPT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2780,IGHV4-34,ARLRYSSSGGHIFDY,IGKV1-33,QQYDNLPYT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2710,IGHV1-8,ARMRSGWPTHGRPDDH,IGLV1-44,VAWDDSRNGLV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2097,IGHV3-9,AKDIIRQGEDGMDV,IGKV1-39,QQSYSTPWT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2243,IGHV4-39,ARQSRGYSYAWSFDY,IGLV2-23,CSYAGIVL,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2694,IGHV1-69,ARDHSGYYDSTSLMSPFFDY,IGLV1-40,QSYDSSLNGDV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2826,IGHV1-46,ARGYGFVPNVLYYFDY,IGLV2-23,CSYAGSSTWL,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2813,IGHV3-53,ARDALYYNGPGRDGMDV,IGKV1-33,QQYDNLPRT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2796,IGHV4-31,ARETYSAYEMPPYFDY,IGLV2-23,CSYARSSTRV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2812,IGHV3-53,ARDALYYNGPGRDGMDV,IGKV1-33,QQYANLPFT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2941,IGHV1-58,AAPYCSSISCNDGFDI,IGKV3-20,QQYGSSPPRYT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2479,IGHV1-69,ARGVVAATPGWFDP,IGKV3-15,QQYNNFLT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2790,IGHV3-53,ARSYDILTGYRDAFDI,IGLV1-40,QSYDSRLSGFVV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2809,IGHV1-3,ASMTRMSEQTYYGMDV,IGKV1-39,QQSYTTLLT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2891,IGHV1-46,ARGAAVPAAGEFDY,IGKV1-5,QQYNSYSYT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2370,IGHV4-61,AGSPVPPTIVGASY,IGLV6-57,QSYDGINRWLV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2952,IGHV3-66,ARDLVTYGLDV,IGKV1-9,QLLNSHPLT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2562,IGHV1-8,ARMRTGWPTHGRPDDF,IGLV1-44,LVWDDSLNGLV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2137,IGHV4-61,AGSPVPPTIVGASY,IGLV6-57,QSYDGINRWLV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2631,IGHV4-39,ARHPVDGYNYGYSDL,IGKV3D-20,QQYGNSPFT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2768,IGHV3-30-3,ARDDNSPQGSGWYFYYYYAMDV,IGLV1-51,GTWDSSLSAYV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2434,IGHV3-53,ARHIPAWGYK,IGKV1-33,HQYDYLPYT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2752,IGHV3-53,ARDFLRWHDL,IGKV1-33,QQYDNLPPV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2832,IGHV3-66,ARGDGGYYSPFDY,IGKV1-39,QQSYSTPQT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2165,IGHV3-66,ARDLVTYGLDV,IGKV1-9,QLLNSHPLT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2955,IGHV3-30,AKGGPNKEVLYFGELLDYGMDV,IGKV2D-29,MQSIQLPYT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2499,IGHV4-39,ARHTVDCGGDCFPNDAFDI,IGLV3-19,NFRDSSGHHPV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2751,IGHV3-9,ARDYCSSTTCPAETYYYMDV,IGLV3-21,QVWDGINDRVV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2835,IGHV3-66,AREVVGYFDC,IGKV1-9,QQLNSYPGYT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2268,IGHV2-5,ARHQIVVLFDM,IGLV2-14,SSYTSSSTLVL,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2760,IGHV2-70,ARATTFFYGMDV,IGLV1-47,AAWDDSLSGLI,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2632,IGHV1-2,ARVVVLGYGRPNNYYDGRNVWDY,IGKV3-20,QQYVEPPFT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2730,IGHV3-9,AKAGYYAYVWGSYRFEYFDN,IGKV1-39,QQSYSTPPWT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2039,IGHV1-46,ARGTLIPAHRGAFDI,IGKV3-20,QQYGNSPQ,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2518,IGHV3-9,AKDIIRQGEDGMDV,IGLV3-19,NSRDSSGNAVV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2939,IGHV3-33,ARDLHQDWVVVVAANVYGMDV,IGLV3-19,NSRDSSGNPRW,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2807,IGHV2-70,ARETPVTAIDY,IGKV1-39,QQSYSTPRT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2838,IGHV1-58,AAPYCSSISCNDGFDI,IGKV3-20,QHYGSSRGWT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2585,IGHV3-48,ARVDYYGSGSVYWYFDL,IGLV2-11,CSYAGIWV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2110,IGHV3-30-3,ARDIDSGYDPTPVFDY,IGKV1-39,QQSYSSLSIT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2355,IGHV1-58,AAPHCNRTSCYDAFDL,IGKV3-20,QQYGSSPWT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2822,IGHV3-53,ARGPEPDAFDI,IGKV1-9,QQSYSNPSYT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2733,IGHV3-53,ARGPEPDAFDI,IGKV1-9,QQLNSYSFET,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2841,IGHV4-59,ARLRWLRGGIDF,IGLV6-57,QSYDSNNQV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2789,IGHV1-46,ARGFHVPAALRNWFDP,IGLV1-44,ATWDDSLNGPV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2786,IGHV3-13,ARVLYDSSGFYNWFDP,IGKV1-39,QQSYEIPPWT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2853,IGHV1-46,ARGAIPPNSRAEIDY,IGKV3-15,QQYYNWPLT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2352,IGHV1-46,ARGGEWRIVPGGRDYFDY,IGKV1-39,HQSYGVPIT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2801,IGHV1-46,ARERSGTYFFDY,IGLV1-44,AVWDDSLHSYV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2253,IGHV3-74,AGSPWLRGDIDY,IGLV6-57,QSYDGSNHAVV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-3010,IGHV3-30-3,ARDLSTTWYLEMWGPDAFDI,IGKV1-5,QQYNSYPYT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-3013,IGHV3-30,AKNLGPYCSGGTCYSLVGDY,IGKV1-33,QQYANLPFT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2945,IGHV3-9,AKLDVGGYDFVSGHYYAFDI,IGKV2-30,MQGTHWPYT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2103,IGHV3-7,ARLGFYYGGADY,IGLV6-57,QSYDGINRAWV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2111,IGHV3-13,ARVLYDSSGFYNWFDP,IGKV1-39,QQSYEIPPWT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2677,IGHV4-39,ARLLWLRGHFDY,IGLV6-57,QSYDSSNYWV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2354,IGHV3-53,ASSSWLRGAFDI,IGLV6-57,QSYDSSKYVV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2842,IGHV1-46,ARGYGFVPNVLYYFDY,IGLV6-57,QSYDSSDVV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2734,IGHV4-61,AGSPVPPTIVGASY,IGLV6-57,QSYDGINRWLV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2821,IGHV1-69,TTTQGGDYGDNLYYLDY,IGLV3-21,QVWDSSSDRLYV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2358,IGHV3-30-3,ARDIDSGYDPTPVFDY,IGKV1-39,QQSYSSLSIT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2357,IGHV3-49,SRVRGSFYGSVGKNYGMDV,IGKV2-28,MQALQTPLYT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2878,IGHV3-7,ARLGFYYGGADY,IGLV6-57,QSYDGINRAWV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2464,IGHV4-31,ARDLGDGYNLRVPAYFDL,IGLV3-25,QSADSSGYV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2808,IGHV1-58,AAPYCSSISCNDGFDI,IGKV1-33,QQYDNLPLA,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2863,IGHV1-46,ARENDYGDYVEPRDYYYGMDV,IGLV3-25,QSADSSAAYVV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-3029,IGHV3-43,AKDEMAYPPSHHYYYYYMDV,IGLV3-25,QSVDSSGTYPHVI,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2462,IGHV3-13,ARVLYDSSGFYNWFDP,IGKV1-39,QQSYEMPPWT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2083,IGHV3-30,AKNLGPYCSGGTCYSLVGDY,IGKV1-33,QQYANLPFT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2313,IGHV3-9,AKVSSITSLLGYYFDS,IGKV3-11,QHRSNWPPRLT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2231,IGHV3-9,AKGRGAGYTSYMDV,IGLV3-21,QVWDSSSDHHVV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2516,IGHV1-46,ARDQQIVPHADGFDI,IGKV3-11,QQRSNWPPRTWT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2817,IGHV3-13,ARVFETKVIRGGRYYYYYYMDV,IGKV1-39,QQSYSNPSYT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2331,IGHV4-39,ARILVIFTLNWFDP,IGLV6-57,QSYDSGNPI,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2765,IGHV3-9,AKGRGAGYTSYMDV,IGLV3-21,QVWDSSSDHHVV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2758,IGHV3-13,ARGGDSGYDLGAWYFDL,IGKV1-39,QQSYSMPPIT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2944,IGHV3-30,AKKGGPYCGGGNCYAGYFDY,IGKV1-33,QQYDNLPLA,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2031,IGHV2-26,ARTEWLLSDNWFDS,IGLV3-25,QSSDSSGVV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2329,IGHV3-23,ARVEGDWLLGGPYYHYYGMDV,IGLV1-47,AAWDDSLSSWV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2783,IGHV1-69,ARGLTGSSAYKDEIYFDY,IGLV3-25,QSADSSGSR,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2894,IGHV3-30,AKGDGSYLMDYFDY,IGKV3-15,QQYDDWPPEVT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2794,IGHV3-7,ARVNDGRPNPLEYYFDY,IGLV3-25,QSADSSGTSVL,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2749,IGHV4-34,ARVGYSQGYYYYYMDV,IGKV1-39,QQSYTTLLT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2709,IGHV3-30,AKNLGPYCSGGTCYSLVGDY,IGKV1-33,QQYANLPFT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2736,IGHV3-30-3,ARDLSTTWYLEMWGPDAFDI,IGKV1-5,QQYNSYPYT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2382,IGHV3-30,AKDLPPYASGWYEGGFDY,IGLV7-43,LLYYGGPWV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2465,IGHV4-4,ARVDHVNVRDY,IGLV2-14,SSYTSSSIPYV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2705,IGHV3-30,ARDQGTVVTHFDY,IGKV1-39,QQSYSTPPWT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2713,IGHV3-43,AKDEMAYPPSHHYYYYYMDV,IGLV3-25,QSVDSSGTYPHVI,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2848,IGHV3-30,ARDLAYHPYRDYGDDDYYYYYGMDV,IGLV3-25,QSADSSGTYRV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2678,IGHV3-20,AVIMSPIPRYSGYDWAGGAFDI,IGLV3-19,NSRDSSGNAVV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2722,IGHV1-69,ARLSGSGWLGYAMDV,IGLV2-14,TSYTSSSTLNVV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2258,IGHV3-20,ARARGPSEQYYDLLTGYYDAFDI,IGKV3-20,QQYGGSLT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2753,IGHV3-13,ARVDFDILTGYYSN,IGKV1-39,QQSYSSEWT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2797,IGHV5-51,ARDLIIESTIAARPGYYGMDV,IGLV3-25,QSADSRGAV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2032,IGHV1-46,ARGGLVPAARNAFDI,IGKV1-5,QQYNSYSWT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2740,IGHV3-30,AKKGGPYCGGGNCYAGYFDY,IGKV1-39,QQSSSSPIT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2287,IGHV1-8,ARGYGLTYYMDV,IGLV3-21,QVWDSSYYHPVV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2514,IGHV3-20,AVIMSPIPRYSGYDWAGDAFDI,IGLV3-19,NSRDSSGNAVV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2717,IGHV1-8,ARGPSILTGFYNPLDY,IGKV1-39,QQSYSTPYT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2417,IGHV4-34,ARVGGYYYYYMDV,IGKV1-39,QQSYTTLLT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2015,IGHV3-9,AMGPFGELLPYYFDY,IGKV3-11,QQRSNWPPYT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2461,IGHV4-31,ARGGSGSYSLFDY,IGKV1-33,QQYDNLYSVH,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2873,IGHV3-11,TGVVAAPAEYFQH,IGLV3-21,QVWDSSSDPFYV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2953,IGHV2-5,AHSGPPDLSPVLSQGWFDP,IGLV3-25,QSADSTGWV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2828,IGHV3-21,ARGGSILWWLIDY,IGLV6-57,QSYDSTSRVV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2554,IGHV1-46,ARDVFWVPAASSFDY,IGKV1-9,QQLNSYLGT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2552,IGHV3-11,ARDPIRDGVWGLNENDY,IGLV4-60,ETWDSNTRV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2906,IGHV5-51,ARLGSESKIDYYYYGMDV,IGKV1-39,QQSYSTPPT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2007,IGHV3-30,AKVSATYYYYYYGMDV,IGKV1-33,QQYDNLLFT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2450,IGHV3-30,AKQGGLYCSGTNCWGGYLDY,IGKV1-33,QQYHNLPPIT,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2342,IGHV2-5,AHRPPSYHGWCYFDY,IGKV1-39,QQSYSTHMST,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2256,IGHV7-4-1,ARDPSYCSSTRCYTVGWFDP,IGLV3-21,QVWDSSSDPVV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2834,IGHV2-5,AHRLPTPQLLPSFENWFDP,IGLV1-36,ASWDDSLIGPV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2082,IGHV3-20,AVIMSPIPRYSGYDWAGGAFDI,IGLV3-19,NSRDSSGNAVV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2128,IGHV4-39,ARILVIFTLNWFDP,IGLV6-57,QSYDSGNPI,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2094,IGHV3-20,AVIMSPIPRYSGYDWAGDAFDI,IGLV3-19,NSRDSSGNAVV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2055,IGHV3-9,AKGRGAGYTSYMDV,IGLV3-21,QVWDSSSDHHVV,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2158,IGHV4-31,ARGGSGSYSLFDY,IGKV1-33,QQYDNLYSVH,RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2016,IGHV1-24,AAAPAVMTAGWFDP,IGLV2-14,SSYTSSTTWV,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2021,IGHV1-24,ATQPAAIGGTPPYY,IGLV1-47,AAWDASLSGHVV,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2026,IGHV1-24,ATSFPIRGDPSYYYYYYGMDV,IGKV1-16,QQYNSYPWT,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2146,IGHV3-48,ARRSYRSSWYYYYGMDV,IGKV1-9,QQLNSYPVT,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2150,IGHV3-30-3,ARDWAPTYYDMPSAFDI,IGLV3-21,QVWDSSSDHPGV,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2190,IGHV3-48,AREARSRYFDWLPSYYFDY,IGLV2-14,SSYTSSSTHVV,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2199,IGHV1-24,ATGFAVFGRAAVPY,IGLV3-1,QAWDSSTVV,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2210,IGHV3-30-3,ARDQEWFRELFLFDY,IGKV1-12,QQANSFPPT,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2212,IGHV3-21,ARVNGNSNWNFGSYYYYYMDV,IGKV3-11,QQRGNWWT,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2215,IGHV3-21,ARWLQLRSDYYYFGMDV,IGKV3-15,QQCYNWPPWT,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2222,IGHV4-59,ARAPRERLQWGEYYFDY,IGLV2-23,CSYAVSTTYVI,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2228,IGHV4-34,ARPPQAARIHYYYYMDV,IGKV3-15,QQYNYWPPLT,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2251,IGHV2-26,ARIVLGASGTYPSPGFDP,IGLV7-43,LLYYGGAWV,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2257,IGHV4-61,ARGHVAAWESCYY,IGKV2-28,MQALQTPQT,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2260,IGHV3-23,AQMGPLGSTSSAADY,IGLV3-1,QAWDSSLVV,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2263,IGHV3-48,ARRSYRSSWYYYYGMDV,IGKV1-9,QQLNSYPVT,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2293,IGHV3-23,AKNERITMLVVVTLFDY,IGLV1-51,GTWDSSLSAVV,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2305,IGHV4-39,AILWRGSSWADRHYYYYSMDV,IGLV1-44,AAWDDSLNGWV,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2307,IGHV3-30-3,ARDLGRGLDP,IGLV3-1,QAWDSSTAV,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2335,IGHV4-39,ARHDGSGEMDTITWGPIYYYMDV,IGLV2-14,SSYTSSTLNVL,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2346,IGHV4-34,ARPPQAARIHYYYYMDV,IGKV3-15,QQYNYWPPLT,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2384,IGHV2-26,ARTTWGTWIQAWYFDI,IGLV2-23,CSYAGGNTFVV,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2394,IGHV3-21,ARWLQLRSDYYYFGMDV,IGKV3-15,QQCYNWPPWT,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2405,IGHV4-39,ASLWFGDLYSFDY,IGKV1-27,QKYNSAPWT,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2438,IGHV3-23,AKLLGSGITLDNDAFDI,IGKV1-39,QQTYSTPLYT,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2444,IGHV3-23,AKDFGSGIVGATGFDF,IGLV3-25,QSADSSGTYVV,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2455,IGHV3-48,AREARSRYFDWLPSYYFDY,IGLV2-14,SSYTSSSTHVV,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2459,IGHV4-39,ARRGNYYDSKNWFDP,IGKV3-15,QQYNNWPPMYT,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2466,IGHV3-21,ARVNGNSNWNFGSYYYYYMDV,IGKV3-11,QQRGNWWT,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2489,IGHV4-39,ARQWKWFGEAWYFDL,IGKV3-20,QQYGSSPFT,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2490,IGHV3-7,ARDPYDLYGDYGGTFDY,IGKV1-5,QQYNSYSLT,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2495,IGHV1-69,AREDYYGSGSLVDPYYYYRMDV,IGKV3-15,QQYNNWWRT,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2525,IGHV3-23,AKDPASGIVGPTHFDY,IGLV4-69,QSWDTGIGV,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2526,IGHV1-24,ATGFAVFGRAAVPY,IGLV3-1,QAWDSSTVV,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2533,IGHV4-31,AREANDSGSFYNGPFDY,IGKV4-1,QQYYSTRT,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2558,IGHV3-30-3,ARDQEWFRELFLFDY,IGKV1-12,QQANSFPPT,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2563,IGHV4-34,ARGWGWGAVAGRAEYYFDY,IGLV2-23,CSYAGSSTWG,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2571,IGHV4-59,ARDQRQFQLLGRFGWFDP,IGKV3-15,QQYNNWPRT,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2622,IGHV4-4,ARGWYFDY,IGLV2-23,YSYAGSSTWV,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2673,IGHV2-26,ARIVLGASGTYPSPGFDP,IGLV7-43,LLYYGGAWV,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2769,IGHV3-30-3,ARDWAPTYYDMPSAFDI,IGLV3-21,QVWDSSSDHPGV,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2816,IGHV4-59,ARAPRERLQWGEYYFDY,IGLV2-23,CSYAVSTTYVI,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2830,IGHV3-23,AKDSRSGIAGVDAFDI,IGLV3-21,QVWDSGSDHVV,NTD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2582,IGHV7-4-1,ARDQDSGYPTYYYYYMDV,IGKV2D-29,MQSIQPPLT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2248,IGHV3-30,ARDSGGNYGDSYFDY,IGLV3-25,QSVDRSGTYFNWV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2245,IGHV3-33,AGSSGEGGLYYYYGMDV,IGLV3-25,QSGDSSGTYVV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2418,IGHV3-23,AKPYGMDV,IGLV2-14,SSYTSTSTPWV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2378,IGHV5-51,ARRDTDFDY,IGLV9-49,GADHGSGSNFVYVV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2574,IGHV4-39,ARQWKWFGEAWYFDL,IGLV4-69,QTWGT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2697,IGHV1-46,ARDLAGVPAALGCWFDP,IGKV3-11,QQRSNWPLIFT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2488,IGHV3-74,AREVEQLAHMVDY,IGLV3-25,QSADSSGTSWV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2368,IGHV5-51,ARRRGGIGIEYGMDV,IGLV3-25,QSTASSGTYVV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2496,IGHV3-33,VRDLALFEVVIQQGV,IGLV3-10,YSTDSSGNHWV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2400,IGHV2-5,AHNRFQYCSSTTCYTLLPFDY,IGKV1-9,QQLNSYPFT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2445,IGHV3-20,ARRRSSSRYSSGWYMYYYYMDV,IGKV1-5,QQYNTYSGT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2147,IGHV3-30-3,ARSTSGSYYYGMDV,IGLV2-14,SSYTSSSTLLYV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2584,IGHV3-15,TTGGYSSYAASDY,IGLV2-14,SSFTSRGALVL,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2195,IGHV3-30,AKGGDGSGWAWDGDNPPTDY,IGKV4-1,QQYYTAPLT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2473,IGHV3-33,AREGQMAATTGIDY,IGLV3-10,YSTDTSGNHWV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2586,IGHV3-9,AKVGWELSIDAFDL,IGKV3-20,QHYGSSRST,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2173,IGHV3-20,ARRRSSSRYSSGWYMYYYYMDV,IGKV1-5,QQYNTYSGT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2369,IGHV3-30,AKDFGGDNTAMVEYFFDF,IGKV1-5,QQYNSYSPT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2427,IGHV4-4,ASRWGDYFDSSGAYDS,IGKV1-12,QQGNSFPLT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2191,IGHV3-20,ARRRSSSRYSSGWYMYYYYMDV,IGKV1-5,QQYNTYSGT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2262,IGHV1-8,AREARYFDWIFEGSDYYYYGMDV,IGLV2-18,SSYTSSSLRV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2660,IGHV3-13,ARADPYQLLGQHYYYGMDV,IGKV3-20,QQYGSSPLIT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2054,IGHV1-69,ARGRGYSNYGASYYMDV,IGKV1-33,QQSDNLPMYT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2226,IGHV5-51,ATHRCSGGFCYLAY,IGLV9-49,GADHGSGSNFVFVV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2700,IGHV3-30-3,AKNLGPYCSGGTCYSLVGDY,IGLV1-40,QSYDSSLSGYV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2386,IGHV3-33,AREGDFWSGYYTGWFDP,IGKV3-15,QQYNNWPRT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2521,IGHV3-30,AKDRTAVFLFFGLGDAFDI,IGLV3-21,QVWDSSSDHWV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2675,IGHV3-30,AKDGSGSYYGWFDP,IGKV6-21,HQSSSLPPT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2942,IGHV2-70,ARATTFFYGMDV,IGLV3-25,QSVDSSGTYRV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2621,IGHV3-33,ARDYCNGVTCNSNY,IGKV4-1,QQYYSSHWT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2300,IGHV4-4,ASRWGDYFDSSGAYDS,IGKV1-12,QQANSLPLT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2570,IGHV4-39,ARDPRVVVTARMYNWFDP,IGKV3-15,QQYNNWPPMYT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2373,IGHV3-66,ARDPGSRYSGGWYDYYYAMDV,IGKV3-20,QQYGSSPPYT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2872,IGHV3-33,AREGPFGDREASGAFDV,IGLV3-10,YSTDSSGKGV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2035,IGHV2-5,AHRRGILTEDAFDI,IGKV1-39,QQSYNTPRT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2383,IGHV3-30,AQGRGGYYSPFDD,IGKV3-15,QQYNNWPLA,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2454,IGHV3-33,AREGQGTYLDY,IGLV3-10,CSTDSSGNQRV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2676,IGHV1-69,ARSCGDCYSADLDF,IGKV3-11,QRRSNWPPFT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2934,IGHV7-4-1,ARPGKAAAFDY,IGKV2-28,MQALQTPWT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2241,IGHV5-51,ARRGEAAGIWYFDL,IGLV9-49,GADHGSGSNFEYVV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2549,IGHV3-33,AREGQWPNQAFDI,IGLV3-1,QAWDSSTHVV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2428,IGHV3-33,ARKGPLWRFDY,IGLV1-40,QSYDSSLSAWV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2545,IGHV4-34,ARGPPVTTFFVFSLLFDP,IGLV1-47,AAWDASLSGWV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2624,IGHV1-69,ARVEGEGVDSYYYGMDV,IGLV3-25,QSTDSSGSYVV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2784,IGHV4-59,ARDGGNAYSSGWYRYYYHMDV,IGKV3-15,QQYNNWPYT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2726,IGHV3-30,ARPSNWYFDL,IGLV2-23,CSYASSSIVV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2718,IGHV4-39,ARRTYYDLWSAYSSTAYYCMDV,IGKV1-9,QQLNSYPLT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2474,IGHV3-15,TTLTYYYDSSAYLNDAFDI,IGLV3-10,YSTDSSGNHRV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2947,IGHV7-4-1,ARGLISLFRGAIFHYYYGMDV,IGLV2-11,CSYAGRYTWV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2177,IGHV2-5,AHRLWFRDAFDI,IGKV1-39,QQTYSTFWT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2420,IGHV3-30,ARDRSNLERLVMTFGGIIAGAFDI,IGKV3-15,QQYHVWPPIT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2818,IGHV4-34,ARCRQMGNFYYYYMDV,IGKV3-20,QQYGSSPPRYT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2027,IGHV3-30,AIYGYYYYGLDV,IGLV3-25,QSADSSGTYFWV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2451,IGHV2-5,VHRHVSGAFDY,IGLV3-1,QAWDSSTGGV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2546,IGHV3-30,AKEGEWELRGNALDI,IGLV3-25,QSVDGSGSSVV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2643,IGHV3-30,ARGSAGNYYYGMDV,IGKV1-39,QQSYSTPGT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2022,IGHV1-18,ARDQGPTYYYGSGSPHYGMDV,IGKV2-40,MQRIEFPWT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2656,IGHV5-51,ARLTFGGSGSYYFYYNGMDV,IGKV3-20,QQYGRSSGT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2529,IGHV7-4-1,VREYGSGHPLPI,IGLV3-25,QSADSSSHWV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2553,IGHV3-30,ARSPPASYYNPSTGYFDY,IGKV1-39,QQSYSTPMHT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2611,IGHV3-33,ARESADISSRLDY,IGLV3-10,YSTDSSGNV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2238,IGHV2-5,AHRAVILNFDH,IGLV3-1,QAWDNDAGVV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2207,IGHV5-51,ASALRERGVQLWSV,IGLV1-40,QSYDSSLGAL,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2143,IGHV3-66,AKEGGSGSLRYYYYGMDV,IGLV1-44,AAWDDSLNGYV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2296,IGHV3-66,ARDPSAYYDILTGYSGDV,IGKV1-5,QQYSIYSWT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2446,IGHV5-51,ATHRCSGGFCYLAY,IGLV9-49,GADHGSGSNFVFVV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2197,IGHV5-51,ARPDYSSGWFSYWYFDL,IGKV3-20,QQYGRSPIT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2142,IGHV5-51,ARRGEAAGIWYFDL,IGLV9-49,GADHGSGSNFEYVV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2274,IGHV3-48,ARDRGWNYGLDY,IGLV3-10,FSMDSSGDLRV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2614,IGHV2-5,AHRLWFRDAFDI,IGKV3-15,QQYNSYSLT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2904,IGHV4-34,ARCRQMGNFYYYYMDV,IGLV1-40,QSFDIGRGGWI,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2681,IGHV3-30,ARALNKGFDP,IGKV4-1,QQYYSSPYT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2371,IGHV3-30,AKGRGNYLTFFDS,IGKV3-15,QQYNNWPGT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2639,IGHV3-30,ARAGGGSYRGPFDY,IGLV2-11,SAYAGSNNLV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2524,IGHV5-51,ASALRERGVQLWSV,IGLV1-40,QSYDSSLGAL,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2430,IGHV4-39,ARAPFQLLDKYYFFYYMDV,IGKV3-11,QQRSNWPPGVT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-3058,IGHV3-30,ARDRSGNYRDAFDI,IGKV4-1,QQYYSSYT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2602,IGHV5-51,ARPDYSSGWFSYWYFDL,IGKV3-20,QQYGRSPIT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2685,IGHV1-46,ARDRLGDGSYLGGGYYGMDV,IGKV3-20,QQYGSSPRLT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2041,IGHV4-61,ARARPDYYYYYAMDV,IGKV1-5,QQYNSYSTWT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2814,IGHV3-30,AKDMVEPLFSHYYYYGMDV,IGLV1-40,QSYDSSLSGYV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2266,IGHV3-49,IRDYDFWGGYYYHPLRAFDI,IGLV2-11,CSYAGSYTYV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2387,IGHV3-30,AKDLTIVVIPAAPNFDY,IGLV2-14,SSYTSSSTPVV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2281,IGHV3-30-3,ARVPVMVRGVYFDY,IGLV2-14,ISYTSSRTLV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2235,IGHV3-53,ARESTQ,IGKV1-5,QQYNTYSQT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-3057,IGHV3-7,ARLVTTVTTANGLYYYSYYYMDV,IGLV1-40,QSYASSLSAHVV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2025,IGHV3-30,AKGGDSSGWAWDGDNPPTDY,IGKV4-1,QQYYTAPLT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2203,IGHV3-30,ARGSAGNYYYGMDV,IGKV1-39,QQSYSTPYT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2453,IGHV7-4-1,ARARLLGYCSSTSCYTIGWGAFDI,IGKV1-33,QQYDNLPPGVSTT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2189,IGHV3-9,TKASRYCSSTICYWNWFDP,IGKV1-39,QQSYSTPT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2513,IGHV3-9,TKASRYCSSTICYWNWFDP,IGKV1-39,QQSYSTPT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2401,IGHV3-30,ARPYTGSYKSYMDV,IGKV4-1,QQYYSISWT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2034,IGHV1-18,ARDLPIKVVVPAADYNWFDP,IGKV1-39,QQSYSTPPT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2322,IGHV3-30,ARGDGYRSQFDP,IGKV3-20,QQYGSSYT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2933,IGHV3-30-3,ARGGATNFDY,IGLV3-21,QVWDSSSDHPEWV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2388,IGHV3-23,AKDQARVQDYIWGSYRSYGMDV,IGKV2-28,MQALQTPRT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2151,IGHV1-69,ARIGSYPEYFQH,IGKV3-11,HYRSNWPPVLT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2403,IGHV3-30,ARGDGDVYNFLLVRNWFDP,IGLV2-14,SSYTSSSTLYV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2013,IGHV3-30,AKGGDSSGWAWDGDNPPTDY,IGKV4-1,QQYYTAPLT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2617,IGHV1-69,ARVSGYGDYGAYSDY,IGKV3-11,QQRSNWPPRLT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2341,IGHV3-30-3,ARSTSGSYYYGMDV,IGLV2-14,SSYTSSSTLLYV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2273,IGHV4-39,AGEEVRGVKLYYYYAMDV,IGLV2-14,SSYTSISTWV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2337,IGHV2-5,AHRLWFRDAFDI,IGKV1-39,QQSYSTPGT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2515,IGHV7-4-1,ARGLVGRIDP,IGKV1-33,QQYDNLLLFT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2610,IGHV7-4-1,ARGRSYGLSLGY,IGKV1-33,QQYDNLLQFT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2422,IGHV3-30,ARVNSGSYYSYFDY,IGKV4-1,QQYYSTPLT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2250,IGHV3-30,ARGSAGNYYYGMDV,IGKV1-39,QQSYSTPYT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2844,IGHV3-30-3,ARAQGGNYYYGMDV,IGLV3-21,QVWDSSSDHHVV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2520,IGHV3-7,ARDVGGYSGYDLGFDYYYYMDV,IGLV3-19,NSRDSSGYIWGWM,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2960,IGHV1-18,ARVQRRRLDY,IGKV2D-29,MQSIQLA,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2006,IGHV3-30-3,ARPQSGGYYAPLDY,IGKV3-20,QQYGSSPWT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2333,IGHV3-7,ARLGGSSWHFDY,IGLV3-1,QAWSSSTAV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2458,IGHV3-30,ARDPSPLVLITSIDY,IGLV3-25,QSADTIGTYWV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2009,IGHV3-30,ARDTATYVLLWSGDFNLDY,IGLV2-14,SSYTSSSTLWV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2616,IGHV3-72,ASVITFGGVIVRSY,IGKV3-20,QYYGSSPFG,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2517,IGHV1-69,ARIGSYPEYFQH,IGKV3-11,HYRSNWPPVLT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2397,IGHV3-7,ARLSGSSWDFDY,IGLV3-1,QAWDSSTGV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2325,IGHV2-5,AHRLWFRDAFDI,IGKV1-39,QQTYSTFWT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2033,IGHV4-4,ARPTAGAGGAFDT,IGLV1-44,SVWDDSLNGPL,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2310,IGHV4-61,ATGYIGTYYYYMDV,IGKV1-39,QQSYSTLT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2669,IGHV3-30,AKGGDGSGWAWDGDNPPTDY,IGKV4-1,QQYYTAPLT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2774,IGHV3-7,VRLGVSSWYFDY,IGLV3-1,QAWGSSRGV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2340,IGHV1-3,AMGPSAFSWLDP,IGLV1-40,QSYDSSLSGWSV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2811,IGHV3-30,ARELMSVG,IGLV1-40,QSYDSSLSGWV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2239,IGHV3-30-3,ARPRSGSYYAYFDY,IGKV1-16,QQYNSHPPT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2429,IGHV3-53,ARESTQ,IGKV1-5,QQYNTYSQT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2883,IGHV3-30,AKDGSIAAADY,IGKV4-1,QQYYSTPWT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2536,IGHV4-61,ARGGLLWFGGAGNYMDV,IGKV4-1,QQYYSTPPYT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2028,IGHV3-30,AKGGDSSGWAWDGDNPPTDY,IGKV4-1,QQYYTAPLT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2017,IGHV4-59,VRGAMAWFDP,IGLV1-40,QSFDSSLSGSDV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2011,IGHV3-30-3,ARGHTGNYYYGMDV,IGKV1-39,QQSYSTFT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2509,IGHV3-30-3,ARPRGGSYQTCFDY,IGKV3-15,QQYNNWPGT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2406,IGHV3-7,ARLGRSSWNFDY,IGLV3-1,QAWDSSTGV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2441,IGHV1-69,ARIGHFDSSGYYLDY,IGKV3-11,QHRTNWPPLFT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2564,IGHV3-30-3,ARAQGGNYYYGMDV,IGLV3-21,QVWDSSSDHHVV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2776,IGHV3-7,ARVVVEVATNKGIHGVDYYYYYYMDV,IGLV3-19,NSRDNSGNLNWV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2587,IGHV2-5,AHRLWFRDAFDI,IGKV1-39,QQSYSTPT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2551,IGHV4-39,ASGPPYMATFSYYFDY,IGLV2-14,SSYTSSSTPFV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2481,IGHV1-69,ARGWFGELLKGTYWFDP,IGKV4-1,QQYYSTPG,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2029,IGHV4-4,ARPTAGAGGAFDI,IGLV1-44,SVWDDSLNGPL,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2590,IGHV1-8,ARGRVGYVGSGSRGYYYYYDMDV,IGLV3-19,NSRDSSGNHLRV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2408,IGHV4-61,ARVGGISPYYYYYYMDV,IGKV1-9,QQLNSYPIT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2565,IGHV4-61,ARGAASFDY,IGKV2-28,MQALQTPLT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2641,IGHV3-30,AKSYNGNYYDAFDI,IGKV3-20,QQYGSSYT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2449,IGHV3-30,ARASYNSNWSIGEYFRD,IGKV4-1,QQYYSPPWT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2619,IGHV3-23,ARVEGDWLLGGPYYHYYGMDV,IGLV1-47,LVWDDSLNGLV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2367,IGHV1-69,ARTSHYDSSGSYFEY,IGKV3-11,HKRSNWPPSLT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2343,IGHV1-18,ARVQRRRLDY,IGKV2D-29,MQSIQLA,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2270,IGHV1-69,AITYYYDSSGYWWDD,IGKV3-11,QQRSNWPPSYT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2187,IGHV3-30-3,ARGGATNFDY,IGLV3-21,QVWDSSSDHPEWV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2478,IGHV3-9,AKGIYYDIFMPLLD,IGKV3-20,HQYGTSPYT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2820,IGHV3-33,ARDQSQGAYILTGYRGYGMDV,IGKV2-28,MQALQTPFT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2620,IGHV3-30-3,ARADTMVRGTYFEY,IGLV2-14,SSYTSSRAVL,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2171,IGHV3-7,ARLSGSSWDFDY,IGLV3-1,QAWDSSTGV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2583,IGHV1-8,ARGGIYYLVRGFIIGYYGMDV,IGKV4-1,QQYYSTPLT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2227,IGHV3-33,ARDQSQGAYILTGYRGYGMDV,IGKV2-28,MQALQTPFT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2160,IGHV3-30-3,ARSTSGSYYYGMDV,IGLV2-14,SSYTSSSTLLYV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2178,IGHV3-7,ARVGSSSWYFDY,IGLV3-1,QAWDSSTAV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2159,IGHV3-30-3,ARSTSGSYYYGMDV,IGLV2-14,SSYTSSSTLLYV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2166,IGHV1-69,ARIGHFDSSGYYLDY,IGKV3-11,QHRTNWPPLFT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2224,IGHV3-30,AKDGSIAAADY,IGKV4-1,QQYYSTPWT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2214,IGHV1-69,ARIGHFDSSGYYLDY,IGKV3-11,QHRTNWPPLFT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2218,IGHV3-30,ARPYTGSYKSYMDV,IGKV4-1,QQYYSISWT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2216,IGHV1-69,ARTSHYDSSGSYFEY,IGKV3-11,HKRSNWPPSLT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2169,IGHV1-69,ARTSHYDSSGSYFEY,IGKV3-11,HKRSNWPPSLT,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2175,IGHV3-7,ARLSGSSWDFDY,IGLV3-1,QAWDSSTGV,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
COV2-2183,IGHV3-30-3,ARADTMVRGTYFEY,IGLV2-14,SSYTSSRAVL,non-RBD,-,SARS-2_infection,Zost et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med doi:10.1038/s41591-020-0998-x 
 2-38 ,IGHV3-21,TRAGWELRLDAFDI,IGLV3-19,NSRDSSGIL,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
 2-7 ,IGHV2-5,AHHKIERIFDY,IGLV2-14,SSYTTSSTV,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
 1-87 ,IGHV1-24,ATGIAVIGPPPSTYYYYGMDV,IGLV2-14,SSYTSSSTYV,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
 1-68 ,IGHV1-24,ATGWAVAGSSDVWYYYYGMDV,IGLV2-18,SSYTSSSTYV,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
 2-51 ,IGHV1-24,ATGWAYKSTWYFGY,IGLV2-8,SSYAGSRMG,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
 4-18 ,IGHV3-30,AKDSGYNYGYSWFDP,IGLV3-25,QSTDNSGTYPNWV,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
 4-19 ,IGHV4-59,ARSAKHWLAPPGDYYYYMDV,IGKV1-9,QQLNSYLT,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
 4-20 ,IGHV1-46,ARPGGGSYQEFDY,IGKV1-39,QQSYNTLQVT,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
 2-36 ,IGHV4-61,AREVYYYDRSGYYASDGFDI,IGKV3-20,QQYGSSPQT,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
 5-24 ,IGHV3-33,ARDPRDYYDFWSGYDYYYGLDV,IGKV3-20,QQYGSSGALT,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
 2-4 ,IGHV1-2,ARDRSWAVVYYYMDV,IGLV2-8,SSYAGSNNLV,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
 5-7 ,IGHV1-46,ARDREPHSDSSGYWDSLKYYYYYALDV,IGKV1-9,QQLNTYPFT,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
 1-20 ,IGHV3-53,ARDLFYYGMDV,IGKV1-9,QQLNSYPC,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
 2-15 ,IGHV1-2,ARGGSRCSGGNCYGWAYDAFDI,IGLV2-14,SSYTSSSTFV,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
 2-17 ,IGHV1-69,ARGVGYRGVIPLNWFDP,IGKV3-15,QQYNNWPPFT,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
 2-30 ,IGHV3-30,ARSILYGGGMDV,IGKV1-9,QQLNSYPLT,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
 2-43 ,IGHV1-2,ARGLGVGCSGGNCYLDYYYMDV,IGLV2-14,SSYTSSSTWV,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
 4-8 ,IGHV1-69,ASLQTVDTAIEKYYGMDV,IGLV3-1,QAWDSSTAV,NTD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
 1-57 ,IGHV3-72,ARVHRWAYCINGVCFGAYSDY,IGKV3-20,QQYGSSPST,RBD,-,SARS-2_infection,Liu et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456 (2020)
MnC4t2p1_F5 ,IGHV4-39,ARGVNYYDRNGYYRNDGFDI,IGKV1-17,LQHNTYPFT,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
MnC4t2p1_E6 ,IGHV3-9,AKDLRRQDYYADWYFDL,IGKV1-12,QQGNSFPFT,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
MnC2t1p1_C5 ,IGHV3-66,ATGARFGESPFDY,IGKV1D-12,QQANSFPGT,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
FnC1t2p1_G5 ,IGHV7-4-1,ARSLRGANLVP,IGKV1-33,QQYDNLPLT,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CnC2t1p1_D6 ,IGHV3-49,TRVRRLWFGSYYYGMDV,IGKV2-28,MQALQTPGT,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CnC2t1p1_E12 ,IGHV3-49,TRVRRLWFGSYYYGMDV,IGKV2-28,MQALQTPGT,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
HbnC4t1p1_D5 ,IGHV3-9,AKDINYDSGGYHKNYFDY,IGKV1-39,QQSYSNPLT,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
MnC1t3p1_G9 ,IGHV3-23,ALASGSYFGGANY,IGLV7-46,LLSYTGARV,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
MnC4t2p2_A4 ,IGHV7-4-1,AKIGSRNSLGV,IGKV3-20,QHFGTSSVT,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
HbnC3t1p1_F4 ,IGHV3-30,AKGGDYEWELLES,IGKV1-5,QHYHSFPLT,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
HbnC3t1p1_G4 ,IGHV3-66,ARDFGDFFFDY,IGKV3-20,QQYGSSPRT,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
MnC2t2p1_C11 ,IGHV1-69,AREGGLDYFGSRNSGWTYTWFDP,IGKV1-39,QQSYSTLYS,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CnC2t1p1_B4 ,IGHV1-18,ARDGELLGWFDP,IGLV2-23,CSYAGSSTWV,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
HbnC3t1p2_B10,IGHV3-66,ARDYGDYFFDY,IGKV3-20,QQYGSSPRT,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
FnC1t1p2_A5 ,IGHV1-8,ARATTDCSSTSCWSLDFWSGYYTGGREKIFDY,IGKV3-20,QQYGSSPGT,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CnC2t1p1_B10 ,IGHV1-69,ARVSGYDSSGYWGDY,IGKV3-11,QQRSNWPPALT,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
MnC4t1p1_A11 ,IGHV3-48,ASSKGFCSGGSCSDY,IGKV3-20,HQYGSSPWT,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
HbnC2t1p2_D9 ,IGHV3-33,ARAARRPVVTDTMAYYMDV,IGKV3-11,QQRSNWPPTWT,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CnC2t1p1_G6 ,IGHV1-2,ARASVATITDFDY,IGLV2-23,CSYAGVRTVV,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
CnC2t1p1_E8 ,IGHV1-2,ARASVSTITDFDY,IGLV2-23,CSYAGVRTVV,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
MnC5t2p1_G1 ,IGHV1-58,AAPRCSGGSCYDGFDI,IGKV3-20,QQYGSSPWT,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
HbnC3t1p2_C6 ,IGHV1-58,AAPYCSSTRCYDAFDI,IGKV3-20,QQYGRSPWT,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
HbnC3t1p1_C6 ,IGHV1-58,AAPHCSSTICYDGFDI,IGKV3-20,QQYGSSPWT,RBD,Yes,SARS-2_infection,Kreer et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 182:843-854.e12
REGN10934,IGHV3-15,TTARWDWYFDL,IGKV1-33,QQHDDLPPT,RBD,Yes,Veloimmune,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
REGN10964,IGHV4-59,ANMVRGVYEDDY,IGKV1-39,QQNYNTPLT,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
REGN10977,IGHV1-69,ARTPFYYDSSGYYLDY,IGKV3-20,QQYVRSPRT,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
REGN10954,IGHV3-66,ARDHGMAAAGYNY,IGKV1-33,QQYDNLPPA,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
REGN10933,IGHV3-11,ARDRGTTMVPFDY,IGKV1-33,QQYDNLPLT,RBD,Yes,Veloimmune,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
REGN10986,IGHV3-66,ARALPYGDLHFDY,IGLV1-40,QSYDSSLSDSYV,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
REGN10989,IGHV1-2,ARGSRYDWNQNNWFDP,IGLV2-14,SSFTTSSTVV,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
REGN10984,IGHV3-66,ARGELGIPYGMDV,IGLV1-51,GTWDSSLSAGV,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
REGN10987,IGHV3-30,ASGSDYGDYLLVY,IGLV2-14,NSLTSISTWV,RBD,Yes,SARS-2_infection,Hansen et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 369:1010-1014
CV30,IGHV3-53,ARDLDVSGGMDV,IGKV3-20,QQYGSSPQT,RBD,Yes,SARS-2_infection,Hurlburt et al. Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. bioRxiv. 10.1101/2020.06.12.148692
MD17,IGHV3-64D,VKDQDSSSWYDAFDI,IGKV1-39,QQSYTTPLT,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
MD29,IGHV3-64D,VKDQDSSSWYDAFDI,IGKV1-39,HQTYTSPYT,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
MD63,IGHV3-64D,VKDQDSNSWYDAFDI,IGKV1-39,QQSYSTPYT,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
MD45,IGHV3-53,ARDLSVRGGMDV,IGKV3-20,QQYGVSPEII,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
MD67,IGHV3-53,ARDLSVRGGMDV,IGKV3-20,QQFGSSPLT,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
MD62,IGHV3-53,ARDLQYYGMDV,IGKV1-12,QQANSFPLT,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.
MD47,IGHV3-23,AKDLVTAPSYEAFDI,IGLV3-21,QVWDSSSHHHVV,RBD,Yes,SARS-2_infection,Noy-Porat et al. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 11: 4303.